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ABSTRACT 
 
The nucleus tractus solitarus (NTS) integrates afferent information to maintain 
cardiovascular homeostasis. Pharmacological experiments have indicated that 5-HT is 
released in this process. In vitro and in vivo experiments were carried out to measure 
this release. 5-HT was detected in the NTS indirectly, by measuring glutamatergic 
inward currents in the slice and directly by voltammetry in the anaesthetised rat. 
 
In the slice, the presence of tonic release of 5-HT was confirmed which, in part, is 
responsible for basal release of glutamate via activation of 5-HT3 receptors. Blockade 
of the high-affinity, low-capacity 5-HT transporter (5-HTT; SERT), with citalopram 
and the low-affinity, high-capacity transporters (organic cation transporter 3; OCT3 
and the plasma membrane monoamine transporter; PMAT), with decynium-22 caused 
a 5-HT1A mediated decrease in glutamate release. Evoked glutamate release was only 
augmented by decynium-22.  
 
In experiments with anaesthetisia, a voltammetric scan optimised for 5-HT was used. 
Stimulation of cardiopulmonary, chemoreceptor and baroreceptor afferents as well as 
electrical stimulation of vagal afferents increased the electrochemical signal, which 
was calcium and frequency dependent. Synthesis inhibitors for 5-HT, but not for 
noradrenaline, decreased the signal confirming it was 5-HT. Decynium-22 increased 
the evoked signal but neither citalopram nor desipramine, at doses shown to 
selectively decrease the removal of 5-HT or noradrenaline, had any effect. Blockade 
of glutamate receptors with kynurenate reduced the evoked 5-HT by ~50% and this 
remaining 5-HT was potentiated by decynium-22.  
 
Preliminary data from rats with heart failure induced by coronary artery ligation 
found that glutamate and 5-HT transmission to be augmented within the NTS.  
 
These data show that 5-HT release is increased by activation of afferent input and this 
release is regulated by OCT3/PMAT not 5-HTT. This suggests that 5-HT may act, in 
part, as a volume transmitter in the NTS. This regulation may be affected by disease 
such as heart failure. 
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1. GENERAL INTRODUCTION 
 
1.1. 5-hydroxytrytamine 
 
History, discovery and nomenclature 
 
The first report, in Italian, of what became known as 5-hydroxytryptamine described a 
substance with vasoconstrictor properties isolated from enterochromaffin cells of the 
rabbit stomach (Vialli & Erspamer, 1933). The authors were unable to elucidate the 
full structure at that time. Later, in 1948 a vasoconstrictor substance was also isolated 
from serum and named serotonin, and in 1949 Rapport indicated that it could be 5-
hydroxytryptamine (Rapport et al., 1948, Rapport, 1949). Confirmation and synthesis 
of 5-hydroxytryptamine followed soon after (Hamlin & Fischer, 1951). Enteramine 
was also finally identified, attributing the pharmacological effects observed to one 
compound; 5-hydroxytryptamine (Erspamer & Asero, 1952). Herein the chemical 
name, 5-hydroxytryptamine (5-HT), will be used to refer to the compound described 
above. Soon after, 5-HT was found to be present in mammalian brain extracts 
(Twarog & Page, 1953) and was then isolated from the canine brain (Amin et al., 
1954). Finally, it was proposed that 5-HT and noradrenaline were two 
neurotransmitters with opposing actions in the CNS (Brodie & Shore, 1957). 
 
1.2. 5-HT as a neurotransmitter 
 
Synthesis 
 
5-HT belongs to a family of neurotransmitter known as the monoamines. This family 
includes the catecholamines, derived from tyrosine; noradrenaline, dopamine and 
adrenaline. Histamine and trace amines (eg. octopamine) are additionally present in 
this group. 5-HT differs slightly in structure; as an indolamine it includes a five- 
membered ring containing nitrogen fused to a benzene ring. 5-HT is synthesised from 
typtophan. Biosynthesis is achieved via two enzymes; tryptophan hydroxylase and 5-
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hydroxytryptophan decarboxylase. First, tryptophan is converted to 5-
hydroxytryptophan and then the secondary product is converted to 5-HT. The 
conversion from tryptophan to 5-hydroxytryptophan is the rate-limiting step. 
Storage 
 
Once present in the cytoplasm vesicular monoamine transporter (VMAT) transports 
5-HT against the concentration gradient into secretory vesicles under a proton 
electrochemical driving force (see Henry et al., 1998, Blakely & Edwards, 2012). 
Presynaptic terminals store 5-HT in conventional clear vesicles and, less commonly, 
in large dense-cored vesicles (see Liu & Edwards, 1997). It has been estimated that 
each vesicle contains between 50-100 molecules of 5-HT. There is also evidence that 
dense core vesicles containing 5-HT also co-package peptides, such as substance P 
(Dey & Hoffpauir, 1986). Ascorbic acid has also been found to be present in the 
vesicles containing 5-HT. Ascorbic acid is a well-known antioxidant and may be 
acting as a preservative for the packaged 5-HT. It is unclear if ascorbate functions as a 
neuromodulator itself, but it has been proposed that ascorbate changes the redox 
potential of receptors (Rebec & Pierce, 1994).  
 
The concept of vesicle ‘pools’ was initiated when an early study proposed that there 
are two distinct presynaptic stores of transmitter in the neuromuscular junction (Liley 
& North, 1953). It was found that repeated stimulation caused an initial rapid decay in 
response, which then quickly reached a steady state. This led to the concept of a 
‘readily releasable’ fraction and a ‘non-readily releasable’ fraction of vesicles. Since 
then, with a combination of ultrastructural imaging and functional assays it is 
generally accepted that most synapses rely on three pools of vesicles (see Rizzoli & 
Betz, 2005, Alabi & Tsien, 2012). The readily releasable pool contains docked 
vesicles, which are immediately available for release but are rapidly depleted after 
brief stimulation (for example Stevens & Williams, 2007). They are most proximal to 
the presynaptic membrane and represent between 1 and 5% of the total vesicular load 
of any given terminal. The recycling pool maintains release under normal 
physiological conditions and accounts for 10-20% of the total number of vesicles. 
These vesicles replenish the readily releasable pool in a matter of seconds due to their 
high mobility in resting terminals. They are scattered more distal from the membrane 
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than the readily releasable pool. Lastly, the reserve pool accounts for the majority of 
the total vesicular load and is located most distal to the pre-synaptic membrane. These 
vesicles are released following intense simulation and often only when the recycling 
pool has been completely depleted (Richards et al., 2003).  
 
Release 
 
Conventional action potential-dependent release of 5-HT from vesicles is, as for other 
transmitters, triggered by a rise in intracellular calcium concentration. This causes 
vesicle fusion with presynaptic membrane by conformational change of the SNARE 
complex leading to release of the vesicle content (see Ramakrishnan et al., 2012).  
Using fast-cyclic voltammetry and mathematical modelling it has been estimated that 
synaptic concentrations of 5-HT peaked at approximately 6mM in the dorsal raphé or 
substantia nigra (Bunin & Wightman, 1998). This concentration was found to drop to 
20nM outside the synapse.  
 
Action potential-independent release of 5-HT also occurs. Amphetamine and 
amphetamine derivatives such as MDMA cause release of 5-HT by this mechanism. 
These compounds are transported into the cytoplasm and by inhibition of the VMAT 
increase the intracellular concentration 5-HT. The increase in cytoplasmic 5-HT 
concentration causes the re-uptake transporters in the pre-synaptic membrane to 
operate in reverse and 5-HT is extruded from the cytoplasm as a result (see Blakely et 
al., 2005). More recently, a role of action potential independent release of 5-HT has 
been shown in the dendrites of dorsal raphé neurons, which allows for increased 
spatial segregation of released transmitter (Colgan et al., 2012).  
 
Peripheral 5-HT 
 
Peripherally, 5-HT is found in platelets and enterochromaffin cells. It is also found in 
gastrointestinal tract (in enterochromaffin cells), urinary system, kidneys, liver, heart 
and sympathetic nerves. It has been shown that 5-HT does not readily cross the blood 
brain barrier when administered peripherally but is metabolized before it can do so 
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(Lexchin et al., 1977). Indeed, peripheral 5-HT is rapidly metabolized by monoamine 
oxidase, primarily in the endothelium of the lungs and liver, to 5-hydroxyindoleacetic 
acid (Verbeuren, 1989). 
 
1.3. Central 5-HT 
 
Anatomy 
 
Following the suggestion that 5-HT is a neurotransmitter in the brain, the 
development of the Flack-Hillarp technique allowed central monoamine-containing 
cell groups to be visualised (Falck et al., 1962). When exposed to formaldehyde 
vapour catecholamines (noradrenaline, dopamine) and 5-HT are converted to 
fluorescent compounds. This effect was used to demonstrate that 5-HT in the CNS is 
distributed in discrete cell groups, with the majority along the midline in a group 
known as the raphé nuclei (Dahlstrom & Fuxe, 1964). Later, immunohistochemical 
studies targeting 5-HT itself validated this distribution (Steinbusch et al., 1978, 
Steinbusch, 1981). These 5-HT containing cells comprise of a small proportion of the 
total CNS neurons. Nevertheless, in the cortex of the adult rat there is an estimated 6 
million per mm3 5-HT positive-varicosities (Audet et al., 1989).  
 
Figure 1.1 shows the anatomical locations of the 5-HT-containing raphé nuclei in the 
rat. The dorsal raphé is the largest of these nuclei, and the most studied, but it is 
estimated that only 40-50% of neurons present contain 5-HT, as shown in the cat and 
rat (Wiklund et al., 1981, Descarries et al., 1982). Dopamine-containing neurons have 
also been identified around the midline of this nucleus (Ochi & Shimizu, 1978). 
Glutamate and GABA positive neurons are dispersed throughout the dorsal raphé, 
with the latter consisting of one population that is co-localised with 5-HT 
(Nanopoulos et al., 1982, Belin et al., 1983, Clements et al., 1991). There is also 
evidence for neuropeptides; substance P is especially of interest as it is also co-
localised with 5-HT (Hokfelt et al., 1978). Situated just caudal and ventral to the 
dorsal raphé is the median raphé but only a minority of neurons contained within are 
5-HT-positive (Wiklund et al., 1981).  
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Contained in the more caudal aspect of the brain are the raphé magnus, pallidus and 
obscurus. Approximately 50% of cells within the raphé magnus contain 5-HT, 25% 
are positive for substance P and 25% are positive for thyrotropin-releasing hormone 
(TRH), with some of these cells found to express all three (Johansson et al., 1981). 
The raphé magnus also contains a number of neuropeptides including encephalin and 
neurotensin (see Bowker et al., 1988). The raphé obscurus continues caudally from 
the raphé magnus along the midline past the level of obex. The majority of the cells 
within this nucleus contain 5-HT and there is also evidence for the presence of the 
same neuropeptides found in the raphé magnus (Steinbusch & Nieuwenhuys, 1983). 
The raphé pallidus is found on the ventral surface of the medulla extending midway 
from the raphé magnus to the caudal extent of the raphé obscurus. Again, this nucleus 
contains both 5-HT-positive cells and neuropeptides (Steinbusch & Nieuwenhuys, 
1983). 
 
Connections 
  
Projections from the dorsal and median raphé constitute the major ascending 5-HT 
innervation to rostral brain areas (Takagi et al., 1980). These projections travel 
ipsilaterally within the median forebrain bundle parallel to noradrenaline-containing 
fibres. These two nuclei supply 5-HT innervation to the hippocampus and thalamus 
(Azmitia & Segal, 1978) as well as septum and midbrain (Swanson & Cowan, 1979, 
Steinbusch, 1981). On the other hand the caudate putamen (Jacobs et al., 1978), 
substantia nigra (Wirtshafter et al., 1987), hypothalamic medial preoptic area, 
suprachiasmatic nucleus and anterior area are thought to be supplied by the dorsal 
raphé alone (van de Kar & Lorens, 1979). Projections to the cortex from these nuclei 
were previously thought to be diffuse and lacking specific synaptic appositions 
(Descarries et al., 1975). However, this is now known not to be the case as evidence 
of specific synaptic connections is well established (see Parnavelas & Papadopoulos, 
1989).  
 
The locus coeruleus receives innervation from dorsal, median and raphé magnus 
(Cedarbaum & Aghajanian, 1978, Morgane & Jacobs, 1979). Within the brainstem 
the facial (Aghajanian & McCall, 1980) and trigeminal nuclei (Schaffar et al., 1984) 
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contain 5-HT positive terminals, however their origin is unknown since projections 
were not found from raphé areas (Travers & Norgren, 1983). The rostral ventrolateral 
medulla (RVLM), the site of the “vasomotor centre” (see later), also receives 5-HT 
innervation from the dorsal raphé (Underwood et al., 1999). Sparse 5-HT innervation 
from the dorsal raphé is detected in the cerebellum (Takeuchi et al., 1982).  
 
Projections from the (caudal) raphé magnus, obscurus and pallidus are mostly 
descending. These nuclei supply 5-HT innervation to the substantia gelatinosa and 
intermediolateral nucleus of the spinal cord. Tract tracing experiments using 
horseradish peroxidase injection into these areas found labelling in all neurons of the 
caudal raphé, including those that are 5-HT positive (Bowker et al., 1982). 
Additionally, anterograde transport studies showed connections from the raphé 
magnus and pallidus to the C1-3, A1 and A2 cell groups (Nicholas & Hancock, 1990).  
 
5-HT positive terminals and fibres are reported in significant numbers throughout the 
nucleus tractus solitarius (NTS; site of termination of cardiovascular afferents, see 
later) in the rat and cat (Steinbusch, 1981, Maley & Elde, 1982). Ultra structural 
evidence shows the highest concentration of 5-HT terminals in the caudal regions of 
the medial NTS in the rat (Pickel et al., 1984, Calza et al., 1985, Curtis et al., 2013). 
5-HT containing neuronal connections between the NTS and raphé nuclei have been 
described by retrograde labelling. Dorsal raphé and raphé magnus, obscurus and 
pallidus all project to the NTS (Thor & Helke, 1987, Schaffar et al., 1988). Primary 
afferent terminals originating from the nodose ganglia (the site of vagal afferent cell 
bodies) form the peripheral 5-HT input into the NTS (Nosjean et al., 1990, Sykes et 
al., 1994). The area postrema is known to contain 5-HT-positive cell bodies 
(Steinbusch, 1981). These cell bodies send 5-HT-containing projections to the NTS as 
well as the dorsal vagal nucleus (DVN) and nucleus ambiguus, the location of vagal 
parasympathetic preganglionic neurons (Shapiro & Miselis, 1985).  
 
On the ventral surface of the brainstem the motor neurons in the ventral respiratory 
group receive 5-HT innervation from the raphé magnus, obscurus and pallidus of the 
rat (Holtman et al., 1990). In the cat the nearby nucleus ambiguus has also been 
shown to be innervated by the medullary raphé (Holtman, 1988). 
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Functions 
 
Central 5-HT-containing nuclei discussed above have been implicated in a wide range 
of physiological and behavioural functions including anxiety, depression, aggression, 
sleep, memory, and reward (see Lucki, 1998). These functions are beyond the scope 
of this thesis and will not be discussed further. However, many of these 5-HT-
containing nuclei are involved in autonomic regulation and an overview of their roles 
will be discussed below.  
 
Several studies have found that electrical and/or chemical stimulation of the dorsal 
raphé and median raphé produce predominantly pressor and sympathoexcitatory 
effects. Electrical stimulation of the dorsal or median raphé causes increases in blood 
pressure, but not heart rate, in anesthetised rats (Kuhn et al., 1980). This effect was 
attenuated by depletion of 5-HT by pre-treatment with para-chlorophenylalanine     
(p-CPA) and prolonged by blockade of 5-HT re-uptake with fluoxetine, suggesting 
the effect is mediated by 5-HT. This agreed with the results of an earlier study (Smits 
et al., 1978). Similar effects have been observed in cats by electrical and chemical 
stimulation of these nuclei (Piper & Goadsby, 1985). However, electrical stimulation 
also activates fibres of passage so experiments using this method should be 
interpreted with care, as many of these fibres cross the midline in the vicinity of these 
raphé nuclei. Chemical stimulation with glutamate or glutamate analogues does not 
attract this caveat. A more recent study stimulated the dorsal and median raphé by 
glutamate microinjection and found approximately 85% of injection sites evoked 
pressor responses, increased renal nerve activity and respiratory rate (Alvarenga et al., 
2005). 
 
The raphé magnus, obscurus and pallidus were first reported to evoke 
sympathoinhibition when electrically stimulated, suggesting a role in autonomic 
regulation (Coote & Macleod, 1974). However, further study has failed to reach 
consensus on a defined role of these nuclei. Most studies report mixed cardiovascular 
and sympathetic responses. In anaesthetised rats stimulation of the caudal raphé 
produces sympathoexcitation (Zhou & Gilbey, 1995, Blessing & Nalivaiko, 2001) and 
sympathoinhibition (Coleman & Dampney, 1995). Studies investigating the effect of 
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these nuclei on cardiovascular reflexes found that stimulation of the nucleus raphé 
obscurus inhibited the bradycardia evoked by activation of the chemoreflex. 
(Weissheimer & Machado, 2007). Interestingly, this effect was found to be mediated 
by 5-HT3 receptors located in the NTS, indicating that 5-HT is released here upon 
raphé obscurus activation. Equally, stimulation of the raphé pallidus caused inhibition 
of the cardiopulmonary reflex in anaesthetised rats (Edwards & Paton, 2000). 
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Figure 1.1 Central 5-HT containing cell groups 
Schematic representation of central 5-HT containing cell groups (B1-9; after 
Dahlstrom & Fuxe, 1964) and their major projections in the rat brain. Not to scale.  
 
5-HT containing cell groups are associated with the following nuclei according to the 
brain atlas of Paxinos and Watson (1998). The distribution of 5-HT-containing cells is 
sometimes diffuse and may be associated with more than one nucleus.  
 
B1: Raphé pallidus nucleus 
B2/4: Raphé obscurus nucleus 
B3: Raphé magnus nucleus 
B5/8: Median raphé nucleus 
B6/7: Dorsal raphé nucleus 
B8: Caudal linear nucleus 
B9: Nucleus pontis oralis 
 
MFB:  Median forebrain bundle 
  
3V: Third ventricle 
4V: Fourth ventricle 
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Figure 1.2 5-HT receptors and their transduction systems 
 
Dendrogram illustrating the evolutionary relationship between currently identified 
sub-classes of 5-HT receptor (adapted from Barnes & Sharp, 1999). Amino acid 
sequence homology compared in human genes, except 5-ht5A and 5-ht5B which are 
murine. The transduction mechanism and structure of each class of 5-HT receptor is 
also shown (Barnes & Neumaie, 2011). 
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1.4. 5-HT receptors 
 
Study of the receptor pharmacology of 5-HT started when John Gaddam proposed 
that 5-HT acted on specific receptors; D (5-HT2A) and M (5-HT3) in the guinea pig 
ileum (Gaddum, 1953b). Further to this, lysergic acid diethylamide (LSD) was shown 
to antagonise the action of 5-HT on the rat uterus (Gaddum, 1953a). Now using 
dibenzyline (phenoxybenzamine; an α-adrenoceptor antagonist) and morphine to 
block the action of 5-HT on guinea pig ileum Gaddum and Picarelli (1957) proposed 
the existence of two classes of 5-HT receptor, D (5-HT2A) on smooth muscle and M 
(5-HT3) in the enteric nervous system. Since then 7 types of 5-HT receptor have been 
identified, some with different sub-types, splice variants and post-translational 
modifications (figure 1.2). This makes the 5-HT family of receptors one of the largest 
of all neurotransmitters (see Hoyer et al., 1994) .  
 
Affinity     
 
5-HT receptors have differing affinities for their endogenous ligand. These 
differences allow further diversification of the role of 5-HT by allowing some 
receptors to respond at lower concentrations and others only at higher concentrations. 
Interestingly, receptors functioning as autoreceptors tend to display a higher affinity 
to 5-HT  (see figure 1.3). Autoreceptors tend to be in extrasynaptic location and 
therefore experience lower concentrations of 5-HT. 
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Figure 1.3 5-HT binding to 5-HT receptors 
 
Comparison of the affinity of 5-HT at cloned human receptors (data from Kilpatrick 
et al., 1989,  Roberts et al., 2001). Functional, distributional and pharmacological 
evidence is available for 5-HT1A/1B/1D as autoreceptor. 5-HT7 and 5-HT5A receptors are 
possible autoreceptors due to pre-synaptic localization on 5-HT cells but no functional 
evidence is yet available. 
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1.4.1. 5-HT1A receptor 
 
Pedigo et al. (1981) first reported two populations of 5-HT binding sites in the cortex 
and striatum. [3H]5-HT binding in these areas displayed very similar properties and 
were thought to be homogeneous. However, the authors noted a high affinity binding 
site in the cortex and a low affinity binding site in the striatum for the neuroleptic 
drug spiperone. These were later identified as 5-HT1A and 5-HT1B, respectively. The 
5-HT1A receptor is one of the most extensively researched of all the 14 5-HT receptor 
subtypes due to availability of selective ligands and accessible experimental systems, 
such as the dorsal raphé electrophysiology. 
 
Molecular biology  
 
The 5-HT1A receptor is a 7-transmembrane domain protein comprised of 422 amino 
acids. It was first identified as a result of human genome screens with a β2 
adrenoceptor clone, with which the 5-HT1A gene shares similarities (Kobilka et al., 
1987). This intronless gene was found to be located on human chromosome 5 (q11.2 
– 13) and was designated as the gene for the 5-HT1A receptor (Fargin et al., 1988). 
Soon after a gene was identified in the rat sharing 89% sequence homology that 
produced a 7-transmembrane domain protein again comprised of 422 amino acids that 
was identified as the rodent 5-HT1A receptor (Albert et al., 1990).  
 
Activation of the cloned receptor expressed in HeLa cells found it to be negatively 
coupled to adenlyate cyclase (Pauwels et al., 1993). Inhibition of cAMP accumulation 
by 5-HT1A activation was found to be rapidly down-regulated after agonist exposure 
(van Huizen et al., 1993). Additionally, there is evidence in hippocampal pyramidal 
cells that the 5-HT1A receptor directly couples to potassium channels (Andrade et al., 
1986). The G1α protein is also able to activate inward-rectifying potassium channels 
independent of cAMP inhibition (Codina et al., 1987). Further, activation of 5-HT1A 
receptors inhibit calcium influx (Penington & Kelly, 1990, Chen & Penington, 1996). 
Together it seems that direct coupling may account for a significant signalling method 
by the 5-HT1A receptor.  
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Distribution 
 
Autoradiographic studies have been used to form a comprehensive pattern of 5-HT1A 
receptor expression within central structures. Using [3H]-8-OH-DPAT the 
hippocampus was found to have the densest binding (Gozlan et al., 1988). The same 
study also found binding in the lateral septal nucleus, cortex and hypothalamus in 
decreasing order of intensity. The dorsal raphé nucleus also displayed a high level of 
binding. The brainstem is also known to be rich in 5-HT1A binding sites, with the 
DVN, NA and NTS having all been shown to express this receptor (Dashwood et al., 
1988). On the other hand, cerebellum and basal ganglia have few binding sites (Pazos 
& Palacios, 1985). Efforts to locate 5-HT1A mRNA found a similar pattern as given 
by receptor binding studies. Wright et al. (1995) found mRNA expression in the 
following order of intensity; subiculum, entorhinal cortex, raphe, dorsomedial and 
ventromedial hypothalamus, with lower levels found in cortex, NTS, hypoglossal 
nucleus, spinal trigeminal nucleus, and the lowest in the cerebellum. 
 
The subcellular location of the 5-HT1A receptor is known to be postsynaptic in the 
hippocampus (Yocca et al., 1992). However, in the dorsal raphé they function as 
somatodendritic autoreceptors, where their activation reduces neuronal firing (see 
Sharp et al., 2007). Their role as autoreceptors is further supported by evidence that 
lesions of 5-HT-containing cells by 5,7-DHT abolish 5-HT1A mRNA expression in 
the dorsal raphe (Miquel et al., 1992). 
 
Pharmacology 
 
5-HT itself binds to the 5-HT1A receptor with a pKi of 8.8 at both rat and human 
receptors (Hoyer et al., 1985, Hoyer et al., 1986). There are several selective high 
affinity agonists available for the 5-HT1A. The aminotetralins are the commonly used 
class of 5-HT1A agonists. This includes 8-hydroxy-2-(di-n-proplylamino)tetralin  (8-
OH-DPAT; Arvidsson et al., 1981), which has a pKi of 8.5 at the rat receptor (Mellin 
et al., 1991). However, 8-OH-DPAT has now also been shown to have agonist action 
at 5-HT7 receptors (Lovenberg et al., 1993). Busperione is an example of a 5-HT1A 
partial agonist with a pKi of 7.6 in rat cortex (Gozlan et al., 1988). However, it is also 
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known to have affinity to the dopamine D2 receptor and the α1 adrenoceptor (see van 
Wijngaarden et al., 1990).  
 
Antagonist availability is also good. One of the most widely used antagonists is 
WAY-100635 (Forster et al., 1995). This is a silent antagonist with a pKi of 9.6 at rat 
cortical 5-HT1A receptors (Johansson et al., 1997). However, the same study noted 
affinity for the α1 and D2 receptors of pKi 7.3 and 7.1, respectively. Other non-
selective antagonists include the β-adrenoceptor antagonists (-)-pindolol and 
propranolol with pKi’s of 7.8 and 6.6, respectively (Hoyer et al., 1985, Gozlan et al., 
1988).  
 
General roles in physiology 
 
Perhaps the best studied of all the 5-HT1A receptor systems is that of the dorsal raphé. 
Here, 5-HT1A is known to inhibit dorsal raphé neuronal firing in anaesthetised rats. 
This effect was first reported by Aghajanian et al. (1968) when systemic 
administration of lysergic acid diethylamide (LSD) was found to inhibit regular firing 
of 5-HT-containing neurons in the midbrain. This was later confirmed by 
iontophoretic application of the drug to these cells (Aghajanian et al., 1972). Later, 
the more selective aggonist 8-OH-DPAT was used and produced a similar inhibition, 
which was blocked by (-)-propranolol and WAY-100635 (Sprouse & Aghajanian, 
1986, Wang et al., 1995). It seems that these 5-HT1A receptors are tonically active as 
systemic (Gartside et al., 1995) or iontophoretic (Wang et al., 1995) application of 
WAY-100635 increases cell firing.  
 
5-HT reuptake inhibitors have been found to reduce the activity of 5-HT-containing 
cells within the dorsal raphé (Gartside et al., 1997). This effect is known to be 
mediated by the 5-HT1A receptor as it is blocked by WAY-100635. This mechanism 
has been postulated to contribute to the clinical latency seen in the treatment of 
depression with these drugs (see Kinney et al., 2000). 5-HT re-uptake inhibitors 
increase extracellular 5-HT concentration in the dorsal raphé leading to increased 
activation of 5-HT1A receptors, reducing firing activity. Consequently, there is a 
reduction of extracellular 5-HT in the terminal fields in the forebrain. However, there 
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is evidence of 5-HT1A receptor activation contributes to the antidepressant effect by 
increasing cellular proliferation in the dentate gyrus (Santarelli et al., 2003).  
 
5-HT1A receptors modulate neurotransmitter release in a variety of systems. 5-HT 
efflux in the areas of the hippocampus (Sharp & Hjorth, 1990, Sharp et al., 1996), 
frontal cortex, nucleus accumbens medial septum, and to a lesser extent the globus 
pallidus (Hjorth & Sharp, 1991) are all found to be reduced by 5-HT1A activation. 
This is presumably due to activation of 5-HT autoreceptors in raphé nuclei (dorsal and 
median) that supply 5-HT innervation to these areas. Acetylcholine release is 
indirectly increased by 5-HT1A activation in the rat frontal cortex (Consolo et al., 
1996b). The authours proposed that postsynaptic 5-HT1A receptors are activated to 
increase dopamine release which, in turn, activate dopamine D1 receptors to stimulate 
acetylcholine release. In the rat hippocampus noradrenaline release was enhanced by 
8-OH-DPAT and this effect was block by administration of WAY-100635 (Hajos-
Korcsok & Sharp, 1996). 5-HT1A control of noradrenaline relase in the hippocampus 
was found to be insensitive to 5-HT depletion by p-CPA (Hajos-Korcsok et al., 1999), 
suggesting it is not an indirect autoreceptor-mediated effect. Finally, there is some 
recent evidence that 5-HT1A receptor activation inhibits glutamate release in the 
trigeminal neurons, at least in the slice preparation with GABA activity blocked (Choi 
et al., 2013).  
 
Role in autonomic control 
 
The archetypical 5-HT1A agonist 8-OH-DPAT has demonstrated the importance of 
these receptors in cardiovascular regulation. Activation of 5-HT1A receptors at the 
level of the rostral ventrolateral medulla (RVLM; vasomotor centre) causes 
sympathoinhibition and a fall in blood pressure. However, blockade of these receptors 
with the 5-HT1A antagonist WAY-100635 fails to cause an increase or change blood 
pressure indicating that these receptors are not under tonic activation (see Ramage & 
Villalon, 2008). These receptors are physiologically involved in reflex activation of 
parasympathetic outflow to cause vagal bradycardia by baroreceptor and 
cardiopulmonary reflex activation. The major site for this action is the nucleus 
ambiguus, which is also the site of origin of vagal preganglionic neurons (Wang & 
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Ramage, 2001). Although the NTS is also rich in 5-HT1A receptors it is doubtful that 
these receptors are involved in afferent excitation of NTS neurons in vivo (Oskutyte et 
al., 2009). The exact function of these NTS 5-HT1A receptors in cardiovascular 
regulation remains to be determined. Another interesting possibility is that 5-HT1A 
receptors could be involved in respiratory regulation. Indeed, 8-OH-DPAT 
microinjected into the dorsal vagal nucleus/NTS was found to increase phrenic nerve 
activity (Sporton et al., 1991). In this respect 5-HT pathways are considered to play 
an important role in respiratory regulation (Hodges & Richerson, 2008). 
 
1.4.2. 5-HT1B and 5-HT1D receptors 
 
Before cloning was possible 5-HT1B and 5-HT1D receptors were originally thought to 
be one class of receptor but with differing interspecies pharmacology. Rodents were 
found to have high levels of 5-HT1B binding whereas human, dog, calf and guinea pig 
displayed high 5-HT1D binding (Hoyer & Middlemiss, 1989). Two human receptor 
genes were initially cloned and, when expressed, gave rise to receptors with a similar 
pharmacological profile as the 5-HT1B in the rat (Hartig et al., 1992). These were 
designated 5-HT1Dα and 5-HT1Dβ. However, when the rodent 5-HT1B receptor was 
cloned it was found to have high sequence homology with the human 5-HT1Dβ 
(Adham et al., 1992, Jin et al., 1992). Closing the circle, a receptor with high 
sequence homology to the human 5-HT1Dα receptor was cloned in rat (Hamblin et al., 
1992) and nomenclature was adjusted accordingly. When cloning data was complete 
it became clear that there were two specific receptors subtypes, 5-HT1B and 5-HT1D, 
expressed by all species but with different distributions and differing pharmacology. 
For example the rat 5-HT1B receptor has a higher affinity for beta-adrenoceptor 
antagonists such as isomoltane, pindolol and propranolol than the human receptor. 
This difference is conferred by a single amino acid change in the gene sequence 
(Oksenberg et al., 1992).  
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5-HT1B receptor  
 
 
5-HT1B receptor distribution has been assessed by autoradiography and 
immunohistochemistry. High levels of [125I]CYP binding in the presence of 
isoprenaline were found in the rat basal ganglia, especially globus pallidus and 
substantia nigra (Pazos & Palacios, 1985). Lower densities were also found in 
entopeduncular nuclei, superficial gray layer of the superior colliculus and 
periaqueductal gray. 5-HT1B binding in the cerebral cortex, amygdala and 
hypothalamus was present but of lower density. Immunocytochemistry confirmed this 
distribution (Sari et al., 1997, Sari et al., 1999). There are some differences between 
the mRNA distribution and the receptor protein. In situ hybridisation studies failed to 
detect transcripts in the globus pallidus and substantia nigra where high levels of the 
receptor are expressed (Bruinvels et al., 1994). This suggests that 5-HT1B is mainly 
located on nerve terminals in these areas as the protein is manufactured in the cell 
body and then transported to where it is functionally active. This was confirmed by 
studies looking at the subcellular location of the 5-HT1B receptor. One group showed 
exclusive expression on axons and axon terminals in the substantia nigra and globus 
pallidus (Sari et al., 1997, Sari et al., 1999). When taken together, the data supports a 
post-synaptic and pre-synaptic receptor expression functioning both as a 
heteroreceptor and autoreceptor. 
 
Pharmacology of the 5-HT1D receptor is complex. Human 5-HT1B/1D receptors share a 
77% sequence homology in their transmembrane domains so, unsurprisingly, ligand 
selectivity between the two sub-types is poor. The two receptors display binding 
profiles that are almost indistinguishable (see Weinshank et al., 1992, Boess & 
Martin, 1994). Many ligands with affinity for the 5-HT1B also have affinity for the 5-
HT1B or 5-HT1A receptors so combinations of ligands can be used effectively to 
distinguish between receptor sub-types. Examples of agonists available are 
sumatriptan, the archetypal 5-HT1A/1B/1D agonist and CP 94253, a potent and selective 
5-HT1B agonist. Antagonists include SB-216641, which displays a 25-fold selectivity 
over human 5-HT1D receptors (Price et al., 1997) and SB-236057, which has a 60-fold 
selectivity over other 5-HT receptors (Selkirk et al., 1998).  
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5-HT1B receptors are well known to act as inhibitory autoreceptors to modify 5-HT 
release in a range of brain areas. In this respect much of this research has been in an 
attempt to understand the clinical latency of 5-HT re-uptake inhibitors as a treatment 
for depression. When these uptake inhibitors are administered acutely, activation of 
pre-synaptic autoreceptors limits the increase in extracellular 5-HT concentration. The 
5-HT1B receptor has been shown to act as such in the forebrain and hippocampus of 
the mouse when treated with paroxetine (Malagie et al., 2001). More recently, 
endogenously released 5-HT was shown to activate the 5-HT1B receptor to reduce     
5-HT release in the substantia nigra (Threlfell et al., 2010). The study used 
voltammetry to detect electrically evoked 5-HT release in rat brain slices.  
 
Various examples of the 5-HT1B receptor acting as a heteroreceptor have been 
reported. Evidence modifying the release of acetylcholine, dopamine, GABA and 
glutamate. In synaptosomes prepared from the rat hippocampus, 5-HT1B receptor 
activation reduced efflux of radiolabelled acetylcholine (Maura & Raiteri, 1986). 
Conversely, 5-HT1B receptors are also known to have a facilitatory effect on the 
release of acetylcholine and dopamine in the rat frontal cortex (Consolo et al., 1996a, 
Iyer & Bradberry, 1996). However, given that 5-HT1B activation inhibits adenylyl 
cyclase this effect could be explained by disinhibition, possibly reducing GABA 
release. There is also direct evidence of 5-HT1B modulating GABA release. One study 
found that 5-HT1B receptors were responsible for the 5-HT-mediated inhibition of 
GABAB IPSPs in the rat midbrain (Johnson et al., 1992). Finally, 5-HT1B activation in 
vitro was found to inhibit glutamate release in the rat cingulate cortex and subicular 
cortex (Tanaka & North, 1993, Boeijinga & Boddeke, 1996).  
 
5-HT1D receptors 
 
5-HT1D receptors, like all in the 5-HT1 class, negatively couple to adenylyl cyclase. 
Unlike 5-HT1B receptors they are expressed at much lower levels in the CNS. 
Indicated by in situ hybridization 5-HT1D receptors are distributed in the basal 
ganglia, hippocampus, cortex, dorsal raphé and locus coeruleus. However, low 
densities of 5-HT1D mRNA is distributed throughout the CNS, including brainstem. 
 40 
Sub-cellular distribution is thought to be predominantly on axon terminals of both 
5-HT and non 5-HT-containing neurons. 
 
Pharmacology of the 5-HT1D receptor is complex. Human 5-HT1B/1D receptors share a 
77% sequence homology in their transmembrane domains so ligand selectivity 
between the two sub-types is poor. The two receptors display binding profiles that are 
almost indistinguishable (Weinshank et al., 1992, Boess & Martin, 1994). Many 
ligands with affinity for the 5-HT1D also have affinity for the 5-HT1B or 5-HT1A 
receptors so combinations of ligands have to be used in order to effectively 
distinguish between receptor sub-types. Examples of agonists available are 
sumatriptan, the archetypal 5-HT1A/1B/1D agonist and PNU-109291, a potent and 
selective 5-HT1D agonist with ~600 –fold selectivity over 5-HT1A/2A receptors (Ennis 
et al., 1998). Antagonists include BRL-15572 which displays approximatley 60-fold 
selectivity for the 5-HT1D  receptor over the closely related 5-HT1B subtype  (Price et 
al., 1997) and GR-127935 which is a 5-HT1B/1D antagonist with greater than 100-fold 
selectivity over other 5-HT subtypes (Clitherow et al., 1994).  
 
Supporting a role as an autoreceptor, one in vitro study on the found that 5-HT1A, 5-
HT1B and 5-HT1D regulated the release of 5-HT. Using voltammetry to measure 
extracellular 5-HT concentration in the rat dorsal raphé nucleus they concluded that, 
when 5-HT reuptake was blocked with paroxetine, all three receptors were activated 
to inhibit release (Davidson & Stamford, 1995b, a). Further, the reduction of 5-HT 
release induced by the 5-HT1B/1D receptor agonist sumatriptan persisted in 5-HT1B 
knockout mice (Pineyro et al., 1995). There is also in vivo evidence supporting this 
observation; electrophysiological recordings from 5-HT-containing neurons were 
used to demonstrate the presence of the 5-HT1D receptor (Pineyro et al., 1996). 
However, this effect was not found under similar experimental conditions in a more 
recent study (Trillat et al., 1997). 
 
There is also evidence that 5-HT1D, acting as a heteroreceptor, regulates the release of 
glutamate, GABA and acetylcholine. Initially, using synaptosomes prepared from rat 
cerebellar tissue one group showed a receptor with 5-HT1D characteristics inhibit 
glutamate release (Maura & Raiteri, 1996). This was later followed up on tissue from 
the human cerebral cortex using the same method (Maura et al., 1998). The same 
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research group also showed that glutamate release evoked by nitric oxide in rat 
cerebellar slices was regulated by a presynaptic 5-HT1D receptor (Marcoli et al., 
2006). 5-HT1D activation can also cause disinhibition by reducing GABA release. 
Once such example was reported in the human cortex where a 5-HT1D -like receptor 
was found to exert an inhibitory action on GABA release in vitro (Feuerstein et al., 
1996). Further, both 5-HT1D and 5-HT1B were shown to inhibit GABA release in 
slices containing the periaqueductal grey area of the rat. The selective agonist 5-HT1D 
L-694247 caused a decrease in GABA-mediated inward currents recorded in PAG 
neurons (Jeong et al., 2008). Finally, synaptosomes prepared from the guinea pig 
hippocampus were found to have a 5-HT1D-like receptor that, when activated, 
inhibited acetylcholine release (Harel-Dupas et al., 1991). 
 
Attributing these functional observations to behavioural or wider physiological effects 
is problematic due to these so-called selective ligands being relatively poorly 
characterized and the interspecies differences between the 5-HT1B and 5-HT1D 
receptors. The 5-HT1D is often present with other 5-HT1-type receptors making it 
difficult to discriminate specific functions. The reason for multiple sub-types 
controlling the same function remains to be determined and will require more 
selective ligands.  
 
Role of 5-HT1B/1D in autonomic control 
 
 
Expressed in peripheral cardiovascular tissues, 5-HT1B/1D receptors are known to 
modulate tone of a range of vessels either by direct actions on vascular smooth 
muscle or by a presynaptic sympathoinhibitory action (see Villalon & Centurion, 
2007). In cats 5-HT inhibits transmission in the sympathetic ganglion which was 
attenuated by the 5-HT1B/1D antagonist GR-127935, but not other 5-HT receptor 
antagonists (Jones et al., 1995). 5-HT1D receptor activation has also been shown to 
inhibit noradrenaline release in the human atrium (Molderings et al., 1996).  
 
Centrally, within the NTS the iontophoretic application of the 5-HT1B/1D receptor 
agonist sumatriptan inhibited the firing rate of most neurons tested. When 5-HT1D was 
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blocked with ketanserin, which has no effect alone, the inhibition was attenuated. In 
the presence of the 5-HT1B antagonist GR-55562 the inhibition was potentiated (Jeggo 
et al., 2007). In the same study, sumatriptan decreased vagal afferent activity evoked 
by electrical and pharmacological (cardiopulmonary afferent) stimulation of the vagus 
nerve. Conversely, activation of the 5-HT1B  receptor was found to increase the same 
evoked activity. It was concluded that the two sub-classes had opposing actions in the 
NTS indicating different anatomical locations. In an earlier study central 
administration of sumatriptan attenuated the reflex response to smoke stimulation of 
the upper airway of the anaesthetised rabbit (Dando et al., 1998).  
 
Overall, data indicate the presence of both 5-HT1B and 5-HT1D receptors in central 
and peripheral autonomic systems, possibly with opposing actions. 
 
1.4.3. 5-ht1E and 5-HT1F receptors 
 
5-ht1e receptors 
Lower case lettering of this receptor indicates that no physiological function have 
been identified. The gene for this receptor has been cloned from human genomic 
libraries (Levy et al., 1992, Zgombick et al., 1992) and the guinea pig (Bai et al., 
2004), but not detected in rat and mice. However, little is known about the physiology 
of the receptor due to lack of selective ligands. Most 5-HT1 receptor ligands are 
known to have affinity at this receptor (Bai et al., 2004). 
 
5-HT1F receptors 
 
When the human gene was first detected in 1993 the 5-HT1F became the 5th receptor 
in the 5-HT family to negatively couple adenylyl cyclase (Adham et al., 1993).  
Distribution of mRNA revealed 5-HT1F transcripts at modest levels in hippocampus 
(CA1–CA3 cell layers), cortex (highest in the cingulate and entorhinal cortices) and 
dorsal raphé nucleus of the guinea pig (Bruinvels et al., 1994). Autoradiography with 
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the selective agonist LY-334370 found a similar distribution in rat, guinea pig, 
monkey and human brain (Lucaites et al., 2005). 
The 5-HT1F receptor is expressed on both 5-HT-containing and non-5-HT-containing 
cell bodies where it acts as both an autoreceptor and heteroreceptor, respectively. 5-
HT1B/D/F receptors have been colocalised using immunohistochemical staining with 
glutamate-containing neurons (Ma, 2001). This suggests a role in controlling 
glutamate release, at least in the trigeminal nucleus.  
 
Research interest in the 5-HT1F receptor was fostered due to the anti-migraine effects 
of the triptan class of anti-migraine drugs. Triptans (sumatriptan, etc..) are non-
selective 5-HT1B/D/F agonists and development of sub-type selective agonists to 
improve therapeutic profile of this target has lead to the development of high-affinity, 
selective 5-HT1F agonists LY 344864 and LY 334370. The latter has ~100 fold 
selectivity of   5-HT1B receptors and have been shown to be effective against migraine 
in animal models, however acting in the trigeminal nucleus and not at vascular sites, 
as previously thought (Phebus et al., 1997). No selective antagonists have been 
developed to date and thus made research into the physiological role of these 
receptors difficult. 
 
1.4.4. 5-HT2 receptors 
 
There are three identified sub-types of the 5-HT2 receptor designated 5-HT2A, 5-HT2B 
and 5-HT2C. When activated all 5-HT2 receptors increase the hydrolysis of 
phosphoinositide and induce a rise in intracellular Ca2+ concentration. Historically 
first reported as 5-HT ‘D’ receptor, which mediated the contraction of guinea pig   
ileum smooth muscle caused by 5-HT (Gaddum & Picarelli, 1957). This was later 
classified as the 5-HT2A receptor. The 5-HT2B receptor was originally described in the 
rat fundus and was given the designation 5-HT2F until nomenclature was agreed. As 
previously mentioned, the 5-HT2C receptor was originally known as the 5-HT1C 
receptor but reclassified due to similar pharmacology and second messenger 
transduction.  
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5-HT2A receptor 
 
The receptor was first reported in rat cortical membranes to have a high affinity for 
spiperone but a relatively low affinity for 5-HT itself (Peroutka & Snyder, 1979). 
Approximately a decade later the receptor was cloned from rat and human cDNA 
libraries (Pritchett et al., 1988, Julius et al., 1990). Autoradiographic studies using 
[125I]-DOI and [3H]-MDL-100907 found high 5-HT2A receptor binding in cortical 
areas, caudate nucleus, nucleus accumbens, hippocampus, and brain stem; particularly 
pontine, trigeminal motor and facial nuclei (Mengod et al., 1990b, Lopez-Gimenez et 
al., 1997). The distribution of the radioligand binding was well matched with mRNA 
distribution (Pompeiano et al., 1994). Interestingly, one of the lowest levels of mRNA 
in the brain stem was found to be the NTS. Mostly overlapping mRNA and ligand 
binding sites indicate that the 5-HT2A receptor is located post-synaptically to 5-HT-
containing terminals.  
 
5-HT2B receptor 
 
As previously mentioned, the 5-HT2B receptor was originally described in the rat 
stomach fundus mediating contractile response to 5-HT. First cloned in 1992 the 
presence of the 5-HT2B receptor in the CNS was originally controversial (Kursar et 
al., 1992). Initial reports of mRNA distribution failed to detect 5-HT2B transcripts in 
the rat brain (Foguet et al., 1992, Pompeiano et al., 1994). Later, 5-HT2B-like 
immunoreactivity was detected in the rat brain (Duxon et al., 1997a). The study found 
reasonably focal distribution of the receptor in the cerebellum, lateral septum, dorsal 
hypothalamus and was particularly high in the medial amygdala. 
5-HT2C receptor 
 
This member of the 5-HT2 class has been cloned in the rat and human (Julius et al., 
1988, Saltzman et al., 1991). The 5-HT2C receptor is mainly distributed in the CNS 
with little peripheral expression. Autoradiography and in situ hybridization found 
high expression in areas of the cortex, limbic system (hippocampus, amygdala and 
nucleus accumbens) and basal ganglia (caudate nucleus and substantia nigra) as well 
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as lower levels in NTS, nucleus ambiguous and raphé nuclei (Molineaux et al., 1989, 
Wright et al., 1995). There is mostly good agreement between ligand binding and 
mRNA distribution with one exception (Mengod et al., 1990a). In the lateral 
habenular nucleus displays high mRNA but low 5-HT2C binding sites suggesting it is 
one of the few locations were 5-HT2C receptors are located pre synaptically.  
 
Pharmacology  
 
Importantly, for the use of these ligands in rat models, most 5-HT2 ligands display 
very similar affinities for the human receptor. Most pharmacological characterization 
is performed on cloned human 5-HT2 receptors in expression systems.  
DOI is the classic agonist at all the 5-HT2 class of receptors. It has a slightly higher 
potency the human 5-HT2A receptor (pEC50 of 8.2, 7.5 and 7 at human 5-HT2A, 5-
HT2B and 5-HT2C receptors, respectively (Jerman et al., 2001)). LSD is a partial 
agonist with a similar potency at all 5-HT2 receptors (Porter et al., 1999). 
Overall the availability of agonists selective between the three 5-HT2 sub-classes is 
poor; again Ro 60-0175 which considered to be selective for 5-HT2C only shows a 
tenfold functional selectivity in the rat over 5-HT2A receptors (Mbaki et al., 2012). 
One ligand of interest is TCB-2, which is described as a potent agonist with high 
affinity at the 5-HT2A receptor (McLean et al., 2006). BW 723C86 is a commonly 
used 5-HT2B agonist that does not cause stereotypical behavioural effects associated 
with 5-HT2C receptor activation in rats (Kennett et al., 1997).  
 
Ketanserin is a widely used selective 5-HT2A receptor antagonist but also has affinity 
for the 5-HT1D receptor (Leysen et al., 1981, Zgombick et al., 1995) as well α1-
adrenoceptors and histamine H1 receptors. MDL-100,907 is probably the most 
selective 5-HT2A antagonist available being between 100 and 1000 fold more 
selective over 5-HT2C and 5-HT2B (Johnson et al., 1996, Gleason et al., 2001). 5-HT2B 
receptor antagonists include RS-127445, which displays approximately 1000-fold 
selectivity for the 5-HT2B receptor over other targets (Bonhaus et al., 1999).  
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General roles in physiology 
 
 
Activation of 5-HT2C receptors causes membrane depolarization by reducing inward 
rectifying potassium currents and increases mobilization of intracellular calcium 
stores. Numerous electrophysiological studies have found 5-HT2A and 5-HT2C-
mediated excitatory responses in CNS neurons. In one such example slices containing 
rat piriform cortex 5-HT caused depolarization of interneurons and pyramidal cells 
(Sheldon & Aghajanian, 1991). The highly selective 5-HT2A receptor antagonist 
MDL-100,907 blocked depolarization of interneurons but the pyramidal cell was 
unaffected (Marek & Aghajanian, 1994). The authors concluded that the 5-HT2C 
receptor depolarizes the pyramidal cells whereas 5-HT2A depolarizes the interneurons. 
Hallucinogens have also been shown to be potent agonists in this preparation. LSD 
and DOI depolarize both pyramidal cells and interneurons of the piriform cortex 
(Marek & Aghajanian, 1996). Indeed, it is thought that these mechanisms mediate 
much of the hallucinogenic properties of these compounds. 
Studies in vivo have shown 5-HT2A receptor activation augments dopamine release in 
the rat nucleus accumbens caused by the reinforcing drugs cocaine, amphetamine and 
morphine (Porras et al., 2002, Navailles et al., 2008). It is thought to contribute to the 
rewarding properties of these drugs. Conversely, an earlier study, also in vivo, found a 
decrease in noradrenaline release in the hippocampus following the administration of 
DOI, which was reversed by non-selective 5-HT2 antagonists (Done & Sharp, 1992). 
The authors concluded this was via an indirect inhibitory pathway. Such an inhibitory 
pathway has been previously described from the prepositus hypoglossal nucleus in the 
brainstem and also involves 5-HT2 receptors (Gorea et al., 1991). 5-HT2C receptor 
antagonists increase the release of dopamine and noradrenaline in the frontal cortex 
when measured in vivo with microdialysis (Millan et al., 1998). This data suggests 
that 5-HT2C receptors are tonically active to inhibit both dopamine and noradrenaline 
release. Interestingly, the authors found no change in 5-HT concentration. 
 
The behavioural effects of 5-HT2A/2C ligands have been well studied. Early studies 
reported systemic administration of 5-HT2 agonists lead to a behavioural syndrome in 
rodents . In mice drugs in the DOx family, LSD, psilocybin and 5-HT releasing agents 
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cause head twitching and in rats ‘wet-dog’ shakes. Animals pre-treated with 5-HT2A 
antagonists or 5-HT2A knock-out mice no-longer display these stereotypical 
behaviours (Fiorella et al., 1995, Gonzalez-Maeso et al., 2007). 5-HT2A agonists 
model many of the positive symptoms of schizophrenia such visual/auditory 
hallucinations and delusions. This, coupled with the fact that some antipsychotic 
drugs such as clozapine and risperidone are high-affinity 5-HT2A antagonists has 
argued a role for 5-HT2A in psychosis (see Gonzalez-Maeso & Sealfon, 2009). 
 
The role of the 5-HT2B receptors in the CNS is poorly understood. Low-density 
expression and poor selectivity of ligands have hampered research into their 
physiological role. However, the 5-HT2B agonist BW-723C86 has been reported to 
have anxiolytic properties when administered systemically (Kennett et al., 1998) and 
directly in to the medial amygdala (Duxon et al., 1997b).  
 
Behavioural effects of the 5-HT2A/2C receptors were initially difficult to distinguish 
from one another due to lack of selective ligands. 5-HT2C receptor agonists also 
produce stereotyped behaviours in rodents such as hypolocomotion, hypophagia, 
anxiety, penile erections and hyperthermia (see Koek et al., 1992). Hypophagia is of 
clinical interest as a target for anti-obesity. Indeed, lorcaserin  (a 5-HT2C agonist) has 
been recently approved for use in the treatment of obesity. Lorcaserin works by 
increasing satiety and therefore reducing food intake (see Carter et al., 2012). 
 
Role in autonomic function 
 
5-HT2 receptors act centrally and peripherally to regulate blood pressure. Peripherally 
they mediate vasoconstriction (see Kaumann & Levy, 2006). Centrally, 5-HT2A 
activation causes sympathoexcitation and vasopressin release (see Ramage, 2001). 
Central application of the 5-HT2A antagonist ketanserin caused no change in 
sympathetic activity in rat suggesting that these receptors were not tonically active, at 
least, in the anesthetised animal (Knowles & Ramage, 1999). However, infusion of 
MDL-100907 was shown to cause a fall in blood pressure (Mbaki et al., 2012). 5-
HT2B activation with the selective 5-HT2B agonist BW-723C86 causes a reduction in 
blood pressure (Knowles & Ramage, 2000). However, the selective 5-HT2B receptor 
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antagonist RS-127445 did not change resting blood pressure in the anesthetised 
female rat suggesting no physiological role (Mbaki & Ramage, 2008).  
Studies aimed at locating the 5-HT2A receptors involved in this cardiovascular 
response found that application of the 5-HT2 agonist DOI to the ventral surface of the 
brainstem caused a rise in blood pressure but no increase in heart rate. This effect was 
attenuated by i.v. propranolol and stellate ganglionectomy. These observations lead 
the authors to conclude that 5-HT2 receptors at the level of the RVLM control a 
selective pathway that increase force but not rate of cardiac contractility (Mandal et 
al., 1990). However, a later study controlled the heart rate and blood pressure of the 
experimental animal artificially and found no change in cardiac contractility, only a 
change in peripheral vascular resistance (Ramage & Daly, 1998). It seems that 5-HT2 
receptors at the level of the RVLM affect sympathetic premotor neurons controlling 
only hind limb vascular resistance.  
5-HT2 receptors have also been implicated the micturition reflex (see Ramage, 2006). 
Indeed, spinal 5-HT2A/2C receptors were found to activate the external urethral 
sphincter (EUS) and the micturition reflex. On the other hand, central activation of 5-
HT2C receptor has been shown to inhibit the micturition reflex in anesthetised female 
rats but antagonists of this receptor alone had no effect, suggesting no physiological 
role (Mbaki & Ramage, 2008). A later study, where drug administration was 
optimized to provide selective and effective doses, supported the view of no 
physiological role in EUS activity or micturition reflex (Mbaki et al., 2012).   
Neurons in the NTS are known to express both 5-HT2A and 5-HT2C so they could both 
play a role in autonomic regulation. In this respect, when DOI was applied to neurons 
receiving vagal input it produced mixed excitation and inhibition (Wang et al., 1997). 
Later, it was found that second-order neurons tended to be inhibited via 5-HT2C 
activation and higher-order neurons were excited by 5-HT2A/2B receptors (Sevoz-
Couche et al., 2000). Further, when DOI was microinjected into the NTS producing a 
depressor response and bradycardia was completely inhibited by the selective 5-HT2A 
antagonist MDL-100907, but not by 5-HT2B and/or 5-HT2C receptor agonists. (Comet 
et al., 2007). The authors concluded that activation of the 5-HT2A receptor alone in 
the NTS mediates the cardiovascular responses produced by non-selective 5-HT2 
agonists. 
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In vitro studies have found a role for 5-HT2 receptors modulating neuronal excitability 
at the level of the NTS. One study found that the 5-HT2A receptor antagonist 
ketanserin blocked the decrease in amplitude of EPSCs evoked by 5-HT (Takenaka et 
al., 2011). 5-HT increased the paired-pulse ratio leading the authors to conclude that 
5-HT was acting presynaptically on 5-HT2A receptors to produce the inhibition. More 
recently, a study using multiple approaches has identified the presence of 5-HT2C 
receptors that are tonically active, at least in the NTS slice preparation. 5-HT2C 
receptor protein and transcripts were found in the NTS using real-time RT-PCR and 
immunohistochemistry in a post-synaptic location. Electrophysiological investigation 
using the selective 5-HT2C receptor agonist CP-809101 augmented postsynaptic 
currents elicited by stimulation of the solitary tract and the 5-HT2C antagonist RS-
102221 inhibited these currents (Austgen et al., 2012). Interestingly, RS-102221 
reduced amplitude, but not frequency, of spontaneous mEPSCs suggesting that 
postsynaptic 5-HT2C receptors are tonically activated by spontaneously released 5-
HT.  
 
1.4.5. 5-HT3 receptors 
 
The 5-HT3 receptor was one of the first classes of 5-HT receptor to be reported 
(Gaddum & Picarelli, 1957). They were first reported as 5-HT ‘M’ receptors but later 
re-classified as the 5-HT3 receptor.  
 
Molecular biology 
 
Unique within the 5-HT receptors as the only ligand-gated ion channel (Derkach et 
al., 1989), the 5-HT3 receptor belongs to a family known as the Cys-loop receptors. It 
is comprised of a pentamer of identical or non-identical subunits arranged to surround 
a water-filled pore in the centre of the protein. Each subunit has a large extracellular 
domain that forms the ligand-binding site (Boess et al., 1992, Green et al., 1995). 
There is significant structural homology between the 5-HT3 and α7- nACh receptor to 
the extent that chimeric receptors are functional (Eisele et al., 1993). Presently, five 
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distinct 5-HT3 receptor subunits (A-E) have been identified, although C-E have are 
not found to be present in rodents (Holbrook et al., 2009). Subunit combinations 
confer different ion channel properties; for example a receptor formed exclusively of 
5-HT3A subunits have lower single-channel conductance than when a 5-HT3B subunit 
is incorporated (Gill et al., 1995). It is also prone to rapid desensitization. 
 
The ion pore is selectively permeable to Na+ and K+ and when activated causes ion 
influx resulting in fast membrane depolarization. There is some evidence of calcium 
permeability. Co-assembly of 5-HT3 and α7-nAch receptor subunits produce Ca2+ 
permeable channels (van Hooft et al., 1998). Later, evidence of 5-HT3 Ca2+ 
permeability has been reported in hippocampal slices (Van Hooft & Wadman, 2003). 
The authors estimated that at physiological membrane potential (-60mV) the 
percentage of charge carried by Ca2+ was 0.1%. This is very low in comparison to 
NMDA receptors where ~18% of charge is carried by Ca2+ (Schneggenburger, 1996). 
 
 
Distribution 
 
In the PNS 5-HT3 receptors are known to be present on the terminals of many sensory 
afferents. 5-HT3 are thought to be responsible for the peripheral transduction of 
chemically-induced pain (Giordano & Dyche, 1989). When treated with capsaicin  5-
HT3 sites in dorsal horn of the rat spinal cord were found to be reduced (Hamon et al., 
1989). This observation suggests that 5-HT3 receptors are located on C-fibre 
terminals. High densities are also found in autonomic nerves, especially the nodose 
ganglia and the vagus nerve in the cat and rabbit (Hoyer et al., 1989). 
 
The presence of 5-HT3 receptors in the rat brain was first reported with the use of 
radiolabelled GR-65630 (Kilpatrick et al., 1987). The highest density was found to be 
in the brainstem with NTS, DVN and area postrema showing particularly high levels 
of expression (Tecott et al., 1993, Miquel et al., 2002). The receptor is also found in 
the hippocampus, amygdala and regions of the cortex, albeit in lower concentrations 
and virtually no binding in pons, cerebellum, or basal ganglia (Waeber et al., 1989, 
Barnes et al., 1990). 
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Pharmacology 
 
Ligands available for the 5-HT3 receptor display good selectivity, which is most likely 
explained by the low sequence homology with other 5-HT receptor sub-types. 
Phenylbiguanide (PBG) is the archetypal full agonist for the 5-HT3 receptor. 
However, it should be noted that there are interspecies differences with the potency of 
this agonist. Some 5-HT3 ligands, including PBG, displays low affinity for the guinea 
pig receptor (Lankiewicz et al., 1998). The closely related compound mCPBG is 
another highly selective agonist a the 5-HT3 receptor with higher affinity than PBG 
(Kilpatrick et al., 1990). There are also many selective antagonists available; 
granisetron and ondansetron are most commonly used and display high affinity for the 
5-HT3 with little or no affinity to other 5-HT receptors or other binding sites (Sanger 
& Nelson, 1989, Youssefyeh et al., 1992). Volatile anaesthetics such as halothane and 
isoflurane, as well as alcohols, can allosterically modulate 5-HT3 receptors (see 
Davies, 2011). Ethanol is known to stabilize the open time of these receptors leading 
to increased conductance (Feinberg-Zadek & Davies, 2010).  
 
General roles in physiology 
 
The primary clinical application for 5-HT3 receptor ligands is as anti-emetics. 5-HT3 
receptor antagonists ondansetron, granisetron and, recently, palonosetron are all used 
to control emesis associated with drugs used in chemotherapy (Navari & Province, 
2006). These drugs are thought to work at the level of the NTS and/or area postrema 
but peripheral 5-HT3 receptors could be involved given the levels of expression in the 
gut (Glatzle et al., 2002). Secondly, 5-HT3 antagonists are routinely used for the relief 
of irritable bowel syndrome (see Gershon, 2004).  
 
Peripherally, the presence of 5-HT3 receptors on sensory afferents indicated a role in 
transduction of pain. Indeed, pain caused intradermal application of 5-HT is mediated 
by 5-HT3 receptors (see Gershon, 2004). Later, studies have shown that genetic 
deletion of the 5-HT3 receptor reduce responses to persistent pain-states after tissue 
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injury, such a formalin-induced inflammatory pain (Richardson et al., 1985). There is 
also in vivo electrophysiological evidence of 5-HT3 receptors facilitating transduction 
of noxious stimuli in the dorsal and ventral horn of the spinal cord (Zeitz et al., 2002, 
Kayser et al., 2007).  
 
Central actions of 5-HT3 receptors are wide ranging and have been implicated in 
several physiological processes and pathological states. 5-HT3 antagonists and genetic 
deletion of the 5-HT3 receptor has antinociceptive effect in the mouse (Rahman et al., 
2004, Asante & Dickenson, 2010). The amygdala is proposed to mediate these effects 
as microinjection of 5-HT3 agonists into this area have found to have anxiogenic and 
antagonists have anxiolytic effects in rodents (Barnes et al., 1992, Kelley et al., 2003, 
Bhatnagar et al., 2004).  
 
5-HT3 receptors have also been implicated in the control release of neurotransmitters 
acetylcholine and dopamine. Acetylcholine release is under tonic inhibitory control of 
5-HT via 5-HT3 receptors in human and rat cerebral cortex (Higgins et al., 1991).  
Due to this effect, 5-HT3 antagonists have been reported to have cognitive enhancing 
effects and have potential for therapeutic application in Alzheimer’s disease (Maura et 
al., 1992, Crespi et al., 1997). With respect to dopamine, 5-HT3 activation causes an 
increase in dopamine efflux in rat brain slices containing striatum (Fakhfouri et al., 
2012) and nucleus accumbens in vivo (Blandina et al., 1989). Further, 5-HT3 
antagonists reduced the increase in dopamine efflux in the nucleus accumbens 
induced by nicotine, ethanol and morphine (Chen et al., 1991). Ondansetron is known 
to reduced alcohol craving in some alcoholics, presumably by the same mechanism 
(Carboni et al., 1989). 
 
Role in autonomic control 
 
5-HT3 receptor ligands are not known to have any direct effect on vasculature or the 
heart, with the exception of dogs where cardiac 5-HT3 receptor activation causes 
tachycardia (Johnson et al., 2000). Activation of 5-HT3 receptors located on vagal 
afferent terminals in the lungs and the heart cause bradycardia and hypotension. This 
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is known as the cardiopulmonary or von Bezold-Jarisch reflex that causes sympathetic 
withdrawal and an increase in vagal drive (see Ramage & Villalon, 2008).  
 
Centrally, several brainstem nuclei display a particularly high density of 5-HT3 
receptors, suggesting an important role in autonomic regulation. Within this area      
5-HT3 receptors modulating glutamate release seem to account for most of their 
central autonomic functions. Iontophoretic application of PBG to vagal preganglionic 
neurons in the dorsal vagal nucleus causes excitation that was blocked by glutamate 
receptor antagonists (Wang et al., 1996). This suggests that activation of presynaptic 
5-HT3 receptors augments glutamate release. A similar study in the NTS also found 
PBG increased excitability by increasing presynaptic glutamate release (Jeggo et al., 
2005). Consistent with this, 5-HT3 antagonist granisetron attenuated the 
cardiopulmonary reflex when microinjected in the NTS (Pires et al., 1998). Also 
consistent with 5-HT3 receptors controlling glutamate release in the NTS, using in 
vivo microdialysis, extracellular glutamate was found to increase in response to local 
infusion of PBG (Ashworth-Preece et al., 1995). However, there have been some 
reports showing that activation of the 5-HT3 receptors in the NTS also cause 
attenuation of the bradycardia associated with the baroreflex, cardiopulmonary reflex 
and chemoreflex (Merahi et al., 1992, Sevoz et al., 1996, Sevoz et al., 1997). The 
effects on the baroreflex and the chemoreflex were attenuated by bicuculline 
suggesting  5-HT3 activation can cause inhibition via a GABAergic mechanism. 
 
Data from in vitro slice preparations also confirm an excitatory role of 5-HT3 
receptors modulating glutamate release in the NTS. The first report of the properties 
of 5-HT3 activation in the NTS showed both pre and postsynaptic effects. The authors 
showed that application of 5-HT and 2-CH3-5-HT caused depolarisation even in the 
presence of glutamate antagonists and when release was blocked with cobalt (Glaum 
et al., 1992). Later, it was shown that presynaptic 5-HT3 receptors were tonically 
active in the NTS slice as glutamate release decreased in the presence of 5-HT3 
antagonist ondansetron (Wan & Browning, 2008). Interestingly, this effect was 
abolished by vagotomy suggesting vagal afferent terminals expressed the 5-HT3 
receptors and/or release 5-HT. Conversely, 5-HT3 activation has been shown to have 
inhibitory effects in the rat and mouse NTS slice (Takenaka et al., 2011, Cui et al., 
2012). When stimulating the solitary tract the resultant EPSP amplitude was reduced 
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in the presence of 5-HT3 agonists 2-CH3-5-HT and SR-57227, this effect was 
antagonised by 5-HT3 blockade. Both studies found that 5-HT3 activation caused 
large increases in spontaneous release of glutamate so it seems 5-HT3 has two distinct 
modulatory effects. The latter study theorised that the increase in spontaneous activity 
depletes the releasable pool of glutamate reducing that available to be released with 
stimulated. 
1.4.6. 5-HT4, 5-ht5 and 5-HT6 receptors 
 
5-HT4 receptors 
 
First reported in 1988, 5-HT4 receptors showed a distinct pharmacological profile to 
other 5-HT receptors positively coupled to adenylyl cyclase. The human 5-HT4 gene 
has ten functional spice variants reported to date but all display similar pharmacology 
(Dumuis et al., 1988).  
 
Distributed peripherally mainly in the gut and heart where they have been found to 
mediate contractility of smooth muscle. In the CNS 5-HT4 receptors are mainly found 
postsynaptically in limbic areas, with maximal expression in the basal ganglia 
(Bockaert et al., 2008).  
 
Selective ligands are available and include agonists BIMU 8 (potent full-agonist), 
tegaserod (partial agonist) and zacopride (mixed 5-HT4 agonist/ 5-HT3 antagonist). 
Selective, high-affinity antagonists include GR-113808, SB-204070 and RS-100235.  
 
5-HT4 receptors function to modulate the release of several neurotransmitters and 
enhance synaptic transmission. Strong roles in learning and memory have been 
proposed as many studies have shown cognitive improvement associated with 
increased 5-HT4 activation (Varnas et al., 2003).  
 
 
 55 
5-ht5 receptors 
 
Despite being discovered more than 20 years ago the 5-ht5 still exists as only a gene 
product. In order to signify the lack of identified physiological roles the abbreviation 
is written in lower case. Two sub-types have been identified (5-ht5a/b), although the 5-
ht5b gene is likely to encode a non-functioning protein in humans, the rodent gene 
does appear to encode a functional protein. The method of signal transduction for this 
receptor is unknown with conflicting reports in expression systems of possible 
inhibition of adenylyl cyclase, presumably via Gi (Bockaert et al., 2004).  
 
Distribution of the receptor is unclear due to lack of selective ligands precluding 
autoradiography. 5-ht5 mRNA in the human brain was found cortex, hippocampus, 
amygdala and cerebellum (Francken et al., 1998, Grailhe et al., 2001). 
 
Selective ligands are non-existent (see Ramage, 2004) but 5-CT is a 5-ht5 agonist and 
SB-699551-A is a putative antagonist with a 30-fold selectivity for human 5-HT5A but 
has affinity to 5-HT transporter at 10 times higher concentrations (Pasqualetti et al., 
1998).  
 
Possible roles have been suggested in regulation of circadian rhythm, however lack of 
selective ligands makes interpretation difficult (Thomas, 2006). Further, genetic 
deletion of 5-ht5A receptors in mice display increased exploratory activity and altered 
response to LSD, which is a 5-ht5A ligand (Sprouse et al., 2004). 
 
5-HT6 receptors 
 
Originally cloned in rat, the 5-HT6 receptor is a G-protein coupled receptor that 
activates adenylyl cyclase (Grailhe et al., 1999). There is only one functional isoform 
of this receptor produced. In situ hybridization of 5-HT6 mRNA in the rat brain 
reveals a distribution confined to the CNS. In order of decreasing density; olfactory 
tubercle, entorhinal cortex, dentate gyrus, hypothalamus, amygdala and substantia 
nigra were all found to contain 5-HT6 transcripts (Ruat et al., 1993a). Later, 
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immunohistochemistry and radioligand binding were used to confirm this distribution 
(Gerard et al., 1997). 
 
There has been a range of high affinity ligands developed for the 5-HT6 receptor. 
Agonists include EMDT and EMD-386088 which are reasonably selective for 5-HT6 
receptors. Recently, ST-1936 has been reported as a high affinity, selective agonist 
(Hamon et al., 1999). Highly selective antagonists are also available which include 
Ro 04-6790 and SB-271046. Many clinically used antipsychotic and antidepressant 
drugs also share affinity with the 5-HT6 receptor, for example clozapine and 
imipramine (Riccioni et al., 2011).  
 
5-HT6 receptor have been shown to be involved in many animal models of cognitive 
function (Monsma et al., 1993). 5-HT6 antagonists have been shown to enhance the 
release of monoamines, glutamate and acetylcholine that can be associated with 
improvements in memory function (Fone, 2008). This has generated a significant 
amount of interest for 5-HT6 antagonists in the treatment of Alzheimer’s disease and 
some have entered clinical trials (Lacroix et al., 2004, Kendall et al., 2011). 
 
1.4.7. 5-HT7 receptors 
 
The 5-HT7 receptor is the most recently identified class in the 5-HT receptor family. 
First reported as an unknown 5-HT receptor active in the vena cava of the swine 
(Trevethick et al., 1984). It was later found to be positively coupled to adenylyl 
cyclase and activated by 5-CT (Trevethick et al., 1986). This novel pharmacology 
distinguished it from other identified 5-HT receptors at the time. Later, three 
independent groups cloned the receptor from the rat and human, confirming the 
existence of a separate class of 5-HT receptor (Sumner et al., 1989). Since then it has 
been cloned in a wide variety of species including mouse, guinea pig, C. elegans, 
Xenopus laevis and honeybee (Bard et al., 1993, Lovenberg et al., 1993, Ruat et al., 
1993b).  
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Molecular Biology  
The gene encoding the 5-HT7 is found on the chromosome 10q23.3-q24.4 and 
contains three introns (Matthys et al., 2011). Splice variants from second and third 
introns have been found to generate 5 receptor isoforms, 5-HT7a–e (Heidmann et al., 
1997). All isoforms are functionally active and no differences in pharmacology or 
signal transduction properties have been reported (Liu et al., 2001). Receptor 
isoforms differences are all located in the C-terminus of the receptor possibly 
regulating trafficking (Heidmann et al., 1998, Krobert et al., 2001) 
Distribution 
 
The 5-HT7 receptor has been found to be expressed in the CNS, PNS and in 
peripheral tissues. In the CNS autoradiography with [3H]-5-CT combined with in situ 
hybridization found strongest binding in the lateral/medial septum, amygdala and 
some areas of thalamus. There were lower levels found in cortex, hippocampus and 
hypothalamus and substantia nigra. Low binding was also observed in dorsal raphé, 
periaqueductal grey, pontine nuclei, NTS, and dorsal horn of the spinal cord (Guthrie 
et al., 2005). Further, one study multiple approaches were used to show the presence 
of 5-HT7 receptors in the CNS (Gustafson et al., 1996). The authors used c-fos 
expression induced by 8-OH-DPAT in the presence of WAY-100635 coupled with a 
5-HT7 antibody to double-label 5-HT7 expressing neurons. This approach greatly 
reduced the possibility of immuno-cross reactivity giving rise to false-positive 
labeling. 5-HT7 immunoreactivity was found in cortex, thalamus, hypothalamus, and 
hippocampus. This largely agreed with the earlier study. Expression of 5-HT7 seems 
to be strongest in limbic areas but it is also expressed in those involved in central 
cardiovascular control, such as the NTS.  
 
Pharmacology 
 
Until recently, there has been paucity of selective 5-HT7 agonists. Two compounds 
have been identified as putative 5-HT7 selective agonists; LP 12 and LP 44 (Neumaier 
et al., 2001). These compounds show >100-fold selectivity over 5-HT1A receptor. 
Unfortunately little data exists from their use as selective 5-HT7 agonists and both 
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compounds are poorly soluble in water. Most studies to date have used non-selective 
agonists 5-CT and 8-OH-DPAT. 5-Carboxamidotryptamine (5-CT) seems to have the 
highest affinity (pKi 9.1 at human 5-HT7(a)). 8-OH-DPAT also has moderate affinity 
with pKi 6.6 at human 5-HT7. For comparison, 5-HT itself displays a receptor affinity 
of 8.1. Unfortunately, both 5-CT and 8-OH-DPAT have agonist activity at 5-HT1A 
and 5-CT also has additional agonist activity at 5-HT1B and 5-HT1D receptors. Indeed, 
many affects originally thought to be mediated by these receptors are now being re-
assessed to 5-HT7 mediated (Leopoldo et al., 2004, Leopoldo et al., 2007).  
 
More recently, highly selective antagonists of the 5-HT7 receptor have been reported. 
The first to display greater than 100-fold selectivity over other 5-HT receptors was 
SB-258719 (Eglen et al., 1997). This compound has a pKi of 7.5, antagonists with 
higher affinity are available but the water solubility of this compound makes it more 
convenient for certain experimental designs. Later, SB-269970 was developed with a 
higher affinity having a pKi of 8.9 at human 5-HT7(a) receptors (Forbes et al., 1998). 
However, as mentioned in section 1.4.7, SB-269970 has only a 50-fold selectivity 
over 5-HT5A receptors (Lovell et al., 2000). 
General Roles in Physiology 
 
Given the distribution of 5-HT7 receptors in the supra-chiasmatic nucleus (SCN) it is 
unsurprising that one of the first identified roles is that in circadian rhythms. Sleep-
wake cycle, body temperature, hormone release and behavioural patterns are all 
synchronized to the light/dark cycle by the SCN. The SCN receives 5-HT input from 
the dorsal raphé via the median raphé nucleus (Hagan et al., 2000). 8-OH-DPAT 
induced a phase-shift in SCN neuronal activity that was antagonised by ritanserin (5-
HT2/7 antagonist) but not pindolol (Glass et al., 2003). This was confirmed in vivo the 
more selective 5-HT7 antagonist DR4004 (Lovenberg et al., 1993). 
 
5-HT7 receptors expressed in the dorsal raphé have been shown to control the release 
of 5-HT in the SCN. Pharmacological and electrical stimulation of the dorsal raphé 
and median raphé nuclei caused increases in extracellular 5-HT concentration in the 
SCN, measured by in vivo microdialysis. Microinjection of the 5-HT7 antagonist 
DR4004 in the dorsal raphé or median raphé reduced the efflux of 5-HT in the SCN 
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(Ehlen et al., 2001). Thus, 5-HT7 receptors control the SCN by regulating the supply 
of 5-HT and directly as it is expressed on cells within the SCN. It should, however, be 
noted that DR4004 has agonist activity at the D2 receptor (Glass et al., 2003).  
The suppression of 5-HT release was attenuated by bicuculline, which suggests that 5-
HT7 activation leads to inhibition of GABA interneurons. In turn, this reduces GABA 
release and reduces the inhibitory tone on 5-HT neurons. Immunohistochemical 
analysis also indicates that 5-HT7 may be located on GABA interneurons and not the 
5-HT-containing neurons themselves (Kogan et al., 2002). 
 
The role of 5-HT7 in thermoregulation was used an effective screen for compounds 
with 5-HT7 activity. 5-CT induced hypothermia in guinea pigs and was used to 
characterize SB-269970 as a selective 5-HT7 antagonist (Duncan et al., 2001). This 
role was confirmed in a comprehensive study using multiple drugs and 5-HT7 knock 
out animals (Hagan et al., 2000). 
The possibility of 5-HT7 receptors as a target for anti-depression was due to their 
ability to modify REM sleep patterns similar to those of known anti-depressant drugs. 
Genetic deletion or antagonism of the 5-HT7 receptor was shown to increase 
antidepressant-like behavior in two models of depression, the forced swim test and 
tail suspension test (Guscott et al., 2003). Recently, the use of 5-HT7 antagonists as an 
adjunct to classical antidepressant drugs to reduce the clinical latency associated with 
these treatments. It was found that SB-269970 enhanced the effect of a number of 
monoamine re-uptake in the forced swim test (Hedlund et al., 2005, Wesolowska et 
al., 2006).  
 
Role in Autonomic Control 
 
Little was known regarding the role of 5-HT7 receptor in central autonomic control 
due to a lack of selective ligands and the relatively late discovery of the receptor 
itself. 5-HT7 is expressed in peripheral tissues such as vasculature and heart as well as 
brain nuclei involved in cardiovascular regulation.  
 
 60 
5-HT7 receptors are known to be expressed in vascular smooth muscle and when 
activated cause dilatation (Wesolowska et al., 2007). Additional peripheral activity 
was found in the cat where activation 5-HT7 on the heart caused tachycardia 
(Centurion et al., 2004).  
 
When administered centrally SB-269970 was found to have no effect on resting blood 
pressure. However, this compound was first found to inhibit the micturition reflex in 
anaesthetised rats (Read et al., 2003) Further, it was also found to inhibit vagal 
bradycardia associated with baroreceptor, cardiopulmonary and chemoreceptor reflex 
activation in anaesthetised and unanaesthetised rats (Kellett et al., 2005, Damaso et 
al., 2007). The receptors involved were believed to be in the NTS and a later study 
reported evidence that 5-HT7 receptors mediated transmission in the NTS (Oskutyte et 
al., 2009). 
 
 
1.5. Neurotransmitter reuptake 
 
Background 
 
The effect of all neurotransmitters is terminated by either removal from the site of 
action by uptake proteins or degradation to non-active compounds by enzymes. The 
neurotransmitter acetylcholine (ACh) is an example of termination by enzyme. This 
fast-acting transmitter requires an enzyme with an extremely high turnover rate to 
terminate the action of ACh. Indeed, acetylcholinesterase has one of the highest 
turnover rates of all enzymes known in mammalian physiology and is capable of 
converting ACh to choline and acetate at a rate of 25,000 per second (see Quinn, 
1987). The choline is then transported back into cells via a high affinity 
plasmalemmal transporter where it can be recycled (Apparsundaram et al., 2000). On 
the other hand, transmitters like glutamate, GABA, 5-HT, dopamine and 
noradrenaline are taken up into cells before being degraded (Masson et al., 1999). The 
advantage here is that, once inside the presynaptic terminal the molecule can be re-
packaged in vesicles ready for release. Experiments performed with tritiated 
adrenaline and noradrenaline found that when these were injected into the circulation 
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of experimental animals 30-40% was taken into tissues where it remained unchanged 
(Axelrod et al., 1959, Whitby et al., 1961). This concept of re-uptake was explored 
further in the brain first using slices of cortical tissue (Dengler et al., 1961). The 
authors concluded that there was an active process concentrating noradrenaline into 
the tissue. Further, this uptake of noradrenaline was shown to be sensitive to 
extracellular sodium and chloride ion concentrations (White & Keen, 1970). These 
were some of the first reports of the high affinity, low capacity re-uptake system we 
now know as DAT (dopamine transporter; SLC6A3), NET (noradrenaline transporter; 
SLC6A2), SERT (5-HT transporter (5-HTT); SLC6A4). Another re-uptake system 
was discovered in the isolated rat heart when perfusion of tritiated noradrenaline 
resulted in grater than proportional increase in rates of uptake at higher concentrations 
(Iversen, 1965). This system was found to be insensitive to known re-uptake 
inhibitors and, as such, was named ‘Uptake 2’. This was later found to be part of the 
OCT (SLC22) family of transporters. This constituted a low affinity but high capacity 
re-uptake system and is know to include PMAT (SLC24). It is important to note that 
PMAT is distinct to VMAT that serves to package monoamines into vesicles and is 
not directly responsible for removing them from the extracellular medium. 
 
Once taken up into tissues monoamines are metabolized by catechol O-
methyltransferase (COMT) and a family of similar enzymes known as monoamine 
oxidases (MAO). These enzymes breakdown all monoamines but these are primarily 
in the cytoplasm so do not terminate the action of monoamines at their receptor. 
However, there is some evidence that COMT in directly involved in the termination 
of dopamine in brain areas with low DAT expression (Matsumoto et al., 2003). 
 
1.5.1. 5-HT transporter (SLC6A4) 
 
Molecular biology 
 
The 5-HT transporter was first cloned in 1991 from an RNA that is associated with   
5-HT-rich regions of the midbrain and brainstem (Blakely et al., 1991). Upon 
expression, this 12 transmembrane domain protein was found to transport 5-HT via a 
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sodium dependent mechanism that is sensitive uptake inhibitors such as paroxetine, 
citalopram and fluoxetine. This transporter, like all others in the SLC6 family, is a co-
transporter and uses the extracellular sodium gradient to drive uptake (Nelson, 1998). 
Sodium is absolutely required for transport to occur. Chloride and potassium ions are 
also co-transported with a predicted stoichiometry of 1 5-HT:1 Na+ :1Cl- (in) and 1 K+ 
(out) but their presence is not required for reuptake to occur (Talvenheimo et al., 
1983). These transporters can also operate in reverse if the intracellular concentration 
of 5-HT is increased and facilitate 5-HT efflux from the nerve terminal under certain 
conditions. Interestingly, the 5-HT transporter has been shown to internalize upon 
activation of PKC, which will decrease 5-HT re-uptake (Bauman et al., 2000).  
 
 
Distribution 
 
The 5-HT transporter has a wide distribution in both brain and the periphery. 
Peripherally, 5-HT transporters are known to be expressed in platelets where they 
sequester 5-HT from the plasma (Sneddon, 1973). They are also present in areas with 
high concentrations of 5-HT such as pulmonary epithelia and enteric system.  
 
Autoradiography with 5-HT re-uptake inhibitor [3H]- citalopram showed dense 
binding in midbrain, hypothalamus and to a lesser extent in the medulla, hippocampus 
and lowest in the cerebellum (D'Amato et al., 1987). However, this protocol displayed 
high (~30%) non-specific binding so resolution was poor. Later, one study optimized 
the binding conditions with [3H]- paroxetine and found highest density binding in the 
dorsal raphé with decreasing levels in the locus coeruleus, substantia nigra, amygdala 
and hippocampus (Chen et al., 1992). Immunohistochemistry revealed a similar 
distribution of 5-HT transporter protein binding (Qian et al., 1995). There is a lack of 
binding data in the rat brainstem, especially the NTS. However, one study found the 
presence of the 5-HT transporter on axon terminals in the medial NTS (Huang et al., 
2004). Additionally, human studies found 5-HT transporter-like binding sites in the 
brain stem (Schain et al., 2013). 
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Investigation into the subcellular location of the 5-HT transporter has found evidence 
of expression on axons as well as 5-HT-containing terminals (Zhou et al., 1998). 
Further, using electron microscopy, evidence for low plasma membrane soma-
dendrite expression of these transporters but high expression along the axon plasma 
membrane (Tao-Cheng & Zhou, 1999). These extrasynaptic 5-HT transporters 
support the view that 5-HT is also a volume transmitter. 
 
5-HT transporter expression is thought to be almost exclusively neuronal in the brain 
with no evidence thus far of glial expression of any SLC6 monoamine transporter, 
unlike GABA and glycine transports in the same class (see Torres et al., 2003, 
Kristensen et al., 2011).  
 
Pharmacology 
 
The first drugs available as 5-HT transporter antagonists were tricyclic 
antidepressants (TCAs) were developed in the 1950’s (see Andersen et al., 2009). 
TCAs displayed poor selectivity over other SLC6 monoamine transporters and 
especially over the noradrenaline transporter (see table 1.1). Their widespread use in 
the treatment of affective disorders, such as depression, lead to intense research into 
more selective reuptake inhibitors. This paved the way for the development of so-
called selective serotonin re-uptake inhibitors (SSRIs; Wong et al., 1974). Despite 
their name, this drug class also prevents the re-uptake of noradrenaline and dopamine 
to a greater or lesser extent. Paroxetine has the highest potency at the 5-HT 
transporter but not the highest selectivity (table 1.1 and 1.2). Citalopram, while not 
the most potent, is the most selective for the 5-HT transporter over the noradrenaline 
transporter and dopamine transporter. Interestingly, fluoxetine is the least selective 
displaying significant affinities for the noradrenaline transporter. Re-uptake inhibitors 
are often used to confirm the identity of electrochemical signals but given the 
selectivity of the drugs available, their use should be carefully considered (Phillips & 
Wightman, 2003). 
 
The main use of these drugs is in affective disorders such as depression, anxiety and 
post-traumatic stress disorder (see Andersen et al., 2009). The biochemical actions 
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(increasing extracellular 5-HT) of these drugs are not directly linked with their 
clinical effectiveness. Indeed, initial increases in extracellular 5-HT will activate 
autoreceptors, especially in the dorsal raphé leading to a decrease in 5-HT release in 
the terminal fields (see Artigas et al., 1996). Additionally, whereas the 
pharmacological effect of these drugs occurs in matter of minutes clinical latency is at 
least three weeks. This suggests additional mechanisms underlying their clinical 
action which have been extensively reviewed elsewhere (Castren, 2005). 
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Table 1.1 Pharmacological profiles of re-uptake inhibitors 
 
Comparison of inhibition constants at cloned human 5-HT, noradrenaline and 
dopamine transporters of a range of monoamine transporter antagonists. Compounds 
are ranked according to potency at the human 5-HT transporter.  
 
 
 
Values taken from (Tatsumi et al., 1997) unless otherwise stated, b(Deecher et al., 
2006), cdata from rat (Andersen, 1989). 
 Compound KD (nM)
a 
h5-HTT hNET hDAT 
Highest Paroxetine 0.13 40 490 
 Clomipramine 0.28 38 2190 
 Sertraline 0.29 420 25 
 Fluoxetine 0.81 240 3600 
 Duloxetine 1 8 240 
 Citalopram 1.16 4070 28100 
 Imipramine 1.4 37 8500 
 Fluvoxamine 2.2 1300 9200 
 Desipramine 17.6 0.83 3190 
 Reboxetine  242b 3b >10000b 
 Cocaine 340 1420 220 
Lowest GBR12909  >100 >100 1c 
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Table 1.2 Selectivity of monoamine re-uptake inhibitors  
 
Comparison of the selectivity of a range of monoamine reuptake inhibitors from 
Table 1.1. Compounds are ranked according to selectivity at the 5-HT transporter 
over the noradrenaline transporter.  
 
 
 Compound Selectivity Quotienta 
Ratio  
5-HTT:NET 
Ratio  
5-HTT:DAT 
Ratio  
NET:5-HTT 
Highest Citalopram 3508.62 24224.1 0.0003 
 Sertraline 1448.28 86.2 0.0007 
 Fluvoxamine 590.91 4181.8 0.0017 
 Paroxetine 307.69 3769.2 0.0033 
 Fluoxetine 296.30 4444.4 0.0034 
 Clomipramine 135.71 7821.4 0.0074 
 Imipramine 26.43 6071.4 0.04 
 Duloxetine 8.00 240.0 0.13 
 Cocaine 4.18 0.6 0.24 
 Desipramine 0.05 181.3 21.21 
 Reboxetine  0.01 N/A 80.67 
Lowest GBR12909 N/A N/A N/A 
 
aSelectivity quotient is calculated as the ratio of the KD’s for each compound at each 
transporter.  
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Role in autonomic control 
 
Their effect on central autonomic control have not been extensively investigated. The 
effects observed are consistent with the acute effect of re-uptake inhibitors on 
transmitters involved in autonomic reflexes. The monoamine re-uptake inhibitor 
fluoxetine was found to potentiate bronchoconstriction, which is facilitated by 5-HT1A 
activation, when applied centrally to the guinea pig (Bootle et al., 1998). Further, 
baroreflex enhancement after repeated fluoxetine administration was reported in rats 
(Moffitt & Johnson, 2004). Another more recent study examined chronic fluoxetine 
treatment in an animal model of chronic heart failure (Henze et al., 2013). Autonomic 
changes were found in rats that received sham surgery indicating fluoxetine treatment 
alone causes reduced sympathetic and vagal drive. In animals with chronic heart 
failure fluoxetine compounded the already reduced control of normal sinus rhythm, 
possibly by desensitization of cardiac β-receptors. The latter effect could be explained 
by peripheral noradrenaline re-uptake inhibition.  
 
In humans fluoxetine rectified the decreased heart rate variability seen in patients with 
post-traumatic stress disorder (Cohen et al., 2000). Decreased heart rate variability 
indicates increased sympathetic tone, which is consistent with increased feelings of 
stress. It remains to be determined whether fluoxetine had a direct effect on 
sympathetic tone or indirectly by reducing stress-induced sympathoexcitation. 
Alternatively, no differences in autonomic variables were found when compared to 
depressed patients on two classes of monoamine reuptake inhibitors (Sattler et al., 
2000) and after sertraline administration in healthy volunteers (Ahrens et al., 2007). 
The noradrenaline re-uptake inhibitor reboxetine was found to increase heart rate in 
human subjects however reboxetine has anti-muscarinic activity that could account 
for this effect (Penttila et al., 2001). 
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1.5.2. Organic cation transporter 
 
Molecular biology 
 
The presence of ‘Uptake 2’ in the cloned cell line Caki-1 derived from human renal 
cell carcinoma was the first step in the molecular characterization of this class of 
transporters (Schomig & Schonfeld, 1990). The authors were the first to draw a 
parallel between the previously identified ‘Uptake 2’ in cardiac tissue and an organic 
cation transport system in the kidney. Later, this organic cation transporter was cloned 
from the rat kidney (OCT1; Grundemann et al., 1994). Since the cloning of rOCT1 
two additional isoforms of the organic cation transporter have been discovered; OCT2 
and OCT3 (Okuda et al., 1996, Grundemann et al., 1998). These transporters are part 
of the SLC22 transporter family (see Koepsell & Endou, 2004). OCTs are 500-600-
amino acid membrane proteins with a predicted 12 transmembrane spanning domains, 
a large glycosylated extracellular loop and a large intracellular loop. Both loops have 
sites for glycosylation and phosphorylation possibly used for regulation. Transport is 
known to be independent from sodium concentration, electrogenic and driven solely 
by the electrochemical gradient of the substrate (see Ciarimboli & Schlatter, 2005).  
 
Distribution  
 
OCT1 and 2 are mainly expressed in the periphery. OCT1 is found in the liver of rat, 
mouse rabbit and human. Additionally, rodent OCT1 is found in kidney, small 
intestine, colon, skin and spleen (see Koepsell & Endou, 2004). OCT2 in rats and 
humans has been found to be mainly expressed in the kidney on the proximal tubules 
(Karbach et al., 2000, Motohashi et al., 2002). OCT3, on the other hand, has a wide 
distribution including heart, liver, kidney and CNS (Wu et al., 1998). OCT3 was 
formally known as extraneuronal monoamine transporter due to original discovery 
transporting neurotransmitters in non-neuronal tissues. However, subsequent 
investigation has found OCT3 expression on neuronal tissue (Verhaagh et al., 1999). 
Central expression of OCT3 is highest in areas rich in monoamines. OCT 3 is the 
primary OCT expressed in the brain and in situ hybridization found mRNA the 
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cerebellum, dorsal raphé, hypothalamic nuclei, cortex and hippocampus (Amphoux et 
al., 2006). In mice OCT3 mRNA has been found exclusively in neuronal cells types 
in the hippocampus and cerebellum, other areas were not investigated (Schmitt et al., 
2003). Interestingly, the authors found that OCT3 mRNA was up-regulated in 5-HT 
transporter knock-out animals supporting overlapping roles of the two transporters. 
However, immunohistochemistry has found OCT3 expressed on glial-like structures 
in the dorsomedial hypothalamic nucleus and striatum of the rat (Gasser et al., 2006, 
Cui et al., 2009). 
Pharmacology 
 
Most of the following data is from cloned human OCTs expressed in heterologous 
expression systems. OCT sequence homology is approximately 80% across species so 
binding data is expected to be comparable in rat models (see Shu, 2011). 
 
OCT3 has a pharmacological profile distinct to that of 5-HTT, DAT and NET. OCT3 
is insensitive to monoamine re-uptake inhibitors such fluoxetine, citalopram. 
However, TCA’s such as desipramine and imipramine have been shown inhibit MPP+ 
reuptake via OCT3 at concentrations above 10µM in human retinal pigment epithelial 
cells (Wu et al., 2000). OCT3 is often defined by its sensitivity to steroids. Indeed, 
corticosterone, progesterone and β-estradiol have all been shown to be inhibitors in 
the low µM-range. Corticosterone is the most potent at OCT3 with IC50 0.29µM 
followed by β-estradiol (2.88) and progesterone (4.28) measured by inhibition of 
MPP+ uptake by OCT3 expressed in HEK cells (Hayer-Zillgen et al., 2002). The 
most potent inhibitors of OCT3 belong to a class of compounds known as 
isocyanines. The first reported is decynium-22 (D-22) with an IC50 90nM measured 
by inhibition of MPP+ uptake by OCT3 expressed in HEK cells (Schomig et al., 
1993, Hayer-Zillgen et al., 2002). D-22 is the most commonly used inhibitor of 
OCT3, however there is little data regarding selectivity of these compounds. There is 
evidence that D-22 is also a α1-adrenoceptor antagonist as it lowers blood pressure in 
anesthetised rabbits (Russ et al., 1996). The same study found that D-22 has a 
relatively short half-life of approximately 9 minutes. Interestingly, D-22 was also 
shown inhibit baroreflex responses to this hypotension possibly by blockade of central 
α1 receptors as D-22 has little affinity for the β- adrenoceptor (Konigs et al., 1996). 
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Interestingly, some drugs of abuse are known to block OCT3 including MDMA, 
ketamine and phencyclidine (Amphoux et al., 2006) but not amphetamine (Zhu et al., 
2010).  
Function 
 
OCTs have a wide range of substrates both synthetic and endogenous (for references 
see Shu, 2011). TEA and MPP+ are readily transported substrates of OCTs and have 
been used to characterise these transporters. Some clinically used drugs have also 
found to be substrates such as metformin, pindolol and propranolol. Endogenous 
substrates include dopamine, adrenaline, noradrenaline and histamine. These 
transports display low affinity (Km) for the endogenous substrates, however they have 
extremely high transport rates (Vmax) making them efficient at removing high 
concentrations of these neurotransmitters from the extracellular medium, particularly 
OCT3 (Amphoux et al., 2006). 
 
Within the brain these transporters have been proposed to work in concert with the 
high-affinity transporters 5-HTT, NET and DAT allowing control of extracellular 
monoamines over a wide range of concentrations (Gasser et al., 2009, Duan & Wang, 
2010). A scheme for the 5-HT clearance has been proposed that incorporates high-
affinity monoamine transporters and OCT3 (Daws, 2009). At low concentrations 
(nM) of 5-HT, the 5-HTT provides the primary means of clearance, while at higher 
concentrations OCT3 takes over (see figure 1.4). Also of note is the possibility of 
other transporters capable of removing 5-HT at high concentration, so-called 
promiscuous transport. In this respect it has been shown, under certain conditions, that 
DAT and NET can transport 5-HT from the extracellular medium (Stamford et al., 
1990, Daws et al., 1998). From this, it is seems that OCT mediated clearance of these 
transmitters occurs only when concentration are high for example during periods of 
intense stimulation (Bunin & Wightman, 1998) or when the high-affinity transport 
has been compromised by drugs or genetic deletion (Baganz et al., 2008, Wultsch et 
al., 2009, Daws et al., 2013). However, synaptic concentrations of 5-HT have been 
calculated to be ~6µM, which was sufficient to saturate 5-HTT (Daws, 2009) so 
OCTs could be responsible for removal of 5-HT under normal physiological 
conditions.  
 71 
 
 
OCT3 in the brain may play a role in volume or ‘paracrine’ transmission mediated by 
monoamines. Unlike traditional point-to point transmission where the pre-synaptic 
terminal is closely apposed to the post-synaptic receptors volume transmission is not 
confined to the synaptic cleft (see Bunin & Wightman, 1999, Fuxe et al., 2005). 
OCT3 may control the spread of monoamines outside the synaptic cleft when the 
capacity of the high-affinity transporters is exceeded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 5-HT clearance by monoamine transporters 
 
Predicted clearance rate of 5-HT from the extracellular medium against concentration. 
The function is polynomial due to the presence of two uptake systems; one high 
affinity, low capacity and one low affinity but high capacity (Bunin & Wightman, 
1998).  
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1.5.3. Plasma membrane monoamine transporter  
(PMAT; SLC29A4) 
 
First cloned in 2004 from the human brain PMAT was shown to be a low-affinity but 
high capacity transporter of monoamines (Engel et al., 2004, Engel & Wang, 2005). 
PMAT is identified as a sodium-independent, electrogenic cation transporter with a 
wide range of substrates. The protein contains 530 amino acids with 10-12 
transmembrane domains, very similar to the OCT family. Similarly, both PMAT and 
OCTs are sensitive to decynium-22 blockade (Hayer-Zillgen et al., 2002, Engel et al., 
2004). However, the same studies found that PMAT was insensitive to the steroid 
corticosterone, unlike OCTs (Engel & Wang, 2005). Direct comparison of transport 
efficiency (Vmax/Km) between human OCT3 and PMAT expressed in HEK cells found 
that 5-HT and dopamine were preferentially taken up by PMAT. Alternatively, OCT3 
has a higher preference for histamine, noradrenaline and adrenaline over other 
biogenic amines (Duan & Wang, 2010). The same study found that PMAT was 
insensitive to inhibitors of high-affinity monoamine transporters such as citalopram, 
GBR-12909 and desipramine. An earlier study substantiated this by showing a range 
of antidepressant and antipsychotic drugs had IC50’s of 10-20µM at the human PMAT 
(Haenisch & Bonisch, 2010). 
 
PMAT distribution has been investigated in mouse and rat brain (Dahlin et al., 2007, 
Vialou et al., 2007). The authors reported PMAT to be widely distributed throughout 
the brain and not necessary associated with monoamine pathways, indeed it was 
completely absent from the rat substantia nigra. Significant expression in the rat 
brainstem was found with the NTS, DVN and hypoglossal nucleus displaying high 
immunoreactivity. Expression of PMAT has been reported to be primarily neuronal. 
Cells double-labeled with glial fibrillary acidic protein and PMAT were not observed 
in any great number in the mouse brain (Dahlin et al., 2007). However, there is 
evidence PMAT expression in cultured human astrocytes where they mediate 
histamine transport (Yoshikawa et al., 2013).  
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1.6. The autonomic nervous system 
 
1.6.1. The nucleus tractus solitarus (NTS) 
 
Background 
 
The nucleus responsible for orchestrating the cardiovascular reflexes is the NTS and 
is the site at which a range of visceral afferent fibres terminate. This nucleus is 
understood to play a central role in autonomic function. One interesting clinical 
example illustrating this role has been described (Biaggioni et al., 1994). This case 
report describes a patient presenting with a complete absence of tachycardia in 
response to hypotension caused by i.v. nitroprusside. Post-mortem histological 
analysis of the patient’s brainstem showed bilateral damage to the NTS alone.  
 
Anatomy 
 
It is located on the dorsal surface of the brainstem with the midpoint at the level of the 
area postrema (AP). The NTS extends caudally from the calamus scriptorius and 
rostrally from obex. There are three subdivisions; rostral, intermediate and caudal (to 
the calamus scriptorius). Vagal and glossopharyngeal afferents are contained within a 
single tract running parallel to the NTS, the solitary tract. Vagal afferents terminate in 
the caudal two thirds of the nucleus whereas the glossopharyngeal afferents terminate 
in the rostral two thirds (Cottle, 1964). This data implies a large overlapping area in 
the intermediate zone of the NTS, a site of cardiovascular integration. More detailed 
mapping studies of the NTS have ensued and will be discussed below.  
 
Cells contained within the NTS have been shown to have a low degree of 
convergence with respect to input. One study stimulated the carotid sinus, aortic and 
vagal nerves and found that ~85% of cells recorded responded from only one input 
(Donoghue et al., 1985). This data suggests that inputs use distinct, separate neuronal 
‘channels’ for each input type. A further study in the brainstem slice found that just 
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over 60% of cells within the NTS received only one input form the solitary tract 
(McDougall et al., 2009). Input to the NTS has been shown to be highly reliable 
operating in multiple redundancies. For example, upon entering the NTS one 
pulmonary afferent branches and forms approximately 40 varicosities around a single 
NTS cell (Anders et al., 1993, Kubin et al., 2006). Electrophysiological studies have 
estimated that one EPSC recorded in a second-order NTS cell is a result of an average 
of 20 release sites (Andresen & Peters, 2008, McDougall & Andresen, 2013). This 
organization makes the primary afferent input extremely reliable. The release 
probability at these synapses is extremely high when compared to others in the brain 
(Doyle & Andresen, 2001).  
 
Subsequent to the afferent primary termination in the NTS onto second-order cells a 
variety of projections are possible (see figure 1.5). Projection to higher order neurons 
can occur before exiting the NTS allowing further processing of inputs. There is also 
the presence of interneurons adding another layer of complexity to these connections 
and are both excitatory and inhibitory (Izzo et al., 1992). It should also be noted that 
there is a diverse array of neurotransmitters acting to modulate the excitatory and 
inhibitory cells within the NTS and will be discussed below. The NTS also receives 
multiple inputs from central areas (see figure 1.6). 
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Figure 1.5 Neuronal circuitry of the NTS 
 
Schematic diagram showing possible organization of the microcircuitry in the NTS 
based on in vivo and in vitro evidence (adapted from Andresen & Paton, 2011). 
Afferents enter the nucleus via the solitary tract and synapses onto second order 
neurons (A, B, C and D). Excitatory connections are shown in red and inhibitory 
connections are shown in blue.  
 
A – Receive afferent input and then project directly out of the NTS to other targets. 
 
B – Polysynaptic pathway receiving GABAergic interneurons then projecting to 
higher order neurons before leaving the NTS. 
 
C – Polysynaptic pathway projecting to higher order neurons before leaving the NTS. 
 
D – GABAergic interneuron 
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Figure 1.6 Central autonomic afferent and efferent systems 
 
Schematic diagram detailing afferent and effect connections of central cell groups 
known to be involved in autonomic processing in the rat (adapted from Saper, 2004). 
 
 
A) Ascending: Cell groups receive direct afferent input from the NTS (solid line) 
and/or indirect input from the parabrachial nucleus (dashed line). 
 
 
 
B) Descending: Direct efferent projections to preganglionic cell groups (grey) in 
the brainstem (solid line) and/or indirect inputs form premotor areas (dashed 
line). 
 
 
 
A5  A5 noradrenergic group 
Amyg  Central nucleus of the amygdala 
AV  Anteroventral third ventricular area 
BST  Bed nucleus of the stria terminalis 
DVN  Dorsal vagal nucleus 
ILC  Infralimbic cortex 
IML  Intermediolateral cell column 
Ins  Insular cortex 
LH  Posterior lateral hypothalamus 
nA  Nucleus ambiguus 
NTS  Nucleus tractus solitarius 
PB  Parabrachial nucleus 
PVN  Paraventricular nucleus 
Thal  Ventroposterior parvocellular nucleus of the thalamus 
VLM  Ventrolateral medulla 
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1.6.2. Neurochemistry of the NTS 
 
The neurochemistry of the NTS is one of the most diverse of all brain areas. The 
literature suggests a role in cardiovascular regulation of a wide range of signalling 
molecules and the receptors present in the NTS. While an exhaustive list of these 
systems individually present is not possible, those of interest with respect to the aims 
for the thesis will be reviewed in more detail.  
 
Glutamate 
 
Glutamate is known to be the major transmitter in the NTS (see Talman, 1997, Baude 
et al., 2009) and its dynamics have been reviewed as part of the previous sections. 
Interestingly, only 17% of NTS neurons excited by aortic baroreceptor afferent 
stimulation were inhibited by the NDMA receptor antagonist AP-5 while the non-
NMDA antagonist CNQX inhibited 50% (Zhang & Mifflin, 1998). This suggests that 
there may be other neurotransmitters involved in afferent processing within the NTS. 
 
ϒ-Aminobutyric acid (GABA) 
 
The NTS contains a high concentration of GABA (Dietrich et al., 1982). Blockade of 
GABAA receptors within the NTS were found to facilitate transmission in the NTS 
evoked by vagal stimulation (Bennett et al., 1987). This indicates that vagal 
stimulation causes GABA release in the NTS. This study and another study by Jordan 
et al. (1988) found that spontaneous activity recorded in NTS neurons was augmented 
by GABAA  blockade suggesting a tonic release of GABA in the NTS. Interneurons 
present in the NTS are thought to be the source of the released GABA (Maqbool et 
al., 1991). The same study traced vagal afferent inputs and found them to terminate 
onto GABA immunoreactive cells. Evidence predominates for GABA-mediated 
inhibition to be exclusively at the post-synaptic level and not released from vagal 
afferent terminals.  
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Glycine 
 
While microinjection of glycine into the NTS can cause bradycardia and hypotension 
or hypertension, strychnine causes no effect on baroreflex (Kubo & Kihara, 1987, 
Talman & Robertson, 1989). Further, strychnine had no effect on vagal afferent-
evoked inhibition of NTS neurons (Wang et al., 2010). Together this data suggests 
that while glycine receptors are present in the NTS, there is no evidence for glycine 
being released by either reflex activation or vagal stimulation.  
 
Acetylcholine 
 
Acetylcholine is indeed present in the NTS (Helke et al., 1980) and cells within the 
NTS express choline acetyltransferase, the enzyme required for acetylcholine 
systhesis (Helke et al., 1983). One in vitro study found activation of glycine receptors 
caused release of tritiated acetylcholine loaded into cells by addition to the incubation 
medium (Talman et al., 1994). Microinjection of acetylcholine into the NTS cause 
hypotension and bradycardia, which was inhibited by atropine (Criscione et al., 
1983). Atropine alone caused a small increase in blood pressure and attenuated the 
baroreflex. Microinjection of physostigmine, an acetylcholinesterase inhibitor, alone 
caused a mild hypotension and bradycardia. Together, this data suggests that 
acetylcholine present within the NTS, is tonically released and also released during 
the activation of the baroreflex.  
 
Nitric Oxide 
 
Nitric oxide synthase, the enzyme responsible for synthesizing nitric oxide (NO), is 
present within the NTS (Vincent & Kimura, 1992). Experiments microinjecting NO 
donors into the NTS produced varied effects on blood pressure and heart rate in 
anesthetised rats (see Krukoff, 1999). Blockade of NO production by L-NAME 
microinjection into the NTS caused a decrease in heart rate and blood pressure, 
suggesting NO is tonically released (Matsumura et al., 1998). Paton et al. (2001) 
proposed that NO produced by nitric oxide synthase in the vascular endothelium 
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inhibits the baroreflex. NO released form the vasculature then diffuses to GABAergic 
interneurons to modulate their activity.  
 
Adenosine 
 
The NTS has a particularly high density of adenosine uptake sites and the adenosine 
deaminase, which is responsible for adenosine turnover in tissue (Bisserbe et al., 
1985, Lawrence et al., 1998). Caffeine, a non-selective adenosine receptor antagonist 
inhibit the bradycardia associated with baroreflex activation (Mosqueda-Garcia et al., 
1989). Selective blockade of adenosine A1 receptors within the NTS causes an 
attenuation of the hypertension associated with stimulation of the hypothalamic 
defence area (HDA; St Lambert et al., 1996). It was later suggested that, for the most 
part, the source of the extracellular adenosine was from metabolism of ATP (St 
Lambert et al., 1997). More recently using enzyme encapsulated microelectrodes 
adenosine release was directly detected in the NTS as a result of HDA stimulation 
(Dale et al., 2002). Hypoxia was also found to increase adenosine release in the NTS, 
but only during the period of re-oxygenation of the tissue following termination of the 
hypoxic stimulus (Gourine et al., 2002).  
 
Adenosine triphosphate  
 
The density of the adenosine triphosphate (ATP) receptor P2X is especially high 
within the NTS (Yao et al., 2000, Yao et al., 2001). Microinjection of ATP into the 
NTS produces hypotension and bradycardia anesthetised in rats, which was blocked 
by the non-selective P2 receptor antagonist suramin (Ergene et al., 1994). The same 
antagonist attenuated the bradycardic response to chemoreflex activation when 
microinjected into the NTS of the working heart brainstem preparation (Paton et al., 
2002). However, a more recent study showed that the selective P2X receptor 
antagonist PPADS has not effect on the hemodynamic changes elicited by activation 
of the chemoreflex in awake rats (Braga et al., 2007). Using enzyme encapsulated 
microelectrodes Gourine et al. (2008) demonstrated that ATP was released in the 
NTS. This release was postulated to arise from slowly adapting pulmonary stretch 
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receptors that terminate in the NTS. This ATP release activated second-order relay 
neurons mediate the Hering-Breuer reflex, which maintains appropriate lung inflation. 
Later, using optogenetic activation of astrocytes the source of the ATP shown to glial 
(Gourine et al., 2010). 
 
Noradrenaline 
 
Noradrenaline innervation in the NTS arises externally from the locus coeruleus 
(McBride & Sutin, 1976) and internally from the A2 group of noradrenaline- 
containing cells (Levitt & Moore, 1979). Blockade of α2 adrenoceptor by yohimbine 
and idazoxan inhibited the depressor and bradycardic responses to aortic depressor 
nerve stimulation (Sved et al., 1992). Yohimbine and idazoxan alone were found to 
increase blood pressure. This indicates that noradrenaline is release in the NTS both 
tonically and as a result of baroreceptor activation. Additionally, one study found that 
noradrenaline efflux was increased in the area of the rabbit NTS as a result of 
baroreceptor activation (Yamazaki & Ninomiya, 1993).  
 
Dopamine 
 
There is evidence of a population of dopamine neurons in the A2 region of the NTS 
(Armstrong et al., 1982, Gonzalez-Cuello et al., 2010). Microinjection of dopamine 
itself into the NTS causes bradycardia and hypotension (Zandberg et al., 1979). D2 
receptors have been found to be present in the NTS but not D1 (Qian et al., 1997). 
Dopamine has been shown to inhibit inward currents produced in NTS cells in 
response solitary tract stimulation and was attributed to D2 receptor activation (Kline 
et al., 2002). However, the D2 receptor antagonist sulpiride had no effect on 
cardiovascular reflexes when administered centrally (Bogle et al., 1990, Dando, 
1995). Dopamine release in the NTS has been detected with microdialysis, but only 
during severe hypoxia (Goiny et al., 1991). 
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5-HT 
 
The role of 5-HT and 5-HT receptors have be discussed in detail in sections 1.4 
 
Peptides 
 
The NTS contains a wide complement of neuropeptides and many elicit 
cardiovascular effects when applied to the NTS. Substance P, neuropeptide Y, 
angiotensin II, vasopressin, cholecystokinin, bradykinin, somatostatin, opioid 
peptides, endothelin and neurotensin have all be shown to be present (see Lawrence & 
Jarrott, 1996). Substance P is especially of interest in the NTS due to the fact it is 
often found co-localised in terminals along with 5-HT (Thor & Helke, 1987). Indeed, 
5-HT and Substance P may even be co-released (see Hodges & Richerson, 2008). 
 
1.6.3. Vagus nerve 
 
The tenth cranial nerve is the longest in the body and the name is derived from the 
Latin Vulgivagus; literally wandering or itinerant. As the name suggests the vagus is 
extensively distributed around the body. Despite being better known for being the 
principle parasympathetic output for the autonomic nervous system it is mainly a 
sensory nerve. Indeed, 30,000 fibres present in the feline vagus nerve 80% afferent 
fibres and only 20% efferent (Foley & DuBois, 1937). These afferent fibres a 
responsible for conveying a wide range of sensory information from various organs in 
the body including respiratory system, heart, vasculature, gut, kidneys and liver. 
Primary vagal afferents all pass through the nodose ganglion before entering the brain 
by way of the jugular foramen and afferents terminate in the brainstem (Agostoni et 
al., 1957).  
 
Within the brainstem vagal afferents terminate within the NTS, or close by, which is 
close to the dorsal surface (Kalia & Mesulam, 1980). The nucleus is responsible for 
integrating afferent information and orchestrating cardiovascular reflexes. Input from 
vagal afferents is either transmitted to higher centres, local interneurons or directly to 
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motor nuclei within the brainstem (see figure 1.5). Output via activation of vagal 
preganglionic occurs either directly or after central integration.  
 
1.6.4. Cardiovascular Reflexes 
 
Baroreflex 
 
Baroreceptors are stretch-activated receptors located in the aortic arch and carotid 
sinus. They monitor blood pressure in order to modulate sympathetic and 
parasympathetic output to counteract excursions from tight physiological ranges 
maintaining correct tissue perfusion. This reflex is known to be disrupted in 
cardiovascular disease (Mortara et al., 1997).  
 
Baroreceptor afferents display a tonic discharge and changes in blood pressure 
modulate this activity. Hypertension increases baroreceptor discharge whereas 
hypotension causes a decrease. Increased baroreceptor discharge activates cardiac 
vagal neurons slowing heart rate and cause sympathetic withdrawal. Conversely, 
when discharge slows sympathetic drive increases causing vasoconstriction and 
cardiac vagal tone withdrawal (Spyer, 1990).  
 
Experimentally this reflex can be activated by introduction of vasoactive compounds 
into the circulation to change blood pressure. Sodium nitroprusside and phenylephrine 
cause causing vasodilation and vasoconstriction, respectively, are commonly used to 
activate the baroreflex. It is also possible to activate the reflex mechanically by 
occlusion of the abdominal aorta or carotid arteries. Alternatively, electrical 
stimulation of the aortic nerve can be used to activate the baroreflex (Sapru et al., 
1981). This method removes the confounding factor of possible changing central 
perfusion seen with the others described.  
 
Baroreceptor afferents are carried by the aortic depressor nerve and carotid sinus 
nerve terminating in the NTS (Ciriello et al., 1981). Mapping of carotid sinus 
baroreceptor with cell bodies in the petrosal ganglion show myelinated and 
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myelinated projections to the lateral NTS rostral to obex on the ipsilateral side 
(Donoghue et al., 1984). After integration in the NTS the baroreflex sends an 
excitatory projection to the nucleus ambiguous that modulates vagal tone. The CVLM 
also receives an excitatory input form the NTS in this pathway that then activates an 
inhibitory input to the RVLM to modulate sympathetic tone (see Dampney, 1994).  
 
Chemoreflex 
 
Recently there has been a renewed research interest in the chemoreflex due to the rise 
in obstructive sleep apnoea. This condition results in significant blood oxygen 
desaturation and increases in dissolved carbon dioxide during bouts of apnoea 
(Sunderram & Androulakis, 2012). These changes in blood gas tensions and pH are 
all monitored by chemoreceptors located in aortic and carotid body, of which the 
latter are thought to be responsible for the majority of the chemoreception in vivo 
(Lahiri et al., 1981). Decreases in PO2, increases in PCO2 and increases in hydrogen 
ion concentration all increases in discharge from single fibres from the carotid body 
or sinus nerve. Decreases in PO2 cause an exponential increase in fibre discharge 
whereas PCO2 is linear (Biscoe et al., 1970, Fitzgerald & Parks, 1971). Interestingly, 
when both PO2 and PCO2 are reduced simultaneously the effect is greater than the 
sum of each individual stimulus (Lahiri et al., 1981). 
 
Experimental activation of the chemoreflex has achieved by introducing cyanide, 
inorganic phosphates or CO2 –saturated saline into the carotid bifurcation. For 
example via the lingual artery with the external carotid artery ligated (Hilton & 
Marshall, 1982). More commonly, administration of sodium or potassium cyanide in 
the systemic circulation is used to activate the chemoreflex. The effect of which is 
abolished by sinus nerve transection (Franchini & Krieger, 1993). Cyanide is thought 
to cause local tissue hypoxia by temporarily inhibiting cellular respiration and 
activating the chemoreceptors.  
 
The cardiovascular and respiratory response to activation of the chemoreflex is often 
variable between species and experimental conditions. In the anaesthetised, freely-
breathing rat carotid body stimulation causes hyperventilation, tachycardia and 
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vasoconstriction (Marshall, 1987). However, when ventilated at a constant rate the 
tachycardia observed was reversed to bradycardia. It is thought that the 
hyperventilation caused by the chemoreflex induces a tachycardia and overcomes the 
bradycardia. Anaesthesia also influences the chemoreflex. So-called ‘depressive’ 
anaesthetics such as pentobarbitone have been shown to attenuate the reflex 
(Marshall, 1987). In awake behaving rats activation of carotid chemoreceptors by 
sodium cyanide cause profound bradycardia and hypertension (Haibara et al., 1995).  
 
Chemoreceptor afferents project to the NTS via the glossopharyngeal nerve with their 
cell bodies in the petrosal ganglia. When antidromically stimulated these afferents 
were found to project most often to the commissural subnucleus of the NTS caudal to 
obex (Donoghue et al., 1984). All projections had a conduction velocity indicative of 
unmyelinated fibres. Microinjection of kynurenate into the NTS of anesthetised rats 
abolishes the baroreflex response (Zhang & Mifflin, 1993). Further, microinjection of 
kynurenate into the RVLM inhibit the sympathoexcitation caused by activation of the 
chemoreflex (Koshiya et al., 1993). Projections from the NTS to the nucleus 
ambiguous are thought to mediate the bradycardiac component of the reflex, similar 
to that seen in the baroreflex.  
 
Cardiopulmonary reflex 
 
 
This autonomic reflex was first described by von Bezold and Hirt in 1867, and further 
characterised by Jarisch and Richter, as a pronounced bradycardia, 
sympathoinhibition and hypotension (see Krayer, 1961). The Bezold-Jarish reflex 
involves the activation of chemosensitive vagal afferents located in the heart and 
lungs. It refers specifically to the activation of C-fibre afferents in the coronary 
circulation (Dawes & Comroe, 1954). Classically, it is activated by introduction of 
veratum alkaloids into the coronary artery. However, the cardiopulmonary reflex can 
be activated by stimulation of a range of unmyelinated mechano- and chemo-sensitive 
cardiopulmonary afferents. 
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The cardiopulmonary reflex is activated by intra-atrial injection of the 5-HT3 agonist 
phenylbiguanide (PBG) which selectively activates peripheral C-fibre terminals as 
they express 5-HT3 receptors (Kay & Armstrong, 1990). This elicits the characteristic 
response of bradycardia, hypotension and apnoea, which is then followed by rapid 
shallow breathing. Physiologically, mechanical activation of pulmonary afferents 
when capillary pressure rises, for example during pulmonary oedema where these 
affects would be beneficial (see Paintal, 1995).  
 
The unmyelinated cardiopulmonary afferents travel via the vagus nerve and terminate 
in the NTS; rostral to the obex in the more medial portions and caudal to the obex is 
the dorsal commissural subnucleus in rats and rabbits (Gieroba et al., 1995). The 
authors determined the distribution of c-Fos positive neurons in the NTS after 
repeated injection of PBG. The reflex is though to be mediated by glutamate release 
in the NTS as it is completely abolished by bilateral microinjection of the non-
selective glutamate antagonist kynurenate (Verberne & Guyenet, 1992). The same 
study also found that microinjections of kynurenate in the CVLM and bicuculline into 
the RVLM attenuate the sympathoinhibition associated with the reflex. This suggests 
that there is an excitatory pathway projecting from the NTS to CVLM and inhibitory 
pathway from the CVLM to the RVLM mediating the reflex. This is pathway is 
similar to that seen the in baroreflex. Interestingly, one study in cats found that 
neurons contained within the medullary raphé were also activated by the 
cardiopulmonary reflex suggesting additional sites of integration (Vayssettes-
Courchay et al., 1997). 
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1.7. Assessing neurotransmitter release 
 
The detection of neurotransmitter release has mostly been indirect. The use of 
electrophysiological techniques to measure the effect of receptor activation is by far 
the most common. However, many other factors affect the electrophysiological 
response to neurotransmitter release so more direct measurements were sought. Some 
of the first attempts included the use of ‘cortical cups’ where a small nylon vessel 
filled with physiological saline is placed on the cortex and the composition of the 
saline is determined after removal (Szerb, 1963). This was the first technique that 
allowed direct assessment of the transmitter molecule itself in response to drug 
treatment or electrical stimulation. The obvious limitations of this technique being the 
practical sampling areas and poor temporal resolution as the experimenter has to wait 
for analyte diffusion into the collection medium. The invention of the push-pull 
cannula by John Gaddum allowed access to deeper brain structures but still sampled 
over a broad area and temporal resolution was not significantly improved (Gaddum, 
1961). Later, the microdialysis coupled with high-performance liquid chromatography 
(HPLC) became the accepted technique to directly measure neurotransmitters and this 
was accompanied by electrochemical techniques; voltammetry, amperometry and 
enzyme-linked biosensors. The relative merits of current techniques will be discussed 
carefully.  
 
1.7.1. Microdialysis 
 
Microdialysis recovers small molecules from the extracellular fluid of the brain by 
circulating a perfusion fluid through a hollow tube with a dialysis membrane covering 
a small window at the tip. The recovered fluid is then analysed using a range of 
techniques to determine the concentration of the chosen analyte(s), this is most 
commonly HPLC (see Ungerstedt, 1991). The main advantage on this technique is it’s 
excellent selectivity (Borland & Michael, 2007). Chromatograms leave little doubt 
when identifying a peak caused by compounds recovered from a microdialysis probe. 
Additionally, a wide range of analytes can be sampled depending on how the 
dialysate is processed. It is possible to recover and determine the concentration of 
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biogenic amines (Zetterstrom & Ungerstedt, 1984, Kalen et al., 1988a, Kalen et al., 
1988b), GABA, glutamate (van der Zeyden et al., 2008), acetylcholine (Kurosawa et 
al., 1989) and a range of neuropeptides (Wotjak et al., 2008) from the dialysate. The 
detection limits for these compounds are extremely low and can often be determined 
simultaneously in one sample. Further, microdialysis probes can be used to deliver 
drugs locally to the sampling site via retrodialysis and multiple probes can be 
implanted in one experimental animal. 
 
However, there are also significant disadvantages of this technique that must be 
considered. Firstly, the temporal resolution is often considerably slower than many 
processes associated with the release, action and re-uptake of neurotransmitters. Many 
studies sample at a rate of once every several minutes, however sub-minute sampling 
has been achieved more recently (Rada et al., 2003, Rossell et al., 2003). The 
diameter of the microdialysis probe is often greater than 250µm with the dialyzing 
window in the region of 200-500µm. The disadvantage here is twofold; the sampling 
area is sufficiently large to preclude specificity of particular brain nuclei and there is 
the possibility of tissue damage. Indeed, assessment of tissue surrounding implanted 
microdialysis probes found inflammation, gliosis and swollen axons radiating 1.4mm 
from the probe surface (Clapp-Lilly et al., 1999). Additionally, dopamine release 
monitored in the vicinity of an acutely implanted dialysis probe was significantly 
inhibited (Borland et al., 2005). Interestingly, the same study found that the effects of 
re-uptake inhibitors were artificially enhanced by implantation of the probe. 
 
1.7.2. Voltammetry  
Principles 
 
Voltammetric detection involves electrical oxidation of compounds in aqueous 
solution with an electrode at a positive (anodal) voltage. The anodal potential removes 
one or more electrons from the compound and thus oxidises it. These electrons are 
detected by an amplifier connected to the electrode as an increase in anodal current. In 
fast cyclic voltammetry the active electrode is a carbon fibre and the voltage is driven 
rapidly positive using a high speed ramp. Different compounds oxidise at different 
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voltages, i.e. at different positions on the ramp, and this generates a characteristic 
current transient that facilitates their identification. Following the positive-going 
ramp, the voltage is then driven negative. This will reverse the oxidation and produce 
a re-reduction reaction for many compounds. The re-reduction generates a cathodal 
current transient, which may also be used for identification of the compound. This is 
only possible for electroactive compounds which include neurotransmitters such as 
dopamine, noradrenaline and 5-HT (see Robinson et al., 2008).  
 
To turn this phenomenon into an analytical method requires some simple electronics 
capable of storing the ‘background’ current profile produce by the voltage scan which 
is then subtracted form subsequent scans (see figure 1.7). Changes in this subtracted 
current can then be calibrated against a known concentration of the analyte to give a 
semi-quantitative determination of concentration. More specific applications of this 
technique involve more complex voltage scan protocols in order to optimize detection 
of the chosen analyte. Scan protocols used to collect the data presented in this thesis 
will be discussed in more detail in METHODS 2.1.5.  
 
Carbon fibre microelectrodes used for voltammetry in biological systems are 
extremely small; diameters of approximately 7µm and tip lengths of 50-200µm are 
common. This allows selective sampling from smaller brain nuclei and very low 
tissue damage. Electrode tracts from a single carbon fibre implantation were found to 
be undetectable by light microscopy (Peters et al., 2004). Further, the sampling rate is 
significantly higher than microdialysis. Voltammetric scans can be applied every 
100ms or faster (Phillips et al., 2003, Dankoski & Wightman, 2013). With this sample 
rate its is possible to resolve the dynamics of neurotransmitter release and re-uptake 
on a more physiologically relevant scale.  
Limitations 
 
Selectivity has long been acknowledged as a problem with voltammetry. There are a 
number of possible interfering electroactive substances in the brain. Uric acid and 
ascorbic acid are present at high concentrations and can cause spurious 
electrochemical signals on voltammograms. Additionally, changes in pH and tissue 
impedance will affect the current change measured by the active electrode. Criteria 
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for the positive identification of an electrochemical signal has been carefully 
considered (see Phillips & Wightman, 2003). Four separate criteria should be verified; 
electrochemical, anatomical, physiological and pharmacological. First, the 
voltammogram recorded in the experimental system should be consistent with the 
analyte of interest taken in a controlled environment. Second, there should be 
sufficient quantities of the analyte of interest in the anatomical location being sampled 
to account for the signal recorded. Third, there should be electrophysiological data 
underpinning a physiological role of the analyte at the concentrations detected. Lastly, 
pharmacological verification by known inhibitors of synthesis, metabolism, and 
storage of the purported analyte can be used.    
 
Other disadvantages include the inability to detect the basal concentrations. All 
changes in current are taken over a current background recorded in presence of basal 
concentrations of the analyte. Further, the range of analytes is limited to electroactive 
species only. See Table 1.3 for a comparison of the relative advantages and 
disadvantages between voltammetry and microdialysis. 
History 
 
The earliest attempt to use voltammetry to measure a neurotransmitter in the brain 
was made by Kissinger et al. (1973). Here, a carbon paste electrode was introduced 
into the caudate nucleus and a ramped voltage (0±1V) applied to the surface. The 
authors were attempting to detect basal extracellular dopamine, however they 
conceded that ascorbate was the likely source of the electrochemical signal they 
encountered in the brain. Using the same technique it was possible to resolve 
increases in electrochemical current caused by 6-hydroxy dopamine microinjected 
into the vicinity of the electrode (McCreery et al., 1974). Refinement of the technique 
by the same group quickly progressed to the measurement of both endogenous striatal 
dopamine release (evoked by electrical stimulation) and 5-HT in the globus pallidus 
released by pharmacological stimulation using para-Chloroamphetamine (Conti et al., 
1978). The same group also reported increased electrochemical currents in the 
hippocampus in response to electrical stimulation of the median raphe, a nucleus 
known to be rich in 5-HT-containg cell bodies (Marsden et al., 1979).  However, the 
temporal resolution of this approach was limited to one sample per minute and, 
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therefore, was unable to accurately determine release kinetics. Furthermore, no 
pharmacological verification of the electrically evoked signal was attempted so it 
remained unidentified.   
 
Around the same period a group in France employed a variant of voltammetry, 
differential pulse voltammetry, in an attempt to measure 5-hydroxyindole compounds 
in brain tissue (Cespuglio et al., 1981a, Cespuglio et al., 1981b). Differential pulse 
voltammetry applies voltage square waves (not ramps) to the working electrode. The 
potential is increased over a range where analyte oxidation is expected in a staircase 
of small potential increments, in this case 50mV pulses from -0.05 to +0.95 V. 
Changes in current are sampled at the peak and directly after each pulse in the 
staircase. Current changes between these two points can be used as an index of 
analyte concentration. This particular approach oxidises ascorbic acid and DOPAC 
before 5-hydroxyindoles are oxidised therefore removing these oxidation currents 
masking those of the 5-hydroxyindoles. However, while the authors of this study did 
manage to reduce the baseline electrochemical signal recorded in the rat striatum with 
the specific 5-HT depleting agent para-chlorophenylalanine they were unable to 
confirm the identity of the electrochemical signal due to oxidation of the 5-HT 
metabolite 5-HIAA at the same potential. Again, sample rates were limited to 1 
minute intervals. 
 
Into in 1990’s, work from a London-based group showed that dopamine-containing 
terminals in the striatum could be forced to release 5-HT in vivo by pre-loading the 
animal with 5-HTP and recording the release with voltammetry (Stamford et al., 
1990). This phenomenon was not explored further but represented an important proof-
of-concept that an uncontaminated 5-HT signal could be detected in vivo. However, 
with the increasing use of brain slice preparations less progress refining 5-HT 
measurement in vivo was seen. Brain slice preparations were used in the first reports 
of voltammetric detection of electrically evoked 5-HT were both pharmacological and 
electrochemical characterisation of the evoked signal was achieved (O'Connor & 
Kruk, 1991). This preparation allowed release of 5-HT to be detected from local 
terminals within the dorsal raphe nucleus, when stimulated electrically. This approach 
allowed 5-HT autoreceptor function to be probed (O'Connor & Kruk, 1992).  
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Later, fast cyclic voltammetry was used to study 5-HT release and re-uptake 
dynamics in the CNS of Drosophila larvae (Borue et al., 2009). However, the first 
report of 5-HT release and re-uptake in the mammalian (rat) brain that was 
comprehensively characterised was from Mark Wightman’s group (Hashemi et al., 
2009). Here, the authors describe 5-HT release in the substantia nigra upon electrical 
stimulation of tracts emerging from the dorsal raphe nucleus. Great effort has been 
taken to confirm the identity of the signal was indeed 5-HT according to an accepted 
criteria (Phillips & Wightman, 2003). This summarises the progression the technique 
of voltammetry in neuroscience over the last 30 years. At inception voltammetry was 
one of a number of methods used to sample extracellular concentrations of 
neurotransmitter, however, through constant refinements to the technique, fast-cyclic 
voltammetry has emerged as a viable method of assessing 5-HT release and re-uptake 
dynamics. This is due to the time and spatial resolution afforded by voltammetry that 
are not possible with techniques currently available for in vivo study.   
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Figure 1.7 Principles of voltammetry 
 
Fast scan-cyclic voltammetry using a carbon fibre microelectrode with dopamine as 
an example analyte. Dopamine was the first electroactive transmitter to be measured 
with voltammetry in vivo.  
  
A) Reaction scheme for the reduction and oxidation of dopamine on the surface of a 
carbon fibre microelectrode driven by an applied voltage. Dopamine is oxidized to 
Dopamine-o-quinone by removal of 2 electrons from the hydroxyl groups attached to 
the benzene ring.  
 
 B) Voltage applied to the carbon fibre microelectrode to drive the oxidation and re-
reduction of electroactive molecules. This is often referred to as the voltage ‘scan’. 
 
C) Background current generated by the voltage scan at the carbon fibre 
microelectrode. The shaded area shows the difference between currents recorded in 
the absence and presence of dopamine.  
 
D) Resultant current from subtraction of the background current recorded in the 
absence of dopamine from that recorded in the presence of dopamine. This is referred 
to as the ‘faradic current’ as it is generated by electrons transferred during reduction 
and oxidation of a particular molecule. 
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Table 1.3  Techniques used to detect neurotransmitters  
 
Comparison of the relative advantages and disadvantages of microdialysis and fast 
cyclic voltammetry when used to assess the dynamics of neurotransmitter release and 
re-uptake in biological systems.  
 
 
 
 
 
 
 
Microdialysis Fast Cyclic Voltammetry 
Recording surface 
dimentions 
~1000-3000µm in length 
200-350µm in diameter 
50-200µm in length 
7µm in diameter 
Extracelluar volume 
sampled 
Large Small 
Sample rate Minutes 2-10Hz 
Basal concentration 
detection 
Possible Limited 
Range of analytes Wide 
Limited to electroactive 
molecules at low potentials 
Selectivity Excellent Limited 
Resolve uptake 
kinetics 
No Yes 
Resolve release 
kinetics 
No Yes 
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1.7.3. Biosensors 
 
Biosensors use a biological component (usually an enzyme) to recognize the analyte. 
A range of biosensors have been developed for the detection of signaling molecules 
including ATP, glutamate and lactate (for examples see Gourine et al., 2005, Tian et 
al., 2009, Brown et al., 2012). These biosensors operate on a similar principle to 
voltammetry. However, instead of oxidizing the analyte directly, enzymes 
encapsulated on the surface of the electrode convert the analyte of interest to an 
electroactive substance (see Dale et al., 2005). One of the enzyme products is usually 
hydrogen peroxide and easily detectable by applying a constant voltage (usually 
~500mV) to the surface of the electrode and the resulting current is monitored. When 
hydrogen peroxide is oxidized on the surface the current will increase giving an index 
of local analyte concentration. 
 
The advantage of this system over voltammetry is the ability to detect molecules that 
are not themselves electroactive. However, an enzyme or an enzyme cascade capable 
of producing hydrogen peroxide from the analyte is essential. Selectivity is assured by 
the enzyme recognition being specific for it’s particular substrate. Additionally, an 
enzyme-free electrode identical to the active electrode can be used to detect any non-
specific changes in current and can be subtracted from the output of the active 
electrode. Other advantages include small sensor size (25-50µm in diameter) and fast 
response time (see Dale et al., 2005). 
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AIMS OF THIS THESIS 
 
1) Using in vitro patch clamp confirm and assess the properties of 5-HT3 
receptors in the NTS and how they exert control on glutamate release. Re-
assess the spontaneous 5-HT release first reported in the NTS slice by Wan 
and Browning (2008). Investigate the effect of re-uptake inhibitors on this 
spontaneous release of 5-HT and how this affects spontaneous glutamate 
release. Additionally, assess the effect of non-classical re-uptake inhibitors on 
this system. 
 
2) Investigate the effects of classical and non-classical re-uptake systems on 
stimulated release of glutamate in the NTS contained within the brainstem 
slice. 
 
3) Characterise the electrochemical signal evoked in the NTS during stimulation 
of the vagus nerve by electrical and physiological means. 
 
4) Assess the efficacy of known re-uptake inhibitors in vivo in the nucleus of the 
solitary tract with microinjections of known concentrations of exogenous 
biogenic amine. Additionally, assess the properties of non-classical re-uptake 
systems that may or may not be present in the NTS.       
 
5) Determine and compare the differences between 5-HT release in the NTS 
under normal physiological conditions and in a rodent model of post-
myocardial infarction-induced heart failure. Additionally, glutamate 
biosensors will be used to assess differences in the dynamics of this 
transmitter.  
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2. GENERAL METHODS 
 
The experiments described in the thesis have been conducted both in vivo and in vitro 
and the methods have been divided as such for clarity. This methods chapter will start 
with a general description of the in vivo preparation, which is standard for 
experiments described in Chapters 4, 5 and 6. Specific experiential methods will be 
described additionally in this chapter or at the start of each method chapter where 
required, for clarity.  
 
 
2.1. In vivo preparation 
 
All procedures were carried out under license conforming to the Animals (Scientific 
Procedures) Act 1986. Experiments were performed on male Sprague Dawley rats 
180-250g in weight obtained from a colony at University College, London. At the end 
of each experiment, all animals were humanely killed with an overdose of sodium 
pentobarbitone (i.v.). 
 
 
2.1.1. General surgical preparation 
 
Induction of anaesthesia 
 
Animals were placed in an induction chamber and anaesthetised with isoflurane (5% 
in 100% O2). The animals were then removed for surgery and anaesthesia was 
maintained with iosflurane (2-3% in 100% O2) via a rodent facemask (Harvard 
Apparatus, Kent, U.K). During surgical preparation core body temperature was 
monitored with a rectal probe and maintained by a thermostatically controlled heating 
pad (Harvard Apparatus) at 37-38°C. 
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Vessel cannulation 
 
With animals in a supine position the right femoral artery and vein were cannulated 
with polyethylene tubing (Portex non-sterile tubing, ED 0.96 mm, ID 0.58 mm). The 
tubing contained heparinized 0.9% saline (25 UI/ml). The arterial cannula was 
connected to a pressure transducer (Statham model P23XL) and amplifier (Grass 
Instruments 7PI) for continuous measurement of blood pressure. The venous cannula 
was plugged distally until ready for drug administration. All cannulae were secured to 
the skin, the surgical wound irrigated with saline and the incision was closed with 2-3 
sutures.  
 
Tracheal cannulation 
 
The ventral aspect of the neck was exposed with a small midline incision. The 
salivary glands were separated by blunt dissection and reflected laterally. The trachea 
was separated from surrounding muscles taking care not to damage the sympathetic 
nerve trunk and carotid artery. The trachea was cannulated with PTFE tubing (ID 
1.5mm) for connection to a small animal ventilator (Harvard Apparatus). Tracheal 
pressure was monitored via a t-piece connection to a pressure transducer (Statham 
model P23XL) and amplifier (Grass Instruments 7PI).  
  
Cannulation of right atrium 
 
In some experiments a cannula (Portex non-sterile tubing, OD 0.96 mm, ID 0.58 mm) 
containing heparinised saline was advanced into the right atrium via the right external 
jugular vein. Until ready for drug administration the tubing was connected to a 
syringe driven infusion pump for constant rate infusion, described below. 
 
Maintenance of anaesthesia 
 
After successful instrumentation of the animal isoflurane flow was reduced (1-0.5%) 
and anaesthesia was continued by slow administration α-chloralose (100-120 mg kg-1, 
i.v.). Isoflurane flow was reduced to zero over a period of 7-10min after α-chloralose 
administration. Depth of anaesthesia was constantly monitored by paw-pinch and/or 
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stability of cardiovascular variables. Supplementary doses of α-chloralose (10-20 mg 
kg-1 i.v.) were given if and when required.  
 
Exposure of the brainstem 
 
After cannulation of blood vessels and trachea the animal was placed in a stereotaxic 
frame (Royal Free Medical Engineering) and secured by ear and an incisor bar clamp. 
The body was allowed to rest on an adjustable stage and adjusted so the ribcage was 
clear of the surface. The head was ventroflexed approximately 25° and a midline 
incision was made from bregma on the skull and continued laterally over the left 
scapula. The nuchal muscles were reflected laterally by cautery dissection to expose 
the atlanto-occipital membrane. The membrane was left intact until just prior to 
electrode placement to reduce exposure of the brainstem and fluid loss.  
 
Exposure of the vagus nerve 
 
The left cervical vagus nerve was exposed blunt dissection from a dorsolateral 
approach by deflection of the left scapula.  
Care was taken when separating the nerves not to damage the others or occlude the 
carotid artery. When the nerve was free from the bundle it was cleaned of connective 
tissue, a silk suture was tied distally and the nerve crushed. This prevents any efferent 
traffic that would directly activate the parasympathetic input to the heart. The nerve 
was then place on a silver hook bi-polar stimulating electrode. The electrode was 
connected to a constant current isolated stimulator (Digitimer DS3) triggered by a 
digital output from a power1401+ (CED, Cambridge, UK) controlled by a script 
written for Spike2 software running on PC. 
 
Correct electrode placement was confirmed by briefly stimulating the vagus (20Hz, 
100µA, 1ms pulse width) and observing the resultant bradycardia and hypotension.  
The exposed portion of the nerve was completely covered in polyvinylsiloxane dental 
impression material (Super Dent®, Carlisle Laboratories). This prevented the nerve 
from drying out and/or fluid build-up causing short-circuit. 
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2.1.2. Neuromuscular blockade 
 
Once all surgery had been completed neuromuscular blockade was induced by α-
bungarotoxin (50 µg per animal i.v.) or decamethonium bromide (1mg kg-1 initial, 
3mg kg h-1) to maintain stability during recording. The depth and stability of 
anaesthesia during neuromuscular blockade was assessed by the stability of blood 
pressure and heart rate and the absence of cardiovascular response to noxious stimuli. 
An intravenous infusion administered by a syringe-driven infusion pump                    
(6 ml kg-1 h-1, Perfusor®, B. Braun) consisting of 50 % Gelofusine plasma substitute 
and 50 % distilled water containing 100 mM NaHCO3 and 10 mM glucose. 
Decamethonium bromide was dissolved in the infusion mixture when required. This 
served to maintain blood volume and prevent metabolic acidosis.  
 
At regular intervals during experiments arterial blood samples were collected and 
blood gases were monitored using a RAPIDLab 248 blood gas analyser (Siemens 
Diagnostics, Deerfield, USA. Blood pH was maintained within range 7.35-7.45, 
PCO2; 35-45mmHg and PO2; 100-130mmHg. Volume and oxygen content of 
inspired air were adjusted or injections of sodium bicarbonate 1M (i.v) were made as 
appropriate to maintain physiological ranges. 
 
2.1.3. Data capture  
 
All recorded variables were digitized to hard-disk drive using a CED 1401Mk2 
analogue to digital conversion interface controlled by a PC running Spike2 (Version 
6) software (Cambridge Electronic Design). In all experiments blood and tracheal 
pressures were amplified (Grass, model 7D) and recorded as waveforms. An on-line 
derivation of heart rate was made from the blood pressure trace using a Spike2 peak 
count function.  
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2.1.4. Histology  
 
At the end of each experiment Pontamine sky blue (PSB) dye (1% in saline) was 
ejected from one barrel of the electrode and/or a dc current of +500nA was applied to 
the carbon fibre microelectrode in situ. The brain was dissected and immersed in 4% 
formalin saline solution for at least 24 h. The area of interest was then dissected from 
the rest of the brain and mounted on a freezing microtome (Leitz, Wetzlar, Germany) 
and when solid cut into 50µm coronal sections. The sections were mounted on 
gelatin-subbed slides and stained with neutral red. The PSB staining and/or the 
electrolesion were visualized under a light microscope and recording sites were 
mapped to a Rat Brain Atlas (Paxinos and Watson, 1998). 
 
2.1.5. Detection of 5-HT 
 
The present study employs adapted fast-cyclic voltammetry (FCV) to measure 
endogenously released 5-HT and the clearance of exogenously applied 5-HT within 
the NTS. As previously mentioned, a commonly used technique to measure 5-HT in 
vivo is microdialysis coupled with high performance liquid chromatography (HPLC). 
While HPLC offers high specificity and the ability to determine basal concentrations 
of a wide range of neurotransmitters it does not offer the temporal resolution of FCV. 
This high temporal resolution is required to determine release and reuptake profiles. 
The general principles have been discussed previously; see INTRODUCTION 1.7.2. 
 
Carbon fibre microelectrodes 
 
Carbon fibre microelectrodes (see figure 2.1) were constructed as follows. Single 
carbon fibres (7µm diameter) were inserted into 2mm outside diameter glass capillary 
tubing (Harvard Apparatus Ltd) filled with acetone and cut flush with the end. The 
acetone was left to evaporate. The filled glass was then loaded into a Flaming Brown 
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horizontal microelectrode puller (Sutter, Model P80/PC) and pulled to a taper. The 
fibre was cut with fine dissecting scissors to a length of ~10mm. A small ingot of a 
low-melting point tin bismuth alloy (Wood’s metal) was inserted into the blunt end of 
the electrode along with a length of copper wire. The alloy was melted with a heat 
gun to form an electrical contact between the wire and the carbon fibre. The carbon 
fibre was finished by a process of spark etching using a high voltage DC supply to cut 
the fibre and etch it to a conical tip approximately 100µm in length (Millar & Pelling, 
2001) 
 
‘Dident’ carbon fibre microelectrodes were used to record endogenously released 5-
HT. This electrode incorporates two carbon fibres in a single assembly separated by 
~10µm. One of these carbon fibres is used a the active electrode and the other serves 
as a ‘micro reference’ that monitors local changes in current unrelated to the 
voltammetric scan and subtracts them from the final signal. This greatly improves 
signal to noise ratio (Pennington et al., 2004). They were constructed by bonding two 
glass capillaries filled with a carbon fibre separated by two further empty glass 
capillaries with epoxy as shown in figure 2.2. This assembly was pulled to a taper 
using a Narishige vertical microelectrode puller (Model PE-2) and finished as 
described above for the single barrelled electrode.  
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Figure 2.1 Single carbon fibre microelectrode 
 
Schematic representation of a single carbon fibre microelectrode used for in vivo 
voltammetric detection. Inset shows the finished tip of the microelectrode after spark 
etching.  
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Figure 2.2 Dident carbon fibre microelectrode 
 
 
A) Schematic cross-section of an electrode assembly before pulling showing 
arrangement of empty glass capillaries and carbon-fibre filled glass capillaries.  
 
B) Schematic representation of the tip of a ‘dident’ carbon fibre microelectrode after 
pulling and finishing with spark etching.  
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Reference and ground electrodes 
 
The reference electrode used was a dry-type Ag/AgCl constructed by immersing 1-
2mm of silver wire exposed from an insulating tube in bleach overnight. This 
reference electrode was then positioned on the surface of the brainstem as close to the 
recording site as possible without disturbing it.  
The ground terminal of the voltammetric system was connected to animal via the 
incisor bar of the stereotaxic frame.  
 
5-HT modified Waveform 
 
All voltammetric measurements were conducting using a Millar voltammeter (P.D. 
Systems, West Mosley, Surrey, UK). 
To measure 5-HT in vivo, an in-house specially designed trapezoidal ramp waveform 
was used (see figure 2.3). This waveform improves the selectivity and signal-to-noise 
ratio for 5-HT detection. Two separate trapezoidal ramps were applied in rapid 
succession to the carbon fibre electrode at a rate of 2Hz. The first ramp is the ‘active’ 
scan as it ramps from 0 to 500mV and then back to -200mV. Using this waveform 5-
HT generates an oxidation current peak at ~350mV and a re-reduction peak at 
~100mV. The second ramp follows the first after 20ms. This ramp is identical in 
shape to the first but is offset negatively by 400mV. No 5-HT oxidation (or re-
reduction) will occur on this ramp. During these scans, the total current through the 
electrode has two components, the voltammetric oxidation/reduction peaks plus a 
‘background current’. The background current is the current that flows simply as a 
result of the electrode impedance in the solution. 
The background current amplitude is normally much greater that the voltammetric 
currents, so changes in background can produce artifactual signals or noise. For 
example, changes in tissue impedance in vivo due to brain swelling/shrinking can 
affect the background current. However, the background current depends mainly on 
dV/dT, so is similar in both ramps. The voltammetric instrumentation electronically 
superimposes and subtracts the currents during the two ramps (figure 2.4). This 
process removes most of the background current from the signal leaving the oxidation 
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and reduction signals intact. During experiments, a background-subtracted signal 
from a pair of scans was obtained in the tissue. This forms a reference signal. This 
signal was subtracted on-line from the on-going signal to form the final voltammetric 
signal (Figure 2.5). 
 
Sampling 
 
Quantification of 5-HT concentration was determined online by sampling the 
amplitude of both oxidation and re-reduction peaks simultaneously and calculating 
the differential between the two. This output was then scaled against a calibration 
taken from a sample of electrodes exposed to a known concentration of 5-HT in vitro 
after use. The carbon fibre electrodes typically lost 50% sensitivity during the course 
of an experiment. This is seen with other biosensors used in vivo (Tian et al., 2009, 
see Patel & Rice, 2013) 
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Figure 2.3  Voltammetric waveform  
 
 
Complete voltammetric scan waveform. Voltage applied to electrode tip and resultant 
background current. Total scan duration 30ms .  
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Figure 2.4  Voltammetric signal processing: Stage 1  
 
 
A) Shows the resultant current from two scans, the shaded area is the increase in 
faradic current caused by oxidation/reduction of 5-HT. 
 
 B) Shows the subtraction of the background current, leaving only the faradaic 
current.  
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Figure 2.5 Voltammetric signal processing: Stage 2 
 
Online processing of voltammetric data. Scans were obtained in phosphate buffered 
saline during increasing 5-HT concentrations. This was achieved by placing an 
iontophoretic micropipette filled with 5-HT (10mM) alongside the carbon fibre in a 
recording chamber filled with PBS. Positive current was applied to the 5-HT barrel to 
eject 5-HT from the micropipette onto the carbon fibre.  
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2.1.6. Exogenous Monoamine clearance 
 
Experimental animals were prepared according to the standard procedure detailed in 
section 2.1.1.  
 
Electrodes 
 
Electrodes were constructed by modifying a previously described design (Daws & 
Toney, 2007) A single barrelled carbon fibre electrode prepared and finished with a 
100-120µm cone-shaped tip (figure 2.1). Separately, a 3-barrel pipette was pulled and 
the tip broken back giving each of the barrels an opening of 3-5µm. Under 
microscopic guidance the carbon fibre microelectrode was positioned 100µm from the 
tip of the 3-barrel pipette (figure 2.6). The assembly was secured with sealing wax 
and correct tip-placement was confirmed under the microscope. The shaft of both 
electrode and pipette were then covered with epoxy resin and allowed to cure 
overnight.  
 
The 3-barrelled pipette was filled with either 5-HT (100µM), noradrenaline (1mM) or 
dopamine (1mM ) dissolved in phosphate buffered saline (pH7.4), in one barrel and 
pontamine sky blue dye (15% solution in saline) in another. Ejection of solutions was 
controlled by pressurising the barrels with nitrogen controlled by a Neurophore 
(Medical Devices). This was coupled to a timing circuit.  
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Figure 2.6 Microinjection electrode construction and application  
 
 
Schematic diagram showing electrode assembly placed within the NTS of the exposed 
dorsal aspect of brainstem in the anesthetised rat. Voltammetric data was processed 
online as shown and stored for subsequent analysis.  
An enlargement of the electrode assembly tip shows the diffusion of the microinjected 
5-HT to the surface of the carbon fibre over a distance of approximately 100µm. It 
should be noted that the diffusion of the microinjected amines through the 
extracellular matrix is affected by different factors. These include, but are not limited 
to, brain region and tissue hypoxia (Rice & Nicholson, 1991, Nicholson & Sykova, 
1998). 
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Figure 2.7 Voltammetric detection of biogenic amines 
 
Reaction schemes showing the electro oxidation and re-reduction of A) dopamine B) 
noradrenaline and C) 5-HT using a triangular voltage scan waveform sweeping from 
0 to 1.4V. D) Shown the triangular voltage scan waveform and the resulting current 
when applied to the carbon fibre microelectrode in phosphate buffered saline and in 
the presence of dopamine.  
 
 120 
 121 
Experimental Protocol 
 
Electrode assembly was lowered into the NTS. The correct position was found using 
sterotaxic coordinates and recording neuronal activity of the gracile nucleus. When 
stroking the ipsilateral foot and flank no longer evoked activity then correct 
positioning was achieved. Additionally, electrode locations were confirmed 
histologically. 
 
Once electrodes were positioned the voltammetric waveform (Figure 2.7) was applied 
at a frequency of 8Hz. This voltage waveform allowed measurement of noradrenaline, 
5-HT and dopamine but precluded selectively between the three compounds. 
Background current was allowed to stabilise over a 15-20min period. 
 
Once stable 5-HT, noradrenaline or dopamine microinjections were started. Pressure 
and time of injection were adjusted so that the peak of the detected monoamine was 
~1µM. Monoamine microinjections were applied at 5 min intervals. This timing was 
found to allow the signal to completely decay before the next application. At least 3 
stable applications of 5-HT or noradrenaline were required before administration of 
test drug or vehicle.  
 
Data Capture and Analysis 
The voltammetric signal was recorded continuously over the course of the experiment 
and derived as previously described to give a relative concentration change. An output 
from the pressure module was also used to record the time, amount and duration of 
pressure application. Using both a peak find and decay time algorithm (Spike2, CED) 
the time taken for the monoamine signal to decay to 80% of its maximum (figure 2.8). 
This decay time was found to give the maximum differences between control and 
drug challenges (Daws et al., 1997, Baganz et al., 2008). 
Decay time was calculated for three monoamine applications prior to administration 
of drug or vehicle and averaged. This was used to calculate a percentage change on 
the decay time of the three subsequent monoamine applications following drug or 
vehicle challenge (figure 2.9). 
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Figure 2.8  Data analysis: Decay time 
 
Sample trace illustrating typical changes in extracellular amine concentration after 
microinjection of 5-HT (100nM). Analysis was the same for all amines tested.  
The maximum concentration change over background was calculated (peak). The 
decay time (T80) was calculated from the point at which the signal was 80% of the 
peak value. 
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Figure 2.9 Data analysis: Quantifying drug effects 
 
Sample trace illustrating a typical experiment. Three microinjections were performed 
before application of test drug. The T80 values for these three microinjections were 
calculated and averaged as ‘baseline’. Drug or vehicle was applied 3 min before the 
subsequent microinjections. Three microinjections were performed in the presence of 
the drug or vehicle. T80 values for these three microinjections were calculated and 
averaged. A percentage change compared to baseline was then calculated.  
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Statistical Analysis 
 
All data is presented as mean ± standard error of the mean (s.e.m). When comparing 
three or more treatment groups statistical analysis was performed using a 1-way 
analysis of variance (ANOVA) to compare drug-treated experimental groups to its 
time-matched control group. Post-hoc analysis was performed using the least 
significant difference test (LSD), to calculate significant differences between means 
of drug and control groups. In some experiments statistical analysis was performed 
using a 2-way ANOVA where multiple observations needed to be compared. Post-hoc 
analysis was performed, in this case, using the Bonferroni correction. 
When comparing two groups of data statistical analysis was performed using 
Student’s unpaired t-test to compare drug-treated experimental groups to its time-
matched control group. 
For all statistical analysis, differences between groups were considered significant 
when P < 0.05. 
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2.2. In vitro Patch Clamp Electrophysiology 
 
2.2.1. Brain Slice Preparation 
 
Rat brainstem slices containing the NTS were prepared using methods described 
previously (Doyle et al., 2004, Wan & Browning, 2008, Zhang et al., 2009) 
 
Rats weighing 75-100g (Charles River, TX) were allowed 1 week acclimatization 
period before sacrifice. Rats were anesthetised with isoflurane and decapitated. The 
skull and vertebrae were cleared with a fine rongeur allowing the brain to be rapidly 
removed and immersed in ice-cold cutting solution (see table 2.1). This process took 
no longer than 60s. The tissue was left for 3-5min to allow it to completely cool.  
 
The block of tissue was prepared by removing any connective tissue and/or 
vasculature visible on the surface. Cyanoacrylate adhesive was used to secure the 
trimmed block (~10mm centered on obex) in the specimen bath of a vibrating 
microtome (Vibratome VT1200s, Leica microsystems, Germany). The bath was filled 
with ice-cold cutting solution continually bubbled with 95%O2/5%CO2 to maintain a 
constant pH. Slices were cut at a thickness of 300µm with a sapphire blade (Delaware 
Diamond Knives, Wilmington, DE, USA). After cutting slices were transferred to a 
recirculating bath (BSC-PC, Warner instruments, MA, USA) filled with aCSF at 
room temperature continually bubbled with 95%O2/5%CO2 for at least 90min prior to 
commencement of recordings.  
NTS-containing slices were prepared in either coronal plane (figure 2.10) for 
recording mEPSCs or in the horizontal plane (figure 2.11) when stimulating the 
tractus. The coronal configuration yielded 2-3 usable slices whereas in the horizontal 
configuration only a single slice was cut per animal.  
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Single slices were placed in a perfusion chamber (RC-26GLP, Warner Instruments, 
CT) and continually perfused with aCSF (see table 2.1) at room temperature (2-3ml 
min-1). Solutions delivered under gravity from 60mL reservoirs and controlled by a 
series of 3-way valves. The slice was held in place with a slice anchor which consist 
of type 316 stainless steel with Lycra® threads, finished with a plastic coating 
(Warner Instruments, CT, U.S.A.). Neurons were visualized using an upright 
microscope (Olympus BX50WI) fitted with near-infrared differential interference 
contrast optics and charge-coupled device camera. The resultant image was displayed 
on a closed-circuit television. Cells were identified as NTS neurons by location and 
morphology. In coronal slices recordings were confined to the cordal aspect of 
intermediate NTS (figure 2.10). In horizontal slices recordings were not confined to a 
specific NTS region (figure 2.11). Healthy cells (see figure 2.12) were identified by 
their characteristic spindle or oval shape (Doyle et al., 2004).  
 
2.2.2. Patch pipette fabrication 
 
Patch pipettes were constructed using a horizontal pipette puller (P-2000 Sutter 
instruments, CA, USA) from thin-walled borosilicate glass with filament (ID 0.90-
mm, OD 1.2-mm, GC150F- Harvard Apparatus Ltd, WPI; U.S.A). Electrodes had tip 
resistances of 3-5MΩ. Immediately prior to recording electrodes were back filled with 
internal solution with composition detailed in table 2.1. 
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Table 2.1 Solution compositions for slice electrophysiology 
 
Sucrose ACSF Cutting Solution  
KCl 3mM 
MgCl2 1mM 
CaCl2 2mM 
NaHCO3 20mM 
MgSO4 2mM 
NaH2PO4 1.25mM 
D-Glucose 10mM 
Sucrose 206mM 
Internal Pipette Solution  
K Gluconate 128mM 
KCl 10mM 
CaCl2 0.3mM 
MgCl2 1mM 
HEPES 10mM 
EGTA 1mM 
ATP 2mM 
GTP 0.25mM             pH adjusted to 7.35 with KOH 
aCSF   
NaCl 126mM 
KCl 3mM 
CaCl2 2mM 
NaHCO3 20mM 
MgSO4 2mM 
NaH2PO4 1.25mM 
D-Glucose 10mM 
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2.2.3. Cellular recording 
 
Recordings were made of neurons in whole-cell configuration voltage clamped at       
-60mV using a patch-clamp amplifier (Axopatch 200B, Axon Instruments, Foster 
City, CA). Data was filtered at 2kHz and sampled at 10kHz using p-Clamp8 software 
(Axon Instruments) and digitized via a Digidata 1320 in or 1440 interface. Data was 
stored on computer for offline analysis. Neurons were accepted for recording if they 
had an initial seal resistance greater than 1GΩ and required less than 100pA to 
maintain the holding potential. Series resistance (access + pipette resistances) during 
recordings were typically 150-300MΩ.  
 
2.2.4. Electrical Stimulation: Horizontal Slice 
 
All electrical stimulation was conducted in horizontal slices to reduce the contribution 
of direct activation of interneurons by field stimulation and increase latency from 
stimulus artifact (Doyle & Andresen, 2001). In all electrical stimulated experiments 
aCSF contained 25µM gabazine (SR-95531) to block GABAA –mediated currents. 
Gabazine was used instead of bicuculline because it has been found to block both 
glycine receptors and SK-type potassium channels leading to possible confounding of 
results (Shirasaki et al., 1991, Pedarzani et al., 2001).  
Stimuli were delivered by placing a 200-µm-diameter concentric bipolar stimulating 
electrode (FHC Inc, ME, USA) on the visible solitary tract 1-2mm from the site 
where recordings were attempted (see figure 2.11). Stimuli were delivered via an 
isolated constant current stimulator (DS4, Digitimer, UK). Pulse trains were 
programmed and triggered via a Master-8 (A.M.P.I, Jerusalem, Israel).  
Pairs of stimuli were applied every 20s to evoke EPSCs. Pulse duration (0.1-1ms) and 
amplitude (10-500mA) was adjusted to produce inward currents of 100±20pA. The 
stimulus interval was altered to allow the first stimulated current to decay completely 
before the second stimulus. In a separate set of experiments a 100-pulse train was 
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delivered to the solitary tract at 20Hz to evoke an increase in spontaneous EPSC 
frequency post-stimulus. The amplitude was adjusted to evoke maximal EPSC inward 
currents (100-500µA). 
 
2.2.5. Experimental Protocol and Data Analysis 
  
 Coronal Slice: Recording mEPSCs 
 
Frequency and amplitude of mEPSCs were sampled continuously. For the coronal 
slice experiments these mESPCs were recorded for 10 min in drug free aCSF – 
control period. To test the whole-cell current recordings were stable the frequency of 
mESPCs over first 200s was compared with that over the last 200s of this 10 min 
period. If the percentage difference in frequency between these two values was ≤20% 
then the recording was considered stable. The mean of these two values was taken as 
control. This was also applied to the amplitude measurements. The test drug/drugs 
were then applied and recordings were made over a 10 min window before changing 
to another drug challenge or to drug free ACSF. The maximum number drug 
challenges were 3 per cell. Frequency and amplitude of mEPSCs were measured over 
200s once the effect of a drug had plateaued (i.e. constant frequency mESPCs over 
200s) which was approximately 5-7 min after application. The drug/s were then 
washed out with aCSF. This was carried out within the 10 min window. In the case 
phenylbiguanide experiments, the 2nd challenge and higher was given after the 
recover from the lower doses. In case of the 5-HT experiments all neurons received 
two challenges of different 5-HT doses. For all experiments with antagonist and 
combined agonist/antagonist/uptake inhibitor only received on challenge of the 
antagonist alone or combination.  
 
 Horizontal Slice: Recording sEPSCs and Evoked EPSCs 
 
The paired-pulse ratio was calculated as the amplitude of the second current relative 
to that of the first; alterations in the paired-pulse ratio are suggestive of a presynaptic 
site of action. 
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Measurement of increases in EPSC activity due electrical stimulation of solitary tract 
were always taken 1 min after stimulation had ceased, as this is when the maximum 
increase in activity was observed and averaged over a 30 s period. Two control 
stimulations of solitary tract (ST) were taken 10 min apart to determine stability. 
Drugs were applied 5 min after the 2nd stimulation and the changes in frequency and 
amplitude were compared to that of the 2nd control stimulation.  
 
2.2.6. Statistical Analysis 
 
All data is presented as mean ± standard error of the mean (s.e.m). When comparing 
three or more treatment groups statistical analysis was performed using a 1-way 
analysis of variance (ANOVA) to compare drug-treated experimental groups to its 
time-matched aCSF control group. Post-hoc analysis was performed using the least 
significant difference test, to calculate significant differences between means of drug 
and aCSF control groups. 
When comparing two groups of data statistical analysis was performed using 
Student’s unpaired t-test to compare drug-treated experimental groups to its time-
matched control group. 
For all statistical analysis, differences between groups were considered significant 
when P < 0.05. 
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Figure 2.10  Anatomy of coronal NTS-containing brain slice 
 
Coronal NTS-containing brain slice as visualised in the recording chamber under low 
power optics (4x) in preparation of patch-clamp recordings. Overlaid with schematic 
diagram of anatomical features used to identify recording location (SolIM).  
 
 
10- dorsal motor nucleus of vagus 
AP- area postrema 
Sol- Solitary tract 
CC- Central canal 
Gr- Gracile nucleus 
SolIM- Nucleus of the solitary tract, intermediate 
SolC- Nucleus of the solitary tract, commissural 
SolDM- Nucleus of the solitary tract, dorsonmedial 
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Figure 2.11   Anatomy of horizontal NTS-containing brain slice 
 
Horizontal NTS-containing brain slice as visualised in the recording chamber under 
low power optics (4x) in preparation of patch-clamp recordings with electrical 
stimulation of the solitary tract.  
 
 
sol- Solitary tract 
Stim.- Stimulating electrode 
4V- 4th Ventricle 
NTS- Nucleus of the solitary tract 
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Figure 2.12   Identification of NTS cells  
 
 
Photomicrograph taken from a live image as visualised for patch-clamp recordings 
using differential interference contrast optics. Figure shows the surface of the SolIM 
region of a coronal NTS-containing slice. Indicated (*) are two cells typical of all 
those from which recordings were attempted. Note the characteristic size and spindle 
shape.
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2.3. Drugs and solutions 
 
The chemical ingredients for aCSF were all obtained from (Sigma-Aldrich, St. Louis, 
MO, USA) 
 
Dissolved in 0.9 % saline or aCSF: 
 
5-HT creatinine sulphate (Sigma-Aldrich, UK) 
5-Hydroxyindole-3-acetic acid (Sigma-Aldrich, UK) 
8-OH-DPAT hydrobromide (Sigma-Aldrich, UK) 
α-bungarotoxin (Sigma-Aldrich, UK) 
α-chloralose (Sigma-Aldrich, UK) was dissolved (10 mg ml-1)  
Citalopram hydrobromide (AbcamBiochemicals, UK) 
Desipramine hydrochloride (Sigma-Aldrich, UK) 
DL-p-chlorophenylalanine methyl ester (Sigma-Aldrich, UK) 
DL -Fluorocitric acid barium salt (Sigma-Aldrich, St. Louis, MO, USA) 
DL -Isocitric acid trisodium salt hydrate (Sigma-Aldrich, St. Louis, MO, USA) 
DL -Norepinephrine hydrochloride (Sigma-Aldrich, UK) 
Dopamine hydrochloride (Sigma-Aldrich, UK) 
Gabazine (Sigma-Aldrich, USA) 
GBR-12909 (AbcamBiochemicals, UK) 
Granisetron hydrochloride (AbcamBiochemicals, Boston, MA) 
Reboxetine mesylate (AbcamBiochemicals, UK) 
Phenylbiguanide (Sigma-Aldrich, UK) 
Phenylephrine (Sigma-Aldrich, UK)  
Pontamine sky blue (BDH, UK) 
Sodium cyanide (BDH, UK) 
Sodium nitroprusside (Sigma-Aldrich, UK) 
Tetrodotoxin (AbcamBiochemicals, Boston, MA) 
WAY-100635 maleate, (Sigma-RBI, St. Louis, MO USA) 
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Dissolved in DMSO: 
 
CNQX (Tocris, USA) 
Decynum-22 (Sigma-Aldrich, UK/USA) 
 
Other drugs and reagents: 
 
D-glucose (BDH, UK) 
Dimethyl sulfoxide (DMSO) (Sigma, UK) 
Gelofusine® (plasma substitute; Braun Medical Ltd, UK) 
Isoflurane (Aerrane®; Baxter Healthcare Ltd, UK) 
Lignocaine spray (Xylocaine®; AstraZeneca, UK). 
Pentobarbitone sodium (Sagatal®; Rhône-Mérieux Ltd, UK) 
Sodium bicarbonate (BDH, UK) 
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3. 5-HT3 AND 5-HT1A RECEPTORS MODULATE SPONTANEOUS 
AND SOLITARY TRACT EVOKED GLUTAMATE RELEASE IN THE 
NTS IN VITRO 
 
3.1. Introduction 
 
The 5-HT3 receptor is known to be densely expressed in the NTS, mainly on vagal 
afferent fibre terminals (Pratt & Bowery, 1989, Reynolds et al., 1989). Following 
nodose ganglionectomy 5-HT3 ligand binding sites in the NTS were reduced by 
approximately 50%. This indicated that 5-HT3 receptors are expressed on the vagal 
afferent terminals themselves. In vivo they have been shown to control glutamate 
release from vagal afferent terminals as blockade of these receptors attenuates vagal 
afferent excitation (Ramage & Mifflin, 1998, Jeggo et al., 2005). One study using the 
brainstem slice preparation to study this system within the NTS found that 
spontaneous glutamate release was attenuated by the 5-HT3 receptor antagonist 
ondansetron (Wan & Browning, 2008). Further, it was found that this effect was 
abolished by vagotomy. Taken together these observations suggest that there is a 
tonic release of 5-HT within the NTS that activates 5-HT3 receptors on vagal 
afferents increasing glutamate release, at least within the slice preparation. The 
source of this 5-HT is unknown but it is likely that there is a 5-HT input from raphé 
cell groups. It is also possible that 5-HT is released from vagal afferents themselves. 
The current understanding of this system is summarised in figure 3.1. 
 
5-HT neurotransmission is highly regulated by its uptake systems, of which there are 
several different types (see INTRODUCTION 1.4). The present experiments sought to 
determine how these different re-uptake systems controlled 5-HT released in the 
NTS slice preparation. Therefore the present experiments were carried out to 
investigate the effects of blockade of the 5-HT transporter with citalopram and 
blockade of the organic cation transporter 3 (OCT3)/plasma membrane monoamine 
transporter (PMAT) with decynium-22 on mEPSCs recorded in NTS cells within the 
brainstem slice preparation. 
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Further, it is widely reported that electrical stimulation of this fibre tract cause 
inward currents in NTS cells mediated by glutamate release (Doyle & Andresen, 
2001, Zhang & Mifflin, 2007). Repeated stimulation of the tractus has also been 
shown to increase spontaneous activity immediately following the stimulus. This is 
known as ‘asynchronous’ release (Andresen et al., 2012). 5-HT3 antagonists have 
been shown to attenuate glutamatergic currents with single pulse stimulation (Wan & 
Browning, 2008). The effect of these reuptake inhibitors on glutamate release elicited 
by both single pulse stimulation and repeated (train) stimulation of the tractus. 
 
This study was carried out at the Department of Integrative Physiology, University of 
North Texas (Heath Science Centre), Fort Worth, Texas, USA. The Institutional 
Animal Care and Use Committee of the University of North Texas Health Science 
Center approved all experimental protocols. 
 
3.2. Specific aims 
 
 
• Reassess the effect of 5-HT3 ligands on mEPSCs recorded within the NTS 
and confirm the presence of tonic 5-HT3 receptor activation.  
 
• Investigate the effect of re-uptake inhibitors citalopram and decynium-22 on 
this tonically released 5-HT. 
 
• Investigate the effect of 5-HT re-uptake inhibitors on evoked synaptic 
currents using electrical stimulation of the solitary tract. 
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Figure 3.1 NTS neuronal inputs 
 
Schematic representation of neuronal input into the NTS. Vagal afferents containing 
glutamate terminate onto second-order cells within the NTS. Glutamate is 
spontaneously released from these afferent terminals and activates AMPA receptors 
expressed by NTS cells. 5-HT-containing terminals from raphe cell groups as well as 
5-HT containing vagal afferents also innervate the NTS. Little is known about 5-HT- 
containing vagal afferents and where they terminate.  
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3.3. Electrophysiological properties 
 
Spontaneous mEPSCs were recorded in 72 NTS neurons in the presence of 1µM 
TTX and 25µM gabazine. Baseline mEPSCs frequency was found to be 2.0 ± 0.6 Hz 
with mean amplitude 13.5 ± 0.8pA. This activity could be completely blocked by the 
application CNQX (10µM; n=3; Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Effect of CNQX on mEPSCs 
 
Representative mEPSC traces from an intermediate NTS neuron voltage clamped at -
60mV. Each panel represents 5 overlapping traces. Bottom trace is recorded in the 
presence of AMPA/kinate receptor antagonist CNQX (10uM).  
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3.4. Effect of 5-HT3 ligands on spontaneous glutamate release 
 
Effect of 5-HT3 agonist phenylbiguanide 
 
Bath application of the 5-HT3 agonist phenylbiguanide (PBG; 1µM, n=7) increased 
mEPSC frequency by 497 ± 112%. Applications of 10µM increased frequency by 
1744 ± 614% (n=4). Experimental traces are shown in figure 3.3. In the presence of 
granisetron (GRN; 1µM, n=5) 1µM PBG now only increased frequency by 58 ± 
15%. Experimental traces are shown in figure 3.6. These values were significantly 
different to time-matched control (n=6) were frequency only changed by -2.8 ± 5.4% 
over the same interval. Combined data is shown in figure 3.7A. The peak effect of 
PBG after bath application is typically reached within 2-3 minutes (figure 3.5).  
 
mEPSC amplitude was increased by 18 ± 5% and 42 ± 20% by applications of 1µM 
(n=7) and 10µM (n=4) PBG, respectively (figure 3.5A). These values were 
significantly different to time-matched control (n=6) where amplitude changed by -
3.3 ± 3.3% over the same interval. In the presence of granisetron (1µM, n=5, figure 
3.6 and 3.5B) 1µM PBG had no effect on amplitude (-3.5 ± 2.9%). Combined data is 
shown in figure 3.7B.  
 
 
Effect of 5-HT3 antagonist granisetron   
 
Bath application of the 5-HT3 granisetron (1 µM; n=6) caused a gradual and 
significant decline in frequency of spontaneous mEPSCs (figure 3.8A and 3.9A). The 
effect reached its maximum of -36 ± 4% between 5 to 7 min following application 
(figure 3.8B). Granisetron had no significant effect on mEPSC amplitude (figure 
3.9B).  
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Figure 3.3 Effect of PBG on mEPSCs: Traces 
Representative mEPSC traces from a neuron recorded in the NTS  during control 
(aCSF + 1µM TTX and 25µM gabazine) and following bath applications of 
phenylbiguanide (PBG; 1 and 10µM) . Each panel represents 6 overlapping traces 5s 
in length.  
Control (1µM TTX, 25µM Gabazine) 
+ 1µM PBG 
+ 10µM PBG 
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Figure 3.4 Effect of PBG on mEPSCs: Frequency Histogram 
Frequency histograms of average mEPSC frequency over time binned into 10s 
periods from a neuron recorded in the NTS treated with 1µM (upper) and 10µM 
(lower-note difference in scale) phenylbiguanide (PBG).  
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Figure 3.5 Effect of PBG on mEPSCs: Amplitude 
 
A)  Cumulative fraction of mEPSC event amplitudes during control and following 
bath applications of phenylbiguanide (PBG; 1-10µM). Events were cumulatively 
binned at 1pA intervals.  
 
B)  Cumulative fraction of mEPSC event amplitudes during control and following 
bath applications of phenylbiguanide (PBG; 1µM) and PBG + granisetron (GRN). 
Events were cumulatively binned at 1pA intervals.  
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Figure 3.6 Attenuation of the effect of PBG with granisetron 
 
A)  Representative mEPSC traces from a neuron recorded in the NTS  during control 
(aCSF + 1µM TTX and 25µM gabazine) and following bath applications of 
phenylbiguanide (PBG; 1µM)  and 1µM PBG + 1µM granisetron (GRN). Each panel 
represents 6 overlapping traces 5s in length. 
  
Control (1 µM TTX, 25µM gabazine) 
+1µM PBG 
+1µM PBG + 1µM GRN  
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Figure 3.7 PBG and granisetron: Combined data 
 
A)   Histogram of mean (±s.e.m) changes in mEPSC frequency of NTS cells 
following bath application of phenylbiguanide (PBG; 1 and 10µM; n=7 and 3, 
respectively) in the presence and absence of granisetron (GRN; 1µM, n=5) compared 
to control (n=7). Compared to control with 1-Way ANOVA followed by Fisher’s 
LSD test; ***P<0.001, ns; non-significant. 
 
B)   Histogram of mean (±s.e.m) changes in mEPSC amplitude of NTS cells 
following bath application of phenylbiguanide (PBG; 1 and 10µM; n=7 and 3, 
respectively) in the presence and absence of granisetron (GRN; 1µM, n=5) compared 
to control (n=7). Compared to control with 1-Way ANOVA followed by Fisher’s 
LSD test; *P<0.05, ns; non-significant.  
 
 
 
 
 
 
  
 151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Control PBG 1µM PBG 10µM PBG 1µM
+
GRN 1µM-20
0
20
40
60
80
%

m
EP
SC
 A
m
pl
itu
de
*
*
ns
Control PBG 1µM PBG 10µM PBG 1µM
+
GRN 1µM-500
0
500
1000
1500
%

m
EP
SC
 F
re
qu
en
cy
***
***
ns
A 
B 
 152 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Effect of granisetron alone on mEPSC frequency 
 
A) Representative mEPSC traces from a neuron recorded in the NTS during control 
(aCSF + 1µM TTX and 25µM gabazine) and following bath applications of 
granisetron (GRN; 1µM). Each panel represents 6 overlapping traces 5s in length.  
B) Frequency histogram of mEPSC frequency over time binned into 10s periods 
from a neuron recorded in the NTS treated with 1µM granisetron (GRN).  
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Figure 3.9 Effect of granisetron on mEPSC frequency: Combined data 
 
Histograms of mean (±s.e.m) changes in mEPSC A) frequency and B) amplitude of 
NTS cells following bath application of granisetron (GRN; 1µM n=6) and aCSF 
(control; n=6). Compared to control with Students unpaired t-test; *P<0.05. 
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3.5. Effect of 5-HT on spontaneous glutamate release 
 
  Effect of 5-HT on mEPSC frequency 
 
5-HT at a range of concentrations (0.3µM - 10µM) was applied to the brainstem slice 
while recording mEPSC activity from a cell within the NTS. Experimental traces are 
shown in figure 3.10. Application of 0.3µM 5-HT decreased the frequency of 
spontaneous mEPSCs in all NTS neurons tested (n=5) by 53 ± 12%, while 1µM 5-
HT had a mixed effect. In 6 of 11 neurons tested there was a significant decrease in 
frequency of 62 ± 10%. In the remaining 5 there was a significant increase in 
frequency of 403 ± 142%. Application of 10µM 5-HT significantly increased 
mEPSC frequency in all cases (n=5) by 1285 ± 276%. Application of 100µM 5-HT 
significantly increased mEPSC frequency in all cases (n=5) by 2462 ± 543%. 
Combined data of inhibitory effects is shown in figure 3.13 and excitatory effects are 
shown in figure 3.14 for clarity.  
 
Time of onset for both excitatory and inhibitory peak responses was approximately 
4-5 minutes. In both cases there was a gradual increase in drug effect to plateau 
starting approximately 1minute after the drug was introduced to the slice bath (figure 
3.11).  
 
Concentrations of 0.3 and 1µM 5-HT in cells that had an inhibitory effect mEPSC 
frequency also had no effect on mEPSC amplitude. In cells that displayed an 
excitatory effect on mEPSC frequency, amplitude was significantly increased (c.f. 
control; -3.2 ± 3.3%) by 21.4 ± 4.8% and 51.7 ± 8.5% when the slice was exposed to 
5-HT concentrations of 10µM and 100µM. However, 1µM 5-HT had no significant 
effect on mEPSC amplitude (-2.7 ± 5.0%; figure 3.12). Combined data is shown in 
figure 3.15.  
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  Effect of 5-HT1A and 5-HT3 antagonists 
 
In the presence of granisetron (1µM, n=6), the highest dose of 5-HT now caused a 
decrease in mEPSC frequency of 30±11 %. This was in addition to the inhibitory 
effect of granisetron alone (see section 3.4). The lowest dose (0.3µM), in the 
presence of the 5-HT1A antagonist WAY-10035 now caused no change in mEPSC 
frequency of 3.3 ±  22.3% (n=8). In both cases there was no significant effect on 
mEPSC amplitude. Combined data is shown in figure 3.14.  
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Figure 3.10 Effect of 5-HT on mEPSC frequency: Traces 
 
Representative mEPSC traces from neurons recorded in   the NTS during control 
(aCSF + 1µM TTX and 25µM gabazine) and following bath applications of 5-HT 
(0.3-100µM). Each panel represents 6 overlapping traces 5s in length. 
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Figure 3.11 Effect of 5-HT on mEPSC frequency: Frequency 
Histograms 
 
Frequency histogram of mEPSC frequency over time binned into 10s periods from 3 
neurons recorded in the NTS treated with A) 0.3µM B) 1µM and C) 10µM 5-HT.  
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Figure 3.12 Effect of 5-HT on amplitude: Cumulative fraction plot 
 
Cumulative fraction plot of mEPSC amplitudes from the same cell during control 
(aCSF + 1µM TTX and 25µM gabazine) and following bath applications of 5-HT 1-
100 µM. Events were cumulatively binned at 1pA intervals 
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Figure 3.13 Effect of low dose 5-HT on frequency: Combined Data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in mEPSC frequency 
of NTS cells following bath application of aCSF (Control: aCSF + 1µM TTX and 
25µM gabazine; n=6), 0.3µM (n=5), 1µM 5-HT (n=5). Additionally, 10µM 5-HT in 
the presence of granisetron  (GRN; 3µM n=6) and 0.3µM 5-HT in the presence of 
WAY-100635 (WAY; 1µM (n=8). Compared to control with 1-Way ANOVA 
followed by Fisher’s LSD test; *P<0.05, **P<0.01, *** P<0.001, ns; non-
significant.  
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Figure 3.14 Effect of high dose 5-HT on frequency: Combined Data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in mEPSC frequency 
of NTS cells following bath application of aCSF (Control: aCSF + 1µM TTX and 
25µM gabazine; n=6), 0.3µM (n=5), 1µM 5-HT (n=5). Additionally, 10µM 5-HT in 
the presence of  granisetron  (GRN; 3µM n=6). Compared to control with 1-Way 
ANOVA followed by Fisher’s LSD test; **P<0.01, *** P<0.001, ns; non-
significant. 
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Figure 3.15 Effect of 5-HT on mEPSC amplitude: Combined data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in mEPSC amplitude 
of NTS cells following bath application of aCSF (Control: aCSF + 1µM TTX and 
25µM gabazine; n=6), 1µM  5-HT (n=5), 10µM  5-HT (n=6) and 100µM (n= 5). 
Data for 1µM 5-HT taken from those cells excited by 5-HT application. Compared to 
control with 1-Way ANOVA followed by Fisher’s LSD test; **P<0.01, *** 
P<0.001, ns; non-significant. 
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3.6. Effect of re-uptake inhibitors on spontaneous glutamate 
release 
 
Experimental traces showing the effect of the various re-uptake inhibitors are shown 
in figure 3.16. Combined data of the effects of citalopram, the 5-HT transporter 
inhibitor, alone and in the presence WAY-100635 is shown in figure 3.17. The 
effects of decynium-22, the 5-HT OCT3/PMAT inhibitor, alone and in the presence 
WAY-100635 is shown in figure 3.18 
 
Effect of 5-HT transporter inhibitor citalopram 
 
Application of the 5-HT transporter inhibitor citalopram (500nM; n=5) caused a 
significant decrease of 54 ± 5% in the spontaneous frequency of mEPSCs, whilst a 
higher dose of citalopram (5 µM; n=5) had a similar effect (-38 ± 6%). These values 
were significantly different to the time-matched control (n=7) where frequency 
changed by -2.5 ± 4.4% over the same interval. In both cases there was no significant 
effect on mEPSC amplitude.  
 
Effect of OCT3/PMAT inhibitor D-22 
 
Similarly blockade of OCT3/PMAT with D-22 1µM (n=4) also caused a significant 
reduction in mEPSCs of 33 ± 4%, while 10µM (n=3) caused a reduction of 44 ± 6%. 
In all cases amplitudes remained unchanged. Again, these values were significantly 
different to the time-matched control over the same interval. In both cases there was 
no significant effect on mEPSC amplitude.  
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  Effect of 5-HT1 A antagonists on uptake blockade 
 
Application of aCSF (control; n=11) and WAY-100635 (1µM; n=12) and no 
significant effect on the spontaneous mEPSC frequency changing by -7.2 ± 2% and 
1.2 ± 4%, respectively. However pre-treatment with WAY-100635 blocked the 
ability of both doses of citalopram (0.5 µM; n=5, 5 µM; n=4) to significantly reduce 
mEPSC frequency now only changing -12 ± 5% and 1.8 ± 23%, respectively. 
WAY-100635 pre-treatment also blocked the ability of both doses of D-22 (1µM; 
n=6; 10µM; n=4) to decrease mEPSC frequency, although for the higher dose of D-
22 a significant increase in mEPSC frequency (57 ± 39%) was now observed. In all 
cases amplitudes remained unchanged. 
 
Effect of corticosterone 
 
Application of the OCT3 inhibitor corticosterone (1µM; n=5; 3µM; n=4) caused no 
change in mEPSC frequency at both doses. After application of the lower dose 
mEPSC frequency changed by -1.5 ± 22% and the higher dose caused change of 10 ± 
19%. Both were found to be not significantly different from control (figure 3.19). 
Again, amplitude remained unchanged.  
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Figure 3.16 Effect of re-inhibitors on mEPSC frequency: Traces 
 
Representative mEPSC traces from neurons recorded in   the NTS during control 
(aCSF + 1µM TTX and 25µM gabazine) and following bath applications of 
citalopram (CIT; 0.5µM), Decynium-22 (D-22; 10µM), WAY-100635 (WAY; 1µM) 
and citalopram and D-22 in the presence of WAY-100635. Each panel represents 6 
overlapping traces 5s in length. 
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Figure 3.17 Re-uptake inhibitors: Citalopram combined data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in mEPSC frequency 
of NTS cells following bath application of aCSF (Control: aCSF + 1µM TTX and 
25µM gabazine; n=7), WAY-100635 (WAY; 1µM, n=12), citalopram (CIT; 0.5µM, 
n=5 & 5µM, n= 5) and citalopram in the presence of 1µM WAY-100635 (0.5µM; 
n=6, 5µM; n=4). Compared to control with 1-Way ANOVA followed by Fisher’s 
LSD test; *P<0.05, **P<0.01, ns; non-significant. 
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Figure 3.18 Re-uptake inhibitors: D-22 combined data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in mEPSC frequency 
of NTS cells following bath application of aCSF (Control: aCSF + 1µM TTX and 
25µM gabazine; n=7), WAY-100635 (WAY; 1µM, n=12), Decynium-22 (D-22; 
1µM, n=4 & 10µM, n= 3) and Decynium-22 in the presence of 1µM WAY-100635 
(1µM; n=6, 10µM; n=4). Compared to control with 1-Way ANOVA followed by 
Fisher’s LSD test; *P<0.05, *** P<0.001, ns; non-significant. 
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Figure 3.19 Effect of corticosterone: combined data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in mEPSC frequency 
of NTS cells following bath application of aCSF (Control: aCSF + 1µM TTX and 
25µM gabazine; n=7), corticosterone (CORT; 1µM, n=5 & 3µM, n= 4). Compared to 
control with 1-Way ANOVA followed by Fisher’s LSD test; ns; non-significant. 
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3.7. Effect of re-uptake inhibitors on stimulated glutamate release 
 
The effect of transporter inhibitors on synaptic transmission was assessed in 26 
further NTS neurons in which EPSCs were evoked by electrical stimulation of the 
solitary tract (TS) in the present of gabazine (25 µM) alone. Application of CNQX 
(10mM n=4) completely abolished in evoked inward current (figure 3.20). 
 
  Effect of 5-HT3 receptor antagonist granisetron  
 
Granisetron (3 µM; n=6) decreased the amplitude of the first evoked EPSC when 
compared to control; -105±6 cf. -84±10 pA (figure 3.21). Percentage change data 
showed that granisetron significantly decreased the amplitude of the first evoked 
EPSC, when compared to control (-17.4 ± 5.3% c.f. -1.7 ± 1.90). Combined data is 
shown in figure 3.23. Paired-pulse ratio (PPR) increased significantly from 0.64 ± 
0.12 to 0.73 ± 0.12 (figure 3.24).  
 
  Effect of 5-HT transporter inhibitor citalopram 
 
Citalopram (0.5 µM; n=10) failed to modify the amplitude of the first evoked EPSC 
when compared to control; -85±10 cf. -90±9 pA (figure 3.22A). Percentage change 
data was calculated and again, no significant change was detected between control 
and after drug application (-8.1 ± 6.0% c.f. -1.7 ± 1.90). Combined data is shown in 
figure 3.23. Paired-pulse ratio (PPR) also remained unaltered (0.66 ± 0.08 c.f. 0.68 ± 
0.06). Combined data is shown in figure 3.24. 
 
 
 
 
 
 
 172 
  Effect of OCT3/PMAT inhibitor D-22 
 
 
D-22 (1µM; n=7) also failed to modify the evoked EPSC when compared to control; 
-95±12 c.f  94±7pA (figure 3.22B). Percentage change data was calculated and 
again, no significant change was detected between control and after drug application; 
-7.6 ± 5.7% c.f. -1.7 ± 1.9%. Combined data is shown in figure 3.23. Paired-pulse 
ratio was also unaltered (0.71 ± 0.08 c.f. 0.71 ± 0.07). Combined data is shown in 
figure 3.24. However, the higher dose of D-22 (10 µM; n = 4) significantly increased 
the amplitude of the first evoked EPSC; 107±20 c.f 131±22.6pA (figure 3.22C). 
Percentage change data showed significantly the amplitude was significantly 
increased when compared to control (27.2 ± 6.8% c.f. -1.7 ± 1.90). Paired-pulse ratio 
decreased significantly from 0.75 ± 0.08 to 0.44 ± 0.07 (figure 2.24).  
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Figure 3.20 Single pulse stimulation: effect of CNQX 
 
Representative evoked EPSC traces from a neuron recorded in   the NTS during 
control (aCSF + 25µM gabazine) and following bath applications of CNQX (10µM).  
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Figure 3.21 Single pulse stimulation: effect of granisetron 
 
Representative evoked EPSC traces from a neuron recorded in the NTS during 
control (aCSF + 25µM gabazine) and following bath applications of granisetron 
(3µM).  
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Figure 3.22 Single pulse stimulation: effect of re-uptake inhibitors 
 
 
A)  Representative evoked EPSC traces from a neuron recorded in the NTS during 
control (aCSF + 25µM gabazine) and following bath applications of citalopram (CIT; 
0.5µM). 
 
B)  Representative evoked EPSC traces from a neuron recorded in the NTS during 
control (aCSF + 25µM gabazine) and following bath applications of  D-22 (1µM). 
 
 
C)  Representative evoked EPSC traces from a neuron recorded in the NTS during 
control (aCSF + 25µM gabazine) and following bath applications of D-22 (10µM). 
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Figure 3.23 Effect of re-uptake inhibitors on EPSC amplitude: 
Combined data 
 
Histogram of mean (±s.e.m) percentage changes over control in evoked EPSC 
amplitude recorded in NTS cells following bath application of the following: aCSF 
(Control: aCSF + 25µM gabazine; n=10), granisetron (GRN; 3µM, n=6), citalopram 
(CIT; 0.5 µM, n=10), D-22; 1µM (n=6) & 10µM (n= 4). Compared to control with 1-
Way ANOVA followed by Fisher’s LSD test; *P<0.05, **P<0.01, ns; non-
significant. 
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Figure 3.24 Effect on EPSC paired pulse ratio: Combined data 
 
Histogram of mean (±s.e.m) of the amplitude ratio of a pair of EPSCs  evoked by 
electrical tractus stimulation. Each control and drug application is taken as matched 
pairs from the same cell. Control: aCSF + 25µM gabazine; n=10), granisetron (GRN; 
3µM, n=6), citalopram (CIT; 0.5 µM, n=10), D-22; 1µM (n=6) & 10µM (n= 4). 
Compared to control with Students paired t-test; *P<0.05, ns;  non-significant. 
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Trains of 100 pulses at 20 Hz 
 
Spontaneous EPSCs were recorded from 17 neurons. The mean frequency and 
amplitude were 1.6 ± 0.3 Hz and 17.1 ± 1.1pA. The frequency ranged between 0.2 to 
4.6 Hz. Electrical stimulation of the TS (100 pulses at 20Hz; figure 3.25) evoked an 
increase in sEPSC frequency of 106 ± 13% when compared to baseline. This 
remained unaltered in one subsequent stimulation (100 ± 6%). Amplitude was not 
significantly affected. Citalopram (0.5µM; n=6) failed to alter this evoked increase in 
sEPSCs (99 ± 23%), however D-22 (1µM; n=8, figure 3.26) caused a significant 
(P<0.01) increase in sEPSCs (242 ± 20%). Amplitude was unaffected by both 
stimulation and drug application. Combined data is shown in figure 3.27. 
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Figure 3.25 20Hz Train stimulation: Traces 
 
Representative experimental traces of spontaneous EPCS from a neuron recorded in 
an NTS neuron. Baseline was recorded in ACSF with 25µM gabazine. Trains of 100 
stimulation pulses were then applied to the solitary tract (*denotes stimulus artifact) 
in ACSF with 25µM gabazine. The stimulus was repeated 10min after application of 
1µM D-22. Each panel represents 6 overlapping traces 5s in length. 
 
Baseline (ACSF + 25µM Gabazine) 
Control stimulation 
+ 1µM D-22 
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Figure 3.26 20Hz Train stimulation: Histogram 
 
Frequency histogram of sEPSC frequency over time binned into 10s periods from a 
neuron recorded in the NTS before and after applying trains of 100 stimulation 
pulses to the solitary tract in the presence and absence of D-22 (1µM).  
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Figure 3.27 20Hz Train stimulation: Combined Data 
 
Histogram of mean (±s.e.m) percentage changes over baseline in spontaneous EPSC 
(sEPSC) frequency and amplitude recorded in NTS cells measured over 60s post 
application of 100 stimulation pulses to the solitary tract. Control; aCSF + 25µM 
gabazine; n=9, Control =10min; aCSF + 25µM gabazine; n=9 10min after initial 
stimulation, citalopram (CIT; 0.5 µM, n=6) and D-22; 1µM (n=6). Compared to 
control with 1-Way ANOVA followed by Fisher’s LSD test; **P<0.0, ns;  non-
significant 
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3.8. Effect of glial metabolic inhibitor fluorocitrate 
 
Application of 50µM fluorocitrate decreased the frequency of spontaneous mEPSCs 
in NTS neurons tested (n=2; figure 2.8) by 41 ± 2%. On the other hand, the inactive 
analogue of fluorocitrate, isocitrate (50 µM) had no effect on mEPSC frequency (-
0.2± 8.6%; n=3). In the presence fluorocitrate and isocitrate mEPSC amplitude was 
changed by -6.9 ± 1% and 0.6 ± 0.9%, respectively. Combined data is shown in 
figure 2.9.  
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Figure 3.28 Effect of isofluorocitrate on mEFPC frequency 
 
Frequency histogram of mEPSC frequency over time binned into 10s periods from a 
neuron recorded in the NTS A) during the application of isocitrate (50µM) and B) 
during the application glial metabolic inhibitor fluorocitrate (50µM). 
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3.9. Discussion  
 
3.9.1. Main findings 
 
The present studies focused on the modulation of glutamate release by 5-HT3 and 5-
HT1A receptors examined in the brainstem slice preparation. The data indicates that 
5-HT3 receptors are tonically activated in this preparation and modulate the 
frequency of glutamate release from a presynaptic location. Attempts to augment this 
spontaneous release of 5-HT with re-uptake inhibitors caused a paradoxical decrease 
in mEPSC frequency. This was found to be caused by activation of presynaptic 5-
HT1A receptors. Indeed, 5-HT itself has a biphasic dose response curve when applied 
exogenously, with low doses causing inhibition via activation of the 5-HT1A receptor. 
Higher doses of 5-HT cause excitation via activation of the 5-HT3 receptor.  
 
The 5-HT transporter re-uptake inhibitor failed to increase the frequency of 
spontaneous EPSCs induced by stimulating the solitary tract with a train of pulses, 
whereas the OCT3/PMAT inhibitor D-22 caused an increase in this release. This 
indicates that OCT3/PMAT are responsible for the removal of 5-HT from the 
extracellular space when concentrations are high subsequent to stimulation.  
 
Finally, preliminary data indicates that glia cells present in the NTS are a source of 
some the spontaneously released glutamate seen in this preparation.  
 
3.9.2. Spontaneous release 
 
The ability of the selective 5-HT3 antagonist granisetron (Sanger & Nelson, 1989) to 
reduce spontaneous glutamatergic mEPSCs confirms the observations of Wan and 
Browning (2008) that there is spontaneous release of 5-HT within the NTS slice. 
This acts via 5-HT3 receptors on vagal afferent terminals to release glutamate in the 
NTS in rat brainstem slice preparations treated with TTX and gabazine. In this 
respect, activation of 5-HT3 receptors in the present experiments with the 5HT3 
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agonist phenylbiguanide causes the expected increases in glutamatergic mEPSCs. 
This effect is attenuated by granisetron. This was a particularly powerful effect 
causing, in some cases, an increase of  >2000% in mEPSC frequency and was dose 
related.  
 
In contrast 5-HT caused a dose related biphasic effect on mEPSCs frequency. At low 
doses inhibition was observed while at high doses there was excitation. This 
excitation was, as seen with PBG, associated with very large increases mEPSCs 
frequency. The inhibition by low doses was found to be blocked by pretreatment 
with the 5-HT1A antagonist WAY-100635 (Forster et al., 1995), while the high dose 
excitation could be reversed to inhibition in the presence of the 5-HT3 antagonist 
granisetron. WAY-100635 alone had no effect on mEPSCs, indicating that this 
spontaneously released 5-HT is not able to activate the 5-HT1A receptor. The affinity 
for 5-HT at 5-HT1A receptors is approximately 20 times higher than at 5-HT3 
receptors; pKi 8.2 at the rat 5-HT1A receptor (Watson et al., 2000) compared to 6.8 at 
the rat 5-HT3 receptor (Kilpatrick et al., 1989). Comparing the dose of 5-HT that 
causes inhibition (0.3 µM) to that which cause excitation (1µM), in the present 
experiments, would suggest that this selectivity would be lower than that seen in an 
in vitro expression system, possibly as low as 3 times. This will also explain why the 
low concentrations of applied 5-HT activated 5-HT1A receptors causing inhibition of 
mEPSCs before activating 5-HT3 receptors to produce excitation. However, as 
spontaneously released 5-HT causes an increase in mEPSCs frequency, this would 
imply that the sites releasing 5-HT are nearer to the 5HT3 than the 5-HT1A receptors. 
Further, the size of the 5-HT3-mediated effect on glutamatergic mEPSCs is 
consistent with that observed in vivo (Wang et al., 1997, Ramage & Mifflin, 1998, 
Jeggo et al., 2005) supporting the view these receptors are important in visceral 
afferent processing in the NTS. 
 
Blockade of 5-HT reuptake via either the high-affinity low-capacity transporter (5-
HT transporter or SERT) with citalopram or the low-affinity high-capacity 
transporters (OCT3/PMAT) with decynium-22 caused a decrease in mEPSCs 
frequency rather than the expected increase. This decrease was prevented by 
pretreatment WAY-100635, indicating that blockade of 5-HT removal from the 
extracellular space allows the spontaneously released 5-HT to activate 5-HT1A 
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receptors. Further, this now overrides the background activation of 5HT3 receptors. 
Surprisingly, blockade of either uptake system, even with larger doses of the uptake 
inhibitors, in the presence of WAY-100635 failed to produce a 5-HT3-mediated 
increase in glutamatergic mEPSCs. Although with the high dose of decynium-22 
there was a small but observable increase in mEPSCs frequency. It should be noted 
that this was a very small effect when compared to that caused by the high dose of 5-
HT added to the slice; a 57 ± 39% increase compared to a 2462 ± 543% increase in 
mEPSCs frequency. This implies that these uptake transporters do not play a major 
role in the regulation of the low levels of extracellular 5HT caused by its 
spontaneous release in the vicinity of these 5HT3 receptors, but do limit the 
availability of 5-HT at 5-HT1A receptors. This is particularly intriguing because the 5-
HT1A receptor effect is predominant when a low concentration of 5-HT is added to 
the slice. Again, this supports the view that the 5-HT3 receptor is in very close 
proximity to this spontaneous 5-HT release site and local extracellular 5-HT 
concentration in this area is not regulated, or is poorly regulated, by uptake 
transporters. This data also indicates that both types of uptake blockade cause a 
similar rise in the background extracellular concentration of 5HT, at least when 5-HT 
is spontaneously released.  
 
Further, the failure of corticosterone, a OCT3 inhibitor (Engel & Wang, 2005), to 
have any effect on mEPSCs frequency suggests that it is PMAT rather than OCT3 
that is primarily involved in the uptake of 5-HT. This view is also supported by in 
vivo data seen in chapter 4 showing corticosterone having no effect on the uptake of 
exogenous 5-HT applied to the NTS.  
 
The ability of 5-HT reuptake blockade to cause activation of 5-HT1A receptors is 
reminiscent of one of the explanations for the delay in onset of the therapeutic affect 
of 5-HT uptake inhibitors in the treatment of depression. That is, although 5-HT 
uptake is blocked immediately, the activation of 5-HT1A receptors causes an initial 
reduction in the overall release of 5-HT in the cortex until the 5-HT1A receptor 
desensitizes (see Artigas et al., 1996). However, there no evidence in the NTS that 5-
HT1A receptors are acting, as they do in the dorsal raphé, as somatodendritic 
autoreceptors. Therefore, NTS 5-HT1A receptors should be considered postsynaptic 
5-HT1A receptors, presumably similar to those that have been well described in the 
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hippocampus (see Riad et al., 2000, Polter & Li, 2010). Further the present 
observation that activation of 5-HT1A receptors failed to decrease the amplitude of 
the mEPSCs indicates that these receptors are presynaptic to the neurons from which 
recordings were made. Although 5-HT3 receptors have been shown to be 
predominantly located on vagal afferents terminals, there is no experimental 
evidence that 5HT1A receptors are also found on these terminals. Nonetheless, in the 
analogous primary afferent system in the spinal cord, a small proportion of the 5HT1A 
receptors have been found on primary afferent fibers along with 5-HT3 receptors. 
(Laporte et al., 1995) Thus, by analogy, there may be a few on vagal afferents 
terminals. It should be noted that the NTS has a high density of 5–HT1A receptors 
(Pompeiano et al., 1992), although in vivo experiments have so far failed to 
determine their role in the regulation of vagal afferent excitation of NTS neurons 
(Oskutyte et al., 2009). 
 
Fluorocitrate is shown to reduce the glutamatergic mEPSC frequency recorded in 
NTS cells. Fluorocitrate, selectively taken up by astrocytes, suppresses the citric acid 
cycle and reduces glutamine production in microglia and astrocytes leading to a 
depravation of energy in these cells (Hassel et al., 1992, Fonnum et al., 1997). The 
turnover of neurotransmitters within a cell is particularly energy intensive so release 
of transmitter would be prevented if energy production were to be halted. This data 
indicates that approximately 40% of the recorded mEPSC result from glutamate 
released from glia. Indeed, glutamate has been previously identified as a 
gliotransmitter (Halassa et al., 2007). To confirm the specificity of fluorocitrate, 
isocitrate, an inactive isomer, was administered but had no effect on mEPSC 
frequency. This, therefore, reduces the likelihood of the observation being a result of 
off-target effects.  
 
 
3.9.3. Evoked release 
 
The present observation that the amplitudes of the evoked (by solitary tract 
stimulation) EPSC is reduced and the pulse paired ratio is increased in the presence 
of granisetron is again similar to that previously observed with the 5-HT3 antagonist 
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ondansetron (Wan & Browning, 2008) and can be interpreted (Mennerick & 
Zorumski, 1995, see Zucker & Regehr, 2002) to indicate that again these 5-HT3 
receptors are presynaptic to the recording site and that vagal afferent excitation 
causes the release of 5-HT in the NTS. Both doses of citalopram failed to affect 
either amplitude of evoked EPSC or the paired pulse ratio. This supports the view 
that the high-affinity low-capacity transporter (the 5-HT transporter) is not involved 
in the regulation of this glutamate-releasing 5HT3 receptor pathway, even when 
driven. However, the ability of decynium-22 to increase the amplitude of evoked 
EPSC and decrease the paired pulse interval does indicate that OCT3/PMAT plays a 
role in the regulation of the extracellular concentration of 5HT, when it is increased 
by vagal afferent stimulation but not the background concentration of 5-HT caused 
by its spontaneous release. This again was observed for a train of stimuli at 20Hz. 
Vagal afferent stimulation at this frequency causes a consistent detectable 5-HT 
release in vivo in the NTS (Hosford et al., 2011, see thesis chapter 5). The combined 
data supports the view that OCT3/PMAT but not the 5-HT transporter is involved in 
the regulation of the increase in the extracellular concentration of 5-HT in response 
to vagal afferent stimulation. However, the failure to see an effect with citalopram is 
surprising, although consistent with in vivo experiments (Hosford et al., 2012). The 
5-HT transporter appears to be only involved in the regulation of extracellular 5-HT 
levels in this 5-HT1A pathway. This is again consistent with the in vivo data that 5-
HT1A receptors are not involved in the regulation of vagal afferent release of 5-HT in 
the NTS (Oskutyte et al., 2009). Even if they were involved, the failure to detect a 5-
HT1A-mediated effect in the presence of either uptake inhibitor would not be 
surprising because a large increase in the extracellular level of 5-HT, as shown by 
adding high doses 5-HT to the slice, would easily override the 5-HT1A-mediated 
inhibitor effect on spontaneous glutamate release. The site(s) at which vagal afferent 
activation causes this release of 5-HT remains to be determined. It could be directly 
from these afferents themselves, possibly a subpopulation, and/or from 5-HT-
containing nerve terminals originating from the medullary raphe, of which there is 
significant histological evidence (see INTRODUCTION 1.3). However, the site must be 
in close juxtaposition to vagal afferent terminals. 
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3.9.4. Conclusion 
 
The present data demonstrates that the low-affinity, high-capacity monoamine uptake 
transporter (PMAT) and not the high-affinity, low-capacity transporter (5-HT 
transporter) is involved in the regulation of the rise in extracellular concentration of 
5-HT in the NTS in response vagal afferent stimulation. This rise in 5-HT activates 
5-HT3 receptors, which in turn cause the release of glutamate, confirming in vivo 
observations (Jeggo et al., 2005). The data from Wan and Browning (2008) indicates 
that this 5-HT-dependent glutamate release comes from vagal afferent terminals. 
However, it has been suggested that glia may also provide either an additional or 
alternate source (Jeggo et al., 2005). Indeed, data from the present study showing 
application of the glia-specific metabolic inhibitor fluorocitrate reduces mEPSC 
frequency supports this view. Nevertheless, when studying spontaneous release of 5-
HT within the NTS in brainstem slices, both types of uptake blockade were equally 
as effective in regulating the extracellular concentration and preventing the 5-HT 
concentration rising high enough to activate 5-HT1A receptors. Such blockade, 
surprisingly, had little effect on 5-HT3 receptor-mediated release of glutamate and 
this was interpreted to indicate that the 5-HT release site is close to these receptors. 
However the role of these 5HT1A receptors in NTS neuronal regulation remains to be 
determined, although they are protected from activation by the spontaneous released 
5-HT by both uptake systems and are preferentially activated by low concentrations 
of 5-HT, at least when compared to 5-HT3 receptors. The physiological reason for 
this remains to be determined. As there is yet no evidence that these 5HT1A receptors 
are involved in the vagal afferent activation of NTS neurons. This suggests that they 
may be involved other NTS functions not related to visceral afferent processing. The 
data does indicate that when dealing with the evoked release of 5-HT the low-
affinity, high-capacity transporter, probably PMAT, is more important than the 5-HT 
transporter for regulating the changes in extracellular cellular levels of 5-HT caused 
by stimulated release.  
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3.9.5. Future experiments 
 
The source of the 5-HT release has yet to been determined. There are a number of 
possible sources for this release and the relative contributions of each source require 
further investigation. This can be achieved by selective removal of 5-HT from two 
sources: 
Firstly, vagal afferent terminals are known to contain 5-HT (Nosjean et al., 1990, 
Sykes et al., 1994) and experiments by Wan and Browning (2008) have shown that 
differentiation by unilateral vagotomy abolishes the inhibitory effect of 5-HT3 
antagonists on mEPSC frequency in the NTS. However, this could be the result of 
either the removal of vagal afferent terminal expressing 5-HT3 or the removal of 
terminals releasing 5-HT, or both. 5,7-Dihydroxytryptamine (5,7-DHT) has been 
used to selectively destroy the 5-HT-containing pathway from the nodose ganglion to 
the NTS (Orer et al., 1991). The experimental approach would involve unilateral 
microinjection of 5,7-DHT into the nodose ganglion to remove the 5-HT-containing 
pathway without destroying the main glutamatergic input into the NTS. Experiments 
can be repeated as previously described on both sides of the NTS in a single 
brainstem slice in order to compare differences between the 5-HT depleted side and 
the control side. If 5-HT3 antagonists were less effective in the depleted side then this 
would support the view that 5-HT is release from afferent terminals within the NTS.  
 
Secondly, 5-HT input from medullary raphe nuclei into the NTS is also a likely 
source of 5-HT seen released within the present experiments. Within the brainstem 
slice there has been some suggestions that the horizontal slice configuration remove 
input originating from medullary nuclei and thus 5-HT release (Cui et al., 2012). 
However, in this configuration the 5-HT-containing terminals will still be present in 
the NTS and may be the source of some of the 5-HT release seen in the horizontal 
slice used for some of the present experiments. In this case it would be necessary to 
target the medullary nuclei themselves in order to remove the input to the NTS. 
Microinjection of 5,7-DHT into the medullary raphe nuclei would be a possible 
experimental approach.  
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4. ASSESSMENT OF MONOAMINE UPTAKE SYSTEMS IN THE 
NTS 
 
4.1. Introduction 
 
Biogenic amine reuptake inhibitors are extremely useful experimental tools are 
routinely used to aid in the identification of electroactive species measured by in vivo 
electrochemistry (see Phillips & Wightman, 2003). However, as with any 
pharmacological agent, correct dosing to maintain selectivity is paramount. 
Unfortunately, much of the current data regarding selectivity of these compounds 
relies on receptor binding studies conducted in expression systems. Further, meta-
analysis (see Stanford, 1996) of the earlier literature shows that compounds 
previously described as ‘serotonin-selective reuptake inhibitors’ are mixed 
noradrenaline and 5-HT re-uptake inhibitors, to a greater or lesser extent (see 
INTRODUCTION 1.5).  
 
Studies into the acute effect of re-uptake inhibitors in vivo often use doses in the rage 
of 5-10mg kg-1 and almost always administer these compounds i.p. (for example 
Hashemi et al., 2009, Karlsson et al., 2013, Ortega et al., 2013). When administering 
i.p higher doses are used due lower bioavailability than with i.v administration and 
plasma concentration is less predictable. However, but due to the ease of application 
of this method it is often used preferentially. Consequently, there is little data 
regarding dosing of these compounds using the i.v. route. It would seem that, given 
the affinity at the binding site is in the low nM range for most re-uptake inhibitors 
(Tatsumi et al., 1997), doses of 10mg kg-1 would ensure maximum occupancy. Still, 
the selectivity and relative potency of these compounds is largely unknown in vivo. It 
is, therefore, difficult to select an appropriate dose when using these pharmacological 
tools and selectivity is extremely important when validating electrochemical signals. 
The present study was designed to address the paucity of data in this area and gain an 
insight into the selectivity and effective doses of re-uptake inhibitors in order for the 
tools to be more confidently used when identification of electroactive species.  
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4.2. Specific Aims 
 
 
• Determine the uptake kinetics of exogenously applied 5-HT, noradrenaline and 
dopamine in the NTS by voltammetry  
 
• Evaluate the effects of commonly used selective re-uptake inhibitors on these 
parameters 
 
• Evaluate the effects of inhibitors of alternative re-uptake systems OCT3 and PMAT 
on these parameters 
 
• Compare selectivity ratios of the drugs currently available 
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4.3. Effect of re-uptake inhibitors on 5-HT clearance  
 
Effect of drugs targeting SERT on decay time 
 
The SERT inhibitor citalopram (1mg kg-1, i.v; n=7, figure 4.1A) caused a significant 
increase in the time taken for the electrochemical signal to decay to 80% of its peak 
value (T80) when compared to control. In the presence of citalopram T80 increased by 
36.9 ± 4.6% over pre-drug control. At the same dose fluoxetine (1mg kg-1, i.v; n=4, 
figure 4.1B) caused a change in T80  of -0.7 ± 5.8% over pre-drug controls. This was 
not significant. These values were compared for significance with a time-matched 
vehicle control that only changed by  -2.6 ± 2.6% (n=6). Combined data is shown in 
figure 4.3. 
 
Effect of drugs targeting the noradrenaline transporter on decay time 
 
 
Reboxetine (1mg kg-1, i.v; n=6, figure 4.2A), a noradrenaline selective re-uptake 
inhibitor, caused an increase of 12.5 ± 3.2% in T80 over pre-vehicle controls. This 
was significantly different from time-matched vehicle control. On the other hand, 
desipramine (1mg kg-1, i.v; n=4, figure 4.2B), a tri-cyclic anti depressant, caused a 
change of 4.7 ± 5.7% in T80 over pre-vehicle controls. This was not significantly 
different from time-matched vehicle control. Combined data is shown in figure 4.3. 
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Figure 4.1 Representative experimental traces of 5-HT clearance: 
Effect of fluoxetine and citalopram  
 
A) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of 5-HT into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of citalopram (1mg kg-1, i.v).  
 
B) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of 5-HT into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of fluoxetine (1mg kg-1, i.v).  
 
Vertical dashed lines indicate the time taken for the signal to decay to 80% of the 
peak concentration (T80). 
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Figure 4.2 Representative experimental traces of 5-HT clearance: Effect 
of reboxetine and desipramine 
 
A) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of 5-HT into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of reboxetine (1mg kg-1, i.v).  
 
B) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of 5-HT into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of desipramine (1mg kg-1, i.v).  
 
Vertical dashed lines indicate the time taken for the signal to decay to 80% of the 
peak concentration (T80).   
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Figure 4.3 Effect of re-uptake inhibitors on noradrenaline clearance: 
Combined data 
 
Histograms of mean (±s.e.m) percentage changes over pre-drug control in the time 
taken for the electrochemical signal to decay to 80% of its peak value (T80). 
Electrochemical signal was produced by microinjection of 0.1µM of 5-HT into the 
NTS. The decay time after drug or vehicle application of three microinjections of 5-
HT was compared with microinjections three pre-drug or vehicle. Saline vehicle 
control; n=6, Citalopram; 1mg kg-1; n=7, Fluoxetine; 1mg kg-1; n=4, Reboxetine; 1mg 
kg-1; n=4 and Desipramine; 1mg kg-1; n=4. 
 
** P<0.01,*** P<0.001, ns;  non-significant; 1-Way ANOVA; compared to saline 
with Fisher’s LSD test. 
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Effect of drugs targeting OCT3 on decay time 
 
In the presence of corticosterone (1mg kg-1, i.v, n=3, figure 4.4A), an inhibitor of 
OCT3, the T80  only changed by 3.4 ± 1.8% over pre-drug controls. Higher doses of 
3mg (n=1) and 10mg kg-1 (n=5) also had a similar effect; the T80 changed by 4.9% and 
3.3 ± 2.4%, respectively over pre-drug controls. This was not significantly different 
from time-matched vehicle controls at any dose. Combined data is shown in figure 
4.5. 
 
Effect of drugs targeting OCT3/PMAT on decay time 
 
In the presence of decynium-22 (D-22; 600µg kg-1, i.v, n=5, figure 4.4B), an inhibitor 
of OCT3/PMAT, the T80 increased by 76.0 ± 12.8% over pre-drug controls. This was 
significantly different from time-matched vehicle control after which T80 only 
changed by 1.7 ± 1.6% (n=8). Combined data is shown in figure 4.5. 
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Figure 4.4 Representative experimental traces of 5-HT clearance: Effect 
of corticosterone and decynium-22 
 
A) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of 5-HT into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of corticosterone (CORT; 1mg 
kg-1, i.v).  
 
B) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of 5-HT into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of decynium-22 (D-22; 600µg kg-
1
, i.v).  
 
Vertical dashed lines indicate the time taken for the signal to decay to 80% of the 
peak concentration (T80).   
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Figure 4.5 Effect of OCT3/PMAT blockade on 5-HT clearance: 
Combined data 
 
Histograms of mean (±s.e.m) percentage changes over pre-drug control in the time 
taken for the electrochemical signal to decay to 80% of its peak value (T80). 
Electrochemical signal was produced by microinjection of 0.1µM of 5-HT into the 
NTS. The decay time after drug or vehicle application of three microinjections of 5-
HT was compared with microinjections three pre-drug or vehicle. DMSO vehicle 
control; n=8, corticosterone 1,3 and 10mg kg-1 (CORT 1,3 and 10mg kg-1; n= 3, 1 and 
5) and decynium-22 (D-22; 600µg kg-1, i.v, n=5).  
 
** P<0.01, ns;  non-significant; 1-Way ANOVA; compared to saline with Fisher’s 
LSD test. 
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4.4. Effect of re-uptake inhibitors on NA clearance  
 
In the presence of reboxetine (1mg kg-1, i.v; n=5, figure 4.6A), a noradrenaline 
selective re-uptake inhibitor, the T80 increased by 58.0 ± 4.2% in T80 over pre-drug 
controls. This was significantly different from time-matched vehicle control after 
which T80 only changed by 0.64 ± 1.2% (n=5).  
 
In the presence of desipramine  (1mg kg-1, i.v; n=5, figure 4.6B), a tri-cyclic 
antidepressant, the T80 increased by 82.6 ± 16.9%  in T80 over pre-drug controls. This 
was also significantly different from time-matched vehicle control. 
 
In the presence of citalopram  (1mg kg-1, i.v; n=4, figure 4.7), the selective 5-HT re-
uptake inhibitor, the T80 only changed by 2.3 ± 3.3%  in T80 over pre-drug controls. 
This was not significantly different from time-matched vehicle control. 
 
Combined data is shown in figure 4.8. 
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Figure 4.6 Representative experimental traces of noradrenaline 
clearance: Effect of corticosterone and decynium-22 
 
A) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of noradrenaline (NA) into the NTS. Pre-drug control 
(black) is overlaid with a microinjection taken in the presence of reboxetine   (1mg 
kg-1, i.v).  
 
B) Representative oxidation currents converted to relative concentration (nM), 
produced by pressure ejection of noradrenaline (NA) into the NTS. Pre-drug control 
(black) is overlaid with a microinjection taken in the presence of desipramine (1mg 
kg-1, i.v).  
 
Vertical dashed lines indicate the time taken for the signal to decay to 80% of the 
peak concentration (T80).   
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Figure 4.7 Representative experimental trace of noradrenaline 
clearance: Effect of citalopram  
 
Representative oxidation currents converted to relative concentration (nM), produced 
by pressure ejection of noradrenaline (NA) into the NTS. Pre-drug control (black) is 
overlaid with a microinjection taken in the presence of citalopram (1mg kg-1, i.v).  
 
Vertical dashed lines indicate the time taken for the signal to decay to 80% of the 
peak concentration (T80).   
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Figure 4.8 Effect of re-uptake inhibitors on 5-HT clearance: Combined 
data 
 
Histograms of mean (±s.e.m) percentage changes over pre-drug control in the time 
taken for the electrochemical signal to decay to 80% of its peak value (T80). 
Electrochemical signal was produced by microinjection of 1µM of noradrenaline 
(NA) into the NTS. The decay time after drug or vehicle application of three 
microinjections of 5-HT was compared with microinjections three pre-drug or 
vehicle. Saline vehicle control; n=5, reboxetine; 1mg kg-1; n=5, citalopram; 1mg kg-1; 
n=4 and desipramine; 1mg kg-1; n=5 
 
*** P<0.001, ns;  non-significant; 1-Way ANOVA; compared to saline with Fisher’s 
LSD test.  
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4.5. Effect of re-uptake inhibitors on dopamine clearance  
 
Effect of drugs targeting DAT on decay time 
 
 
After application of the DAT inhibitor GBR 12909 (1mg kg-1, i.v; n=3, figure 4.9) the 
time taken for the electrochemical signal to decay to 80% of its peak value (T80) only 
changed by -1.0 ± 1.8% compared to pre-drug control. This was not significantly 
different to a time-matched vehicle control that changed by  -11.8 ± 5.9% (n=3, figure 
4.10).  
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Figure 4.9 Representative experimental trace of dopamine clearance: 
Effect of GBR 12909 
 
 Representative oxidation currents converted to relative concentration (nM), produced 
by pressure ejection of dopamine (DA; 1mM) into the NTS. Pre-drug control (black) 
is overlaid with a microinjection taken in the presence of GBR 12909 (1mg kg-1, i.v).  
 
Vertical dashed lines indicate the time taken for the signal to decay to 80% of the 
peak concentration (T80). 
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Figure 4.10 Effect of re-uptake inhibitors on dopamine clearance: 
Combined data 
 
Histograms of mean (±s.e.m) percentage changes over pre-drug control in the time 
taken for the electrochemical signal to decay to 80% of its peak value (T80). 
Electrochemical signal was produced by microinjection of 1mM of dopamine (DA) 
into the NTS. The decay time after drug or vehicle application of three 
microinjections of 5-HT was compared with microinjections three pre-drug or 
vehicle. Saline vehicle control; n=3, GBR 12909 1mg kg-1 n=3). 
 
ns; non-significant; Compared to control with Students paired t-test. 
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4.6. Discussion  
 
4.6.1. Main findings 
 
The present study investigates the selectivity of a range of monoamine re-uptake 
inhibitors in vivo. The results can be used to determine the effective dose of these re-
uptake inhibitors when they are to be used in experiments in order to identify an 
unknown electroactive species.  
 
Citalopram, at a dose of 1 mg kg-1, was found to cause selective inhibition of 5-HT 
uptake without affecting noradrenaline uptake in the NTS. Desipramine, at doses of 
1mg kg-1, was found to have the reverse selectivity, blocking noradrenaline but not 5-
HT uptake in the NTS. Interestingly, reboxetine at a dose of 1mg kg-1 was found to 
inhibit both noradrenaline and 5-HT uptake, albeit to a lesser extent with respect to 5-
HT. Decynium-22 (D-22; 600 µg kg-1) was also found to inhibit 5-HT reuptake, 
probably via blockade of PMAT not OCT3.  
 
 
4.6.2. Drugs targeting 5-HT and noradrenaline transporters 
 
Citalopram 
 
Citalopram, at doses of 1 mg kg-1 (i.v.), inhibited the clearance of 5-HT in the NTS. 
The dose chosen did not affect the uptake of noradrenaline. This is consistent with 
literature in that citalopram has been shown to highly selective for 5-HT high-
-affinity, low-capacity transporter (5-HTT or SERT) compared to high-affinity, 
low-capacity noradrenaline transporter (NET). The original study Hyttel (1977) 
demonstrated that the uptake of noradrenaline into isolated mouse atria was affected 
only at micromolar concentrations compared to low nanomolar concentrations 
inhibiting 5-HT uptake into blood platelets. The same study also found that the 
metabolites of citalopram were also weak inhibitors of noradrenaline uptake but 
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potent 5-HT uptake inhibitors. Later, using rat lung slices, citalopram was also shown 
to be highly selectivity for the 5-HT transporter over noradrenaline transporter (Drew 
& Siddik, 1980). This study found that the concentrations up to 100µM of citalopram 
did not affect the uptake of noradrenaline, whereas 5-HT uptake was inhibited at 
5nM. Studies using tissue from the CNS, in this case synaptosomes prepared from rat 
cortical tissue, found that citalopram had a selectivity ratio of approximately 4900 for 
5-HT over noradrenaline (see Hyttel, 1982). Further evidence for high selectivity of 
citalopram for the 5-HT over the noradrenaline transporter was shown in brain slices, 
have a selectivty ratio of >1380 (Diggory et al., 1980). These experiments using 
tissue ex vivo have been largely confirmed by transporter binding studies using 
expression systems in vitro. Using HEK293 (human embryonic kidney) cells 
expressing the 5-HT or the noradrenaline transporter similarly high ratio of 3500 was 
found (Tatsumi et al., 1997). One early attempt at measuring noradrenaline uptake in 
vivo in the brains of rats and mice used 4,α-dimethyl-meta-tyramine to deplete 
noradrenaline, the effect of which can be blocked by re-uptake inhibitors (Carlsson et 
al., 1969). Using the same method Hyttel (1977) found that noradrenaline depletion 
was unaffected by citalopram up to doses of 180 mg kg-1, when administered 
subcutaneously (s.c.). The data from the present study confirms that citalopram is a 
potent an selective inhibitor of 5-HT re-uptake in vivo, which is in agreement with the 
literature, using both in vitro, ex vivo and indirect measurements of citalopram’s 
ability to block re-uptake.  
 
Fluoxetine 
 
Interestingly, fluoxetine at a dose of 1 mg kg-1 (i.v.) failed to alter the removal of 
microinjected 5-HT from the NTS. This probably simply reflects the failure of this 
dose; 1 mg kg-1 may not allow a high enough concentration to reach in the brain to 
block the transporter. However, this is surprising as fluoxetine is known to have a 
lower Ki at the human 5-HT transporter than citalopram, 0.81 vs. 1.16nM Tatsumi et 
al. (1997). It would, therefore, be expected that i.v. doses equal to citalopram would 
be sufficient to inhibit the uptake of 5-HT. Indeed, there is evidence that fluoxetine 
blocks 5-HT re-uptake in vivo from a recent microdialysis study at doses of  1.5mg 
kg-1 when administered i.p. (Johansson et al., 2012). The authors report an increase in 
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extracellular 5-HT concentration 30 min after administration of fluoxetine, which did 
not peak until 60 min post-administration. It could also be possible that the failure of 
1mg kg-1 fluoxetine could be a result of differences in pharmacokinetics compared to 
citalopram. Fluoxetine could take longer to penetrate the CNS and given the short 
duration of the present experiment (approximately 15 min post administration), the 
full effects of the drug may not be seen. 
 
Reboxetine  
 
The present study showed that reboxetine 1 mg kg-1 (i.v.), as expected, blocked the 
high-affinity, low-capacity noradrenaline transporter, however at this dose reboxetine 
also inhibited the uptake of 5-HT. In vitro, reboxetine has a selectivity ratio of 81 for 
the noradrenaline transporter over the 5-HT transporter (Deecher et al., 2006). This is 
poor when compared to citalopram and fluoxetine as they have selectively ratio of 
3500 and 300 for the 5-HT transporter over the noradrenaline transporter (in vitro), 
respectively (Tatsumi et al., 1997). In vivo one study using microdialysis to measure 
both dopamine and 5-HT efflux in the frontal cortex in response to tail pinch found 
that reboxetine significantly increased extracellular dopamine concentration, but had 
no effect on 5-HT (Page & Lucki, 2002). Conversely, an earlier study found that 
reboxetine caused a small increase in extracellular 5-HT in the striatum but dopamine 
was unaffected (Sacchetti et al., 1999). From this data there seems to be regional 
differences in selectivity with reboxetine, however, in each case it could be possible 
that increased noradrenaline release feeds forward to increase dopamine and 5-HT 
release as microdialysis measures endogenous release. The present study confirms 
that reboxetine at doses of 1 mg kg-1 is not highly selective for noradrenaline uptake 
compared with 5-HT within the NTS.  
 
Desipramine 
 
Unlike reboxetine, desipramine 1 mg kg-1 (i.v.) did not significantly affect the uptake 
of 5-HT. Desipramine is known to have the higher affinity (in vitro) at the 
noradrenaline transporter (Tatsumi et al., 1997) and less selectivity for noradrenaline 
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over 5-HT, having a selectivity ratio of 20 compared to reboxetine (80). However, in 
vivo doses of desipramine at 10 mg kg-1 acutely administered s.c. failed to have any 
effect on extracellular 5-HT concentration measured by microdialysis (Hajos-Korcsok 
et al., 2000). This supports the possibility of higher selectivity in brain tissue than 
expression systems and agrees with the data from the present study that desipramine 
an extremely selective noradrenaline re-uptake inhibitor. 
 
It should be noted that desipramine is also known to be a non-competitive inhibitor of 
OCT3 (Zhu et al., 2010). However, data in the present study demonstrate that 5-HT is 
removed via PMAT, not OCT3 and this is supported by the desipramine having no 
effect on 5-HT clearance. It could, however, be possible that the reduction in 
noradrenaline removal rates seen with desipramine could be, in part, be due to 
blockade of OCT3. 
 
GBR-12909 
 
GBR-12909 failed to modify the clearance of exogenously applied dopamine in the 
NTS. Again this indicates that dose is not high enough. In this respect this study has 
shown that fluoxetine also at a dose of 1 mg kg-1 had no effect of the clearance of 
5-HT. However, a dose of 0.75mg kg-1 i.v. has been previously shown to produce a 
potent and long lasting inhibition of the dopamine re-uptake in the striatum 3 seconds 
after administration (Espana et al., 2008). Alternatively, the NTS may not express 
dopamine transporters in appreciable amounts necessary to remove the concentration 
of dopamine introduced exogenously in this experiment. Given that only limited roles 
for dopamine have been identified in the NTS (see INTRODUCTION 1.6.2) and given 
that 5-HT and noradrenaline are the predominate monoamine transmitters released 
within the NTS, extracellular dopamine concentrations are likely to be low. 
Expression of dopamine transporters may not be required at the same densities as 
5-HT and noradrenaline transporters.  
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Table 4.1 Re-uptake inhibitor selectivity: Summary of results  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.6.3. Drugs targeting OCT3 and PMAT 
 
Decynium-22 
 
Decynium-22 (D-22; 600µg kg-1; i.v) significantly reduced the clearance of 
exogenously applied 5-HT in the NTS. D-22 is a potent inhibitor of OCT3 and PMAT 
(Schomig et al., 1993, Duan & Wang, 2010). It has also been shown that D-22 is 
readily centrally penetrant (Horton et al., 2013). The present data indicates that OCT3 
and/or PMAT are responsible for the removal of 5-HT from the extracellular space 
within the NTS. D-22 has previously been shown to block uptake of exogenous 5-HT 
in vivo, in the hippocampus, only when 5-HT transporter function is comprised by 
genetic deletion (Baganz et al., 2008). This may represent regional differences in how 
extracellular 5-HT is metabolised. Hippocampal uptake of 5-HT may rely on more 
heavily on the 5-HT transporter and OCT3/PMAT takes over at higher concentrations 
of 5-HT. The data indicates that the uptake mechanisms are more evenly weighted 
within the NTS 
Compound 
Substrate 
Selective at 
Dose 
 (1mg kg-1) 
5-HT NA  
Citalopram ✔ ✖ ✔  
Desipramine ✖ ✔ ✔  
Reboxetine ✔ ✔ ✖  
Fluoxetine ✖ − − 
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Corticosterone  
Corticosterone failed to affect the uptake of 5-HT when administered i.v. at doses 
from 1-10mg kg-1. Corticosterone is an inhibitor of OCT3 with an IC50 0.29µM when 
measured in vitro in an HEK cell expression system (Hayer-Zillgen et al., 2002). 
Corticosterone is a selective inhibitor for OCT3, whereas PMAT is insensitive to 
steroids (Gasser et al., 2006, Duan & Wang, 2010, Hill & Gasser, 2013). This data 
would suggest that the inhibition of 5-HT uptake by D-22 is a result of blockade 
PMAT not OCT3. 
 
4.6.4. Conclusion 
The present experiments were to determine an effective dose for a range of re-uptake 
inhibitors in vivo. It was found that citalopram and desipramine are the drugs of 
choice to selectively manipulate the 5-HT and noradrenaline transporter because they 
were selective at doses of 1mg kg-1 within the NTS (see table 4.1). Further, PMAT was 
also shown to be responsible for the removal of 5-HT from the extracellular space, 
even with 5-HT transporter function intact.  
 
4.6.5. Future experiments 
 
Determine the effect of D-22 on the re-uptake of noradrenaline. PMAT is capable of 
removing noradrenaline from the extracellular medium, however PMAT is 70% more 
effective at removing 5-HT over noradrenaline when measured in vitro (Duan & 
Wang, 2010). Doses effective at inhibiting 5-HT removal may fail to modify 
noradrenaline uptake. With carful dosing it may be possible to use D-22 to selectively 
inhibit 5-HT uptake via PMAT while noradrenaline remains unchanged. 
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5. ACTIVATION OF CARDIOVASCULAR AFFERENTS CAUSE 5-
HT RELEASE IN THE NTS DETECTED DIRECTLY BY FAST-
CYCLIC VOLTAMMETRY  
 
5.1. Introduction 
 
Although glutamate is the principal neurotransmitter in the NTS there are many other 
transmitters involved in modulating cardiovascular reflexes (see INTRODUCTION 
1.6.2). One of these proposed modulating transmitters is 5-HT, which has been 
identified to play an important role in many facets of cardiovascular regulation (see 
Ramage & Villalon, 2008).The extensive innervation of the NTS by 5-HT afferents is 
consistent with such a role. First, there is evidence of 5-HT terminals originating 
centrally from raphé magnus and dorsal raphé (Schaffar et al., 1988, Sim & Joseph, 
1992). Second, 5-HT-containing terminals from vagal afferents (Sykes et al., 1994) 
originating from the nodose ganglion (Gaudin-Chazal et al., 1982, Nosjean et al., 
1990) as well as the petrosal ganglion (Thor et al., 1988) are found in the NTS. Third, 
there is evidence of 5-HT-containing interneurons within the NTS (Calza et al., 
1985). However, it should be noted that there are no further corroborating reports of 
5-HT interneurons in NTS.  
 
There is also extensive expression of 5-HT receptor subtypes within the NTS itself 
(see INTRODUCTION 1.3). Of these expressed subtypes, 5-HT3 (Jeggo et al., 2005) and 
5-HT7 (Oskutyte et al., 2009)receptors have been shown to play a physiological role 
in cardiovascular reflex pathways, at least in vivo. Both studies showed that 
antagonists of 5-HT receptors reduce the response in NTS cells when activated by 
vagal stimulation. This strongly suggests that 5-HT is released from vagal afferents.  
 
Until now there have been no attempts to measure this release of 5-HT directly. This 
is partly due to the technological limitations of microdialysis, where large probe 
surface areas preclude sampling from a discrete nucleus, even in larger animals. 
Indeed, where microdialysis has been attempted in the NTS of the cat or piglet, 
dialysate recovered was not often confined to the nucleus (Allchin et al., 1994, 
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Waters et al., 1997, Potts & Fuchs, 2001). However, fast-cyclic voltammetry is 
widely used to investigate dopamine release and re-uptake dynamics in vivo with an 
extremely small electrode allowing sampling from small brain nuclei, such as the 
NTS (see INTRODUCTION 1.7). The present study will use the technological advances 
afforded by voltammetry to detect any electrochemical changes within the NTS as a 
result of vagal stimulation (figure 5.1). Additionally, the advantage of performing 
such experiments within a whole animal allows monitoring of end organ responses 
simultaneously with neurotransmitter dynamics in the region of interest. With this 
unique experimental approach this study aims to correlate neurochemical changes 
with cardiovascular outcomes.  
 
 
5.2. Specific Aims 
 
 
• Assess the suitability of voltammetry to detect 5-HT release in a small brain 
nucleus such as the NTS. Determine the selectivity profile of the trapezoidal 
ramp and differential scans (see METHODS 2.1.5) for 5-HT and other 
interfering electroactive molecules commonly found in the brain.  
 
 
• Determine if an electrochemical signal is produced in the NTS as a result of vagal 
stimulation and identify the species responsible for this signal using the four 
criteria set down for the purpose by (Phillips & Wightman, 2003) 
 
• Determine the source of the electrochemical species. Is the release from terminals 
arising from central locations or peripherally from vagal afferents? 
 
•  Investigate whether activation of cardiovascular reflexes causes release of 
electroactive substances within the NTS.  
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Figure 5.1 Diagrammatic representation of the in vivo electrochemistry 
preparation 
 
Schematic representation of a sagittal section of the brainstem showing the nucleus 
tractus solitarius (NTS), nucleus ambiguus (NA), caudal ventrolateral medulla 
(CVLM) and the rostral ventrolateral medulla (RVLM). Vagal afferent fibre terminals 
containing glutamate and 5-HT are shown synapsing in the NTS together with the 
carbon fibre microelectrode with the steps for voltammetric recording. The top left 
inset shows the molecular scheme of the oxidation and re-reduction reaction occurring 
on the surface of the carbon fibre used for 5-HT detection. The bottom left insert 
shows the effects of vagal afferent stimulation on heart rate and blood pressure. 
Activation of ambigual neurons increases parasympathetic drive (-) to the heart, 
causing a bradycardia. Activation of the CVLM inhibits the RVLM, which then 
reduces sympathetic drive (+) to the arterial blood vessels. This sympathetic 
withdrawal causes vasodilation and thus a fall in blood pressure. 
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5.3. Results: Selectivity 
 
Figure 5.2 shows voltammograms recorded in vitro in the presence of electroactive 
substances commonly found in the brain. Selectivity between the analyte of interest 
(5-HT) and possible interfering substances was determined in vitro and a ‘rejection 
ratio’ was determined to compare selectivity. Rejection ratio refers to the difference 
between the current produced at the same concentration between two electroactive 
compounds. For example if a rejection ratio was 50 to 1 between compound A and B 
then it would require 50 times the concentration of compound A to produce the same 
current change as compound B. 
 
5-HT at a concentration of 0.1µM produces a total increase in faradic current of 70nA. 
When compared with other electroactive neurotransmitters tested this gives a 
rejection ratio of approximately 8 to 1 for noradrenaline (9nA at 0.1µM) and 
approximately 100 to 1 for dopamine (7nA at 1µM). Ascorbic acid, commonly found 
packaged in 5-HT containing vesicles, was found to produce no current changes when 
sampled at the points of maximum current change for 5-HT, even at concentrations 
1000 times higher. 5-HIAA, which is a direct metabolite of 5-HT, was found to 
produce currents of 22nA at concentrations of 10µM. This gave a rejection ratio of 
approximately 320:1 over 5-HT.   
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Figure 5.2 Selectivity over other electroactive substances 
 
Voltammograms recorded 0.1mM phosphate buffered saline with addition of the 
following electroactive substances known to found in in the brain. Active scan voltage 
ramp is shown by dashed line. 5-HT, 5-HIAA; 5-Hydroxyindoleacetic acid, NA; 
Noradrenaline, DA; Dopamine, AA; Ascorbic acid.   
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5.4. Results: Electrochemistry 
 
As shown in Figure 5.3 the faradic current profile obtained in vivo in the NTS (figure 
5.4) immediately after electrical stimulation of the vagus nerve (20Hz, 10x threshold) 
broadly overlies the faradic current profile recorded in vitro (0.01M phosphate 
buffered saline) in the presence of 30nM 5-HT. The peak of the oxidation current both 
in vivo and in vitro occurs at voltages of 500mV. The re-reduction current starts to 
occur at the same position of the negative voltage ramp and covers the same range of 
voltages, however the peak is slightly delayed in vivo. Additionally, the oxidation 
peak is typically larger than the re-reduction peak in vivo and this is reversed in vitro.  
 
It is expected that there will be slight differences between the faradic current profile 
recorded in vitro and that recorded in vitro. Firstly, electrical impedance of the 
recording medium will be different; brain tissue will have higher impedance than 
saline, which will result in a lower effective voltage being delivered to the tip of the 
electrode. This difference will cause a rightward shift in the oxidation and re-
reduction peak as lower voltages will be applied at the same time point of the scan, 
thus delaying the oxidation and re-reduction of 5-HT. Additionally, there are several 
electroactive species present in the extracellular fluid in vivo that could interact with 
5-HT directly to change its oxidation state after it is released form the nerve terminal. 
The increased re-reduction peak could be the result of 5-HT oxidised by means other 
than the voltammetric scan. The already oxidised 5-HT would then diffuse to the 
electrode and be re-reduced as the electrode cannot distinguish between 5-HT 
oxidised by the voltammeter and by other means.  
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Figure 5.3 Comparisons of voltammograms  
 
Typical faradic current traces (voltammograms) recorded in vivo after electrical 
stimulation of the vagus overlaid with a current trace recorded in vitro in the presence 
of 30 nM  5-HT solution in phosphate buffered saline. The dashed line indicates the 
voltage ramp applied to the carbon fibre microelectrode. The vertical lines indicate 
the maximum of the oxidation and re-reduction currents recorded in vivo. The total 
current passed (oxidation + re-reduction) is used to calculate the extracellular 
concentration change.  
  
Figure 5.4 Histology  
 
Recording sites with the NTS are shown for a sample of 10 experiments (✖ denotes 
recording site). Electrode tip locations were determined by current-induced lesions 
were recovered histologically after the experiment that were subsequently mapped to 
coordinates using a rat brain atlas.  
 
Inset shows an example of a typical photomicrograph of a coronal section of the rat 
brainstem showing the electrode lesion in the NTS. The tissue was stained with 
neutral red and photographed in black and white for increased contrast. Scale bar is 
1mm    
 
AP; Area postrema 
CC; Central canal 
GN; gracile nucleus 
NTS; nucleus of the solitary tract 
XII; hypoglossal motor nucleus   
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5.5. Results: Vagal stimulation frequency response 
 
Stimulus intensity for electrical stimulation of the vagus nerve was calculated as 
multiples of the threshold at which evoked neuronal spike activity is detected in the 
NTS. When stimulated at threshold (1x threshold) frequencies of 5- 50Hz produced 
changes in extracellular 5-HT of 4.6 ± 1.5, 4.4 ± 1.1, 5.8 ± 2.3 and 6.8 ± 3.0nM, 
respectively (figure 5.6). All values expressed as multiples of threshold. This was not 
significantly different from the baseline variability, which was calculated to be 0.3 ± 
2.0 nM over the same time period as the peak change in 5-HT concentration following 
stimulation.   
 
When stimulated at threshold (5x threshold) frequencies of 5- 50Hz produced changes 
in extracellular 5-HT of 12.0 ± 4.6, 24.5 ± 6.4, 32.0 ± 11.0 and 44.1 ± 15.6nM, 
respectively (Figure 5.6). Frequencies of 20 and 50Hz produce changes in 
extracellular 5-HT concentration that were significantly different from baseline 
(P<0.05; 1-Way ANOVA; compared with Fisher’s LSD test).  
 
When stimulated at threshold (10x threshold) frequencies of 5- 50Hz produced 
changes in extracellular 5-HT of 12.1 ± 5.2, 17.9 ± 7.2, 30.0 ± 7.8 and 50.3 ± 10.8 
nM, respectively (Figure 5.6). Again, frequencies of 20 and 50Hz produce changes in 
extracellular 5-HT concentration that were significantly different from baseline 
(P<0.01; 1-Way ANOVA; compared with Fisher’s LSD test). 
 
Representative experimental traces from one subject contributing to the data 
described above are shown in figure 5.5.  
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Figure 5.5 Vagal stimulation frequency response: Experimental Traces 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rat: traces showing 
the change in extracellular 5-HT in response to electrical stimulation of the central 
end of the left vagus (1ms pulse-width, 10s duration) at 3 min intervals at different 
frequencies and thresholds. Threshold range was between 70-110 µA. Threshold was 
defined as the current at which evoked neuronal activity was detected in the NTS. 
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Figure 5.6 Frequency response: Histogram 
 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the different frequencies and thresholds for electrical stimulation of the 
central end of the left vagus (1ms pulse-width, 10s duration) at 3 min intervals at 
different frequencies and thresholds (threshold range was between 70-110 µA) on 
changes (Δ) in the 5-HT concentration in the NTS as detected by fast cyclic 
voltammetry. Each column is the mean data from 5 rats. Stimulation levels (x 
threshold) were randomised from rat to rat. The error bars show the s.e.m.  
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5.6. Results: Effect of kynurenate and cadmium 
 
Haemodynamic baseline data 
 
Baseline heart rate and blood pressure was measure 30s prior to commencement of 
the experimental protocol. The 10mM kynurenate experimental group had a baseline 
blood pressure of 98 ± 5 mmHg and a baseline heart rate of 387 ± 12 bpm. The 50mM 
kynurenate experimental group had a baseline blood pressure of 102 ± 8 mmHg and a 
baseline heart rate of 397 ± 12 bpm. The 50mM cadmium chloride experimental 
group had a baseline blood pressure of 101 ± 8 mmHg and a baseline heart rate of 401 
± 16 bpm. The vehicle control (30µl, 0.01M PBS) experimental group had a baseline 
blood pressure of 103 ± 5 mmHg and a baseline heart rate of 395 ± 16 bpm. 
 
5-HT release baseline data 
 
Three stimulations were performed prior to the application of the test drug or vehicle 
in each experimental group. The average absolute increases of extracellular 5-HT 
measured in each of these groups were as follows: 10mM KYN; 33 ± 9nM, 50mM 
KYN; 28 ± 4nM, cadmium; 29 ±5nM and vehicle; 22 ± 7nM. 
 
Effect of kynurenate 
 
Topical application of 10mM kynurenate (KYN) produced an increase in baseline of 
10 ± 2 bpm and 12 ± 1 mmHg in heart rate and blood pressure, respectively. The 
higher dose, 50mM, caused an increase in baseline of 26 ± 8 bpm and 29 ± 2 mmHg 
in heart rate and blood pressure, respectively. Topical application of vehicle caused a 
change of -5 ± 6 bpm and 2 ± 4 mmHg in heart rate and blood pressure, respectively. 
 
In the presence of kynurenate the extracellular increase in 5-HT produced by vagal 
stimulation (20Hz, 10x threshold) was attenuated (figure 5.9). At doses of 10mM the 
pre-drug change in extracellular 5-HT was reduced by 51.8 ±5.0 %. Equally, at the 
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higher dose of 50mM the change in extracellular 5-HT was reduced 51.3 ±5.3 %. 
Both were changes significantly different from those in subjects receiving time-
matched vehicle (PBS; 0.01M, topical), which only caused a change of -0.44 ± 2.8% 
from pre-drug control stimulations.  
 
In the presence of 10mM kynurenate vagal stimulation produced a decrease in mean 
blood pressure of 18.6 ± 1.5 mmHg. This is not significantly different from vehicle 
control, in the presence of which vagal stimulation produced a decrease of -28.8 ± 5.7 
mmHg. However, with the higher dose of 50mM, vagal stimulation now caused a rise 
in blood pressure of 12.4 ± 1.2 mmHg. This was significantly different from vehicle 
control.  
 
In the presence of 10mM kynurenate vagal stimulation produced a decrease in heart 
rate of -22.7 ± 8.9 bpm. This is not significantly different from vehicle control, which 
produced a decrease of -28.8 ± 5.7 mmHg. However, with the higher dose of 50mM 
vagal stimulation now caused a rise in heart rate of 6.2 ± 3.8 bpm. This was 
significantly different from vehicle control. 
 
Figure 5.7 shows representative experimental traces of the effect of kynurenate on 
both baseline heart rate and blood pressure as well as changes to extracellular 5-HT, 
heart rate and blood pressure during vagal stimulation.  
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Effect of cadmium chloride 
 
Topical application of 50mM cadmium chloride (CdCl2) produced an increase in 
baseline heart rate and blood pressure of 37 ± 11 bpm and 41 ± 13 mmHg, 
respectively. 
 
In the presence of 50mM cadmium chloride the extracellular increase in 5-HT caused 
by vagal simulation (20Hz, 10x threshold) was reduced by 92.0 ± 14.2% when 
compared to pre-drug controls (figure 5.9). This was significantly different from time-
matched vehicle control (PBS; 0.01M, topical), which only caused a change of -0.44 
± 2.8% when compared to pre-drug control stimulations. 
 
Topical application of cadmium chloride also attenuated both the reduction in mean 
blood pressure and heart rate caused by vagal simulation. In the presence of cadmium 
chloride blood pressure was now only reduced by 7.6 ± 1.5 mmHg and heat rate only 
reduced by -7.2 ± 3.4 bpm. Again, both these changes were significantly different 
when compared to the change recorded in the presence of vehicle control (heart rate; -
35.2 ± 3.4 bpm and blood pressure -28.8 ± 5.7 mmHg). 
 
Figure 5.8 shows representative experimental traces of the effect of cadmium chloride 
on both baseline heart rate and blood pressure as well as changes to extracellular       
5-HT, heart rate and blood pressure during vagal stimulation. 
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Figure 5.7 Effect of kynurenate: Experimental Traces 
 
Two anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
effect of topical (30µl) application of kynurenate (a) 10mM and (b) 50mM on the 
increase in the 5-HT concentration in the NTS and the decreases in blood pressure 
(BP) and heart rate (HR) evoked by electrical stimulation (20Hz, 1ms, 10s at 10X 
threshold) of the central end of the left vagus. 
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Figure 5.8 Effect of cadmium: Experimental Traces 
 
An anaesthetised artificially ventilated, neuromuscular -blocked male rat showing the 
effect of topical (30µl) application of 50mM cadmium chloride on the increase in the 
5-HT concentration in the NTS and the decreases in blood pressure (BP) and heart 
rate (HR) evoked by electrical stimulation (20Hz, 1ms, 10s at 10X threshold) of the 
central end of the left vagus.   
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Figure 5.9  Effect of kynurenate and CdCl2: Combined data 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects of topically (30 µl) applied kynurenate (KYN; 10 & 50 mM, 
n=6 & 7) and cadmium chloride (CdCl2; 50 mM, n=5) or 0.01M phosphate buffered 
saline (control; n=7) on increases in the 5-HT concentration in the NTS and the 
decreases in mean arterial blood pressure (BP) and heart rate (HR) evoked by 
electrical stimulation (20Hz, 1ms, 10s at 10X threshold) of the central end of the left 
vagus. The bars show the s.e.m. These changes were compared to control using a one-
way analysis of variance (ANOVA) and the means compared with Fisher’s LSD test. 
** P<0.01; *** P<0.01  
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5.7. Results: effect of metabolic inhibitors PCPA and AMPT 
 
Intravenous application of the tryptophan hydroxylase inhibitor PCPA (40mg kg-1; n= 
4) caused a significant (P<0.05) reduction in the expected increase in extracellular 5-
HT concentration in the NTS following vagal stimulation (20Hz, 10x threshold for 
10s) over time (figure 5.10). The increase in extracellular 5-HT caused by first the 
simulation after application of PCPA was reduced to 60 ±  4 % of the pre-drug control 
value. This was significantly different from the change at the same time point after 
administration of saline control (1ml kg-1; n=6), which was 100 ± 8 % of the pre-drug 
control value (figure 5.11). The significant PCPA-induced reduction persisted from 
this time point and reached a maximum difference at 30min (41 ± 6 % of the pre-dug 
control). However, by 33 min the significant reduction had recovered to 66  ± 13% of 
the pre-drug control, which was not significant from saline control at the same time 
point (90.3 ± 9%). By the end of the experimental protocol, 45min after drug 
administration, the change in extracellular 5-HT concentration had recovered to 74 ± 
9% of pre-drug control values.  
 
Intravenous application of the tyrosine hydroxylase inhibitor AMPT (200mg kg-1; n= 
4) caused no significant change in the expected increase in extracellular 5-HT 
concentration in the NTS following vagal stimulation (20Hz, 10x threshold for 10s) 
over time. The increase extracellular 5-HT caused did not differ significantly from 
control at any time point during the experimental protocol.  
 
There was no significant differences in hypotension or bradycardia produced by vagal 
stimulation between the AMPT, PCPA or vehicle control groups at any time point 
during the experimental protocol. There was, however, a generalised increase in the 
bradycardia over all groups as time progressed. By the final time point (45min) the 
heart rate changes had increased to 132 ± 18 in control, 137 ± 13 in the PCPA group 
and 187 ± 43% of pre-drug/vehicle values. Percentage changes were used here due to 
high intraexperimental variability during the extended recording times.  
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Figure 5.10 Effect of PCPA: Experimental Traces 
 
An anaesthetised artificially ventilated, neuromuscular -blocked male rats showing 
the effect PCPA (40 mg kg-1; i.v., bottom trace) compared with vehicle control 
(saline; top trace) on the increases in the 5-HT concentration in the NTS evoked by a 
series of electrical stimulations (20Hz, 1ms for 10s at 10X threshold) of the central 
end of the left vagus given at 3 min intervals as shown by the line (VS) about the 
traces. At the beginning of both sets of traces the control evoked increase in 5-HT is 
shown for that rat followed a by a gap of 18 min. 
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Figure 5.11  Effect of PCPA and AMPT: Graph 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: Graph 
comparing the effects of i.v. saline (control; 1ml kg-1, n=6), PCPA (40mg kg-1, i.v, 
n=4) and AMPT (200mg kg-1, i.v., n=4) on increases in the 5-HT concentration in the 
NTS evoked by electrical stimulation (20Hz, 1ms, 10s at 10X threshold) of the central 
end of the left vagus. The bars show the s.e.m. These changes were compared to 
control using a 2-way analysis of variance (ANOVA) followed by Bonferroni’s post-
hoc test. * P<0.05; 
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5.8. Results: Effect of drugs inhibiting re-uptake systems 
 
Baseline data 
 
Baseline heart rate and blood pressure were measured 30s prior to commencement of 
the experimental protocol. Additionally, three stimulations were performed prior to 
the application of the test drug or vehicle in each experimental group. The average 
absolute increases of extracellular 5-HT measured in each of these groups. See table 
5.1 for a comprehensive list.  
 
Effect of re-uptake inhibitors on baseline haemodynamic values 
 
Injection of all re-uptake inhibitors was associated with a small increase in baseline 
blood pressure and heart rate, with the exception of D-22. Table 5.1 contains the 
complete data. Injection of D-22 (600µg kg-1, i.v) caused a decrease in blood pressure 
of -49 ± 7mmHg and an increase in heart rate of 86 ± 15 bpm. In a separate set of 
experiments (figure 5.16) the decrease in blood pressure was mimicked by injection 
of the ganglion blockade by chlorisondamine (1mg kg-1, n=3). This caused a decrease 
in blood pressure of 44 ± 8mmHg, which was not significantly different from that 
caused by D-22. In these experiments, evoked 5-HT changed by 5.2 ± 10%, which 
was significantly different from the DMSO control in this experiment (-3.1 ± 2.6%). 
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Effect of re-uptake inhibitors on vagal stimulation 
 
Intravenous application of the selective 5-HT transporter inhibitor citalopram (1mg 
kg-1; n= 6, figure 5.12) caused no significant change in the evoked increase in 
extracellular 5-HT concentration in the NTS following vagal stimulation (20Hz, 10x 
threshold for 10s) when compared to application of vehicle (DMSO, 1ml kg-1; n=6) 
control, which caused a change of -3.1 ± 2.6%. After administration of citalopram the 
change over pre-drug control stimulations was only -1.3 ± 5.2%. There was also no 
effect on the bradycardia and hypotension caused by vagal stimulation in the presence 
of citalopram. Hypotension was -37 ± 5 mmHg and bradycardia was -40 ± 3 bpm. 
This was compared to vehicle control, after which hypotension was -37 ± 4 mmHg 
and bradycardia was 48 ± 6 bpm.  
 
Intravenous application of the mixed 5-HT and noradrenaline transporter inhibitor 
fluoxetine (1mg kg-1; n= 5, figure 5.13) caused no significant change in the evoked 
increase in extracellular 5-HT concentration in the NTS following vagal stimulation 
(20Hz, 10x threshold for 10s) when compared to application of vehicle control. After 
administration of fluoxetine the change over pre-drug control stimulations was only 
1.7 ± 5.6%. There was also no effect on the bradycardia and hypotension caused by 
vagal stimulation in the presence of fluoxetine. Hypotension was -31 ± 2 mmHg and 
bradycardia was -39 ± 6 bpm. 
 
Intravenous application of the noradrenaline transporter inhibitor desipramine (1mg 
kg-1; n= 5, figure 5.14) caused no significant change in the evoked increase in 
extracellular 5-HT concentration in the NTS following vagal stimulation (20Hz, 10x 
threshold for 10s) when compared to application of vehicle control. After 
administration of desipramine the change over pre-drug control stimulations was 8.8 
± 12.6%. There was also no effect on the bradycardia and hypotension caused by 
vagal stimulation in the presence of desipramine. Hypotension was -23 ± 6 mmHg 
and bradycardia was -52 ± 9 bpm.  
 
Intravenous application of the OCT3 and PMAT inhibitor D-22 (600µg kg-1; n= 5, 
figure 5.15) caused a significant potentiation (P<0.001) of the evoked  increase in 
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extracellular 5-HT concentration in the NTS following vagal stimulation (20Hz, 10x 
threshold for 10s) when compared to application of vehicle control (Figure 5.15). The 
first simulation subsequent to application of D-22 was increased 111 ± 21% over pre-
drug control stimulations (Figure 5.14). D-22 also increased the bradycardia caused 
by vagal stimulation to 98 ± 11 bpm, which was significantly different from vehicle 
control (48 ± 6 bpm). Additionally, hypotension caused by vagal stimulation in the 
presence of D-22 was reduced to -9 ± 2 mmHg. 
 
Combined data is shown in figure 5.27. 
 
Effect of 5-HT1A receptor blockade and re-uptake inhibition 
 
Intravenous application of the 5-HT1A receptor antagonist WAY-100635 (1mg kg-1; 
n= 4, figure 5.18A) caused no significant change in the expected increase in 
extracellular 5-HT concentration in the NTS following vagal stimulation (20Hz, 10x 
threshold for 10s) when compared to application of vehicle control. After 
administration of WAY-100635 the change over pre-drug control stimulations was -5 
± 9.3%. In the presence of citalopram (1mg kg-1; n=5, figure 5.18B) the change was -
3 ± 5%. Both were not significantly different from vehicle control.  
 
Injection of WAY-100635 alone and in the presence of citalopram was associated 
with a small decrease in baseline blood pressure and an increase in heart rate. This 
was not seen when it was administered in the presence of citalopram (see table 5.1). 
Alone, WAY-100635 decreased the bradycardia caused by vagal stimulation to  -20 ± 
1bpm, which was significantly different from vehicle control (46 ± 5 bpm). 
Additionally, hypotension caused by vagal stimulation in the presence of WAY-
100635 was also reduced to -17 ± 4 mmHg, which was significantly different from 
vehicle control (36 ± 6 mmHg). Interestingly, this was reversed when WAY-100635 
was administered in the presence of citalopram. Bradycardia caused by vagal 
stimulation was 48 ± 6 bpm and hypotension was 34 ± 6 mmHg, both not 
significantly different from control. Combined data is shown in figure 5.19. 
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Figure 5.12  Vagal stimulation trace: Citalopram 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
effect of citalopram (1 mg kg-1; i.v.) on the increase in the 5-HT concentration in the 
NTS and the decreases in blood pressure (BP) and heart rate (HR) evoked by 
electrical stimulation (20Hz, 1ms, 10s at 10X threshold) of the central end of the left 
vagus. 
 250 
 251 
Figure 5.13  Vagal stimulation trace: Fluoxetine 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
effect of fluoxetine (1 mg kg-1; i.v.) on the increase in the 5-HT concentration in the 
NTS and the decreases in blood pressure (BP) and heart rate (HR) evoked by 
electrical stimulation (20Hz, 1ms, 3s at 10X threshold) of the central end of the left 
vagus. 
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Figure 5.14  Vagal stimulation trace: Desipramine 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
effect of desipramine (1 mg kg-1; i.v.) on the increase in the 5-HT concentration in the 
NTS and the decreases in blood pressure (BP) and heart rate (HR) evoked by 
electrical stimulation (20Hz, 1ms, 3s at 10X threshold) of the central end of the left 
vagus.  
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Figure 5.15  Vagal stimulation trace: D-22 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
effect of decynium-22 (D-22; 1 mg kg-1; i.v.) on the increase in the 5-HT 
concentration in the NTS and the decreases in blood pressure (BP) and heart rate 
(HR) evoked by electrical stimulation (20Hz, 1ms, 3s at 10X threshold) of the central 
end of the left vagus.  
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Figure 5.16  Vagal stimulation trace: Chlorisondamine 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
effect of chlorisondamine (1 mg kg-1; i.v.) on the increase in the 5-HT concentration 
in the NTS and the decreases in blood pressure (BP) and heart rate (HR) evoked by 
electrical stimulation (20Hz, 1ms, 3s at 10X threshold) of the central end of the left 
vagus. 
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Figure 5.17  Comparison of the effect of fluoxetine, citalopram, 
cdecynium-22 and desipramine (re-uptake inhibitors): Combined data 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects of i.v. saline (control; 1ml kg-1, n=6), fluoxetine (1 mg kg-1, 
n=5), citalopram (1mg kg-1, n=6), decynium-22 (D-22; 600µg kg-1, n=6) and 
desipramine (1mg kg-1, n=6) on increases in the 5-HT concentration in the NTS and 
the decreases in mean arterial blood pressure (BP) and heart rate (HR) evoked by 
electrical stimulation (20Hz, 1ms, 3s at 10X threshold) of the central end of the left 
vagus. The bars show the s.e.m. These changes were compared to control using a one-
way analysis of variance (ANOVA) and the means compared with Fisher’s LSD test. 
** P<0.01; *** P<0.01. 
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Table 5.1 Baseline values: re-uptake inhibitor experiments 
 
 
 
Test 
Change (Δ) from 
baseline caused by 
test 
Baseline values 
Δ BP 
(mmHg) 
ΔHR 
(bpm) 
Evoked 
5-HT 
(nM) 
BP 
(mmHg) 
HR 
(bpm) 
Vehicle 
DMSO 
(100µl kg-1) 
2 ±5 5 ± 8 25 ± 9 90 ± 6 390 ± 9 
Fluoxetine 
(1mg kg-1) 
15 ± 5 20 ± 4 33 ± 8 115 ± 18 410 ± 15 
Citalopram 
(1mg kg-1) 
10 ± 2 12 ± 5 28 ± 4 105 ± 8 388 ± 10 
D-22 
(600µg kg-1) 
-49 ± 7 86 ± 15 29 ± 10 97 ± 4 399 ± 6 
Desipramine 
(1mg kg-1) 
20 ± 4 15 ± 4 38 ± 5 89 ± 4 380 ± 4 
WAY-
100635 
(1mg kg-1) 
-12 ± 5 11 ± 4 28 ± 3 96 ± 7 389 ± 10 
WAY-
100635 
(1mg kg-1) 
+ 
Citalopram 
(1mg kg-1) 
-15 ± 5 18 ± 8 23 ± 8 110 ± 3 415 ± 12 
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Figure 5.18  Effect of WAY-100635 alone and in the presence of 
Citalopram: Experimental Traces   
 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rats showing the 
effect of A) WAY-100635 (1 mg kg-1; i.v.) alone and B) in the presence of citalopram 
(1 mg kg-1; i.v.) on the increase in the 5-HT concentration in the NTS and the 
decreases in blood pressure (BP) and heart rate (HR) evoked by electrical stimulation 
(20Hz, 1ms, 3s at 10X threshold) of the central end of the left vagus.  
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Figure 5.19 Effect of WAY-100635 alone and in the presence of 
citalopram: Combined data 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects (i.v.) of saline (control, n=5), WAY-100635 (1 mg kg-1, n=4) 
alone and in the presence of citalopram (1mg kg-1, n=5) on increases in the 5-HT 
concentration in the NTS and the decreases in mean arterial blood pressure (BP) and 
heart rate (HR) evoked by electrical stimulation (20Hz, 1ms, 3s at 10X threshold) of 
the central end of the left vagus. The bars show the s.e.m. These changes were 
compared to control using a one-way analysis of variance (ANOVA) and the means 
compared with Fisher’s LSD test. * P<0.05 
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5.9. Results: D-22 and KYN 
 
Kynurenate (KYN; 10mM) was applied topically to the brainstem, as detailed in 
section 5.6. Prior to application of KYN the extracellular increase in 5-HT produced 
by vagal stimulation (20Hz, 10x threshold) changed by 5 ± 6% over pre-DMSO 
vehicle controls (n=5, figure 5.20) in the vehicle group and -6 ± 7% in the D-22 group 
(n=5, figure 5.20). 3min post application of KYN extracellular 5-HT increases were 
reduced by 41 ± 6% in the vehicle group and -35 ± 9% in the D-22 group. 6min post 
application of KYN extracellular 5-HT increases were reduced by 60 ± 3% in the 
vehicle group and -57 ± 6% in the D-22 group. This was significantly different (P< 
0.001) from the extracellular increase in 5-HT pre-KYN application. There were, 
however, no significant differences between the vehicle control group and D-22 
group, at this stage. Subsequently in the presence of D-22 (600µg kg-1), extracellular 
increases in 5-HT produced by vagal stimulation returned to that observed pre-KYN 
now only changing 5 ± 17 % from pre-KYN control stimulations. This was 
significantly different (P< 0.001) from DMSO (100µl kg-1) vehicle control that was 
still reduced by 53 ± 5% of pre-KYN control stimulations (figure 5.21).  
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Figure 5.20 Effect of decynium-22 (D-22) in the presence of Kynurenate: 
Experimental Traces   
 
Two anaesthetised artificially ventilated, neuromuscular-blocked male rats showing 
the effect of topically applied kynurenic acid (30 µl, 10 mM) on the increase in the 5-
HT concentration in the NTS evoked by a series of electrical stimulations (20Hz, 1ms, 
3s at 10X threshold) of the central end of the left vagus. Stimulations were applied at 
3 min intervals as shown by the line (VS) above the traces. Also shown is the effect of 
decynium-22 (D-22; 600 µg kg-1, top set of traces) or vehicle (DMSO, 100 µl kg-1; 
bottom set of traces) 6min after application of KYN.  
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Figure 5.21 Effect of kynurenate and D-22: Graph 
 
Percentage mean (±s.e.m) peak changes over control in extracellular 5-HT 
concentration recorded by voltammetry in the NTS following electrical vagal 
stimulation (20Hz, 10x threshold) before (Pre-KYN) topical application of 10mM 
kynurenate, 3 min and 6 min post-application (KYN +3min and KYN, +6min, 
respectively). After 6min decynium-22 (D-22; 600µg kg-1) or vehicle (DMSO; 100µl 
kg-1 ) is applied i.v.  
 
*** P<0.01 2-way ANOVA; compared to vehicle with Bonferroni’s test. 
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5.10. Results: Cardiovascular reflex activation 
 
Cardiopulmonary reflex 
 
Activation of the cardiopulmonary reflex by intra atrial application of the 5-HT3 
agonist phenybiguanide (PBG; 3µg per animal, n=4) caused an increase in 
extracellular 5-HT of 7±1.5nM, 10µg per animal (n=4) caused an increase of 23 ± 
1.6nM and 30µg per animal (n=5, figure 5.22) caused an increase of 46 ± 5.2nM. 
Effects caused by 10 and 30µg per animal were significantly different (P< 0.001) 
from changes measured over the same time period after intra atrial application of 
saline (100µl per animal), -1.3 ± 2nM. Mean changes over baseline are shown in 
figure 5.26. 
 
Chemoreflex reflex 
 
Activation of the chemoreflex by i.v application of the sodium cyanide (NaCN; 50µg 
per animal, n=3) caused a increase in extracellular 5-HT of 13.0 ± 3.5nM, 100µg per 
animal (n=3) caused a change of 40.4 ± 10.6nM and 200µg per animal (n=3, figure 
5.23) caused a change of 53.5.2 ± 9.3nM. Changes in extracellular 5-HT caused by 
100 and 200µg per animal were significantly different (P< 0.001) from changes 
measured over the same time period after intra atrial application of saline (100µl per 
animal), -1.3 ± 2nM. Mean changes over baseline are shown in figure 5.27. 
 
Depressor reflex 
 
Activation of the depressor reflex by i.v. application of noradrenaline (NA; 0.5µg per 
animal, n=3) caused a change in extracellular 5-HT of 0.7 ± 1.7nM, 10µg per animal 
(n=4) caused a change of 11.6 ± 5.7nM and 50µg per animal (n=4, figure 5.24) caused 
a change of 23.2 ± 11.5nM. Effects caused by 50µg per animal were significantly 
different (P< 0.05) from changes measured over the same time period after intra atrial 
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application of saline (100µl per animal), -1.3 ± 2nM. Mean changes over baseline are 
shown in figure 5.28. 
 
Pressor reflex 
 
Activation of the pressor reflex by i.v. application of sodium nitroprusside (SNP; 5µg 
per animal, n=4) caused a change in extracellular 5-HT of 1 ± 4.0nM, 10µg per 
animal (n=4) caused a change of 3.5 ± 2.0nM and 50µg per animal (n=4, figure 5.22) 
caused a change of 3.2 ± 5.4nM. These effects were not significantly different from 
changes measured over the same time period after intra atrial application of saline 
(100µl per animal), -1.3 ± 2nM. Mean changes over baseline are shown in figure 5.29. 
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Figure 5.22  Cardiopulmonary reflex: Traces 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
increase in the 5-HT concentration in the NTS and decreases in arterial blood pressure 
(BP) and heart rate (HR) caused by stimulation of the cardiopulmonary reflex by 
intra-atrial (i.a) injection of phenylbiguanide (PBG; 30 µg in 10 µl). 
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Figure 5.23 Chemoreflex: Traces 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
increase in the 5-HT concentration in the NTS and decrease in arterial blood pressure 
(BP) and biphasic changes in heart rate (HR) caused by stimulation of the 
chemoreflex reflex by intra atrial (i.a) injection of sodium cyanide (NaCN; 200 µg in 
10 µl). 
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Figure 5.24  Depressor reflex: Traces 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
increase in the 5-HT concentration in the NTS and increases in arterial blood pressure 
(BP) and decrease in heart rate (HR) caused by an i.v. injection of noradrenaline (NA; 
50µg).  
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 Figure 5.25 Pressor reflex: Traces 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing no 
change in the 5-HT concentration in the NTS, a decrease in arterial blood pressure 
(BP) and increase in heart rate (HR) caused by an i.v. injection of sodium 
nitroprusside (SNP; 50µg )  
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Figure 5.26  Cardiopulmonary reflex: Histogram 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects of intra-atrial (i.a) injections (10 µl) of different doses (3, 10 & 
30 µg; n = 5) of phenylbiguanide with that of saline on the 5-HT concentration in the 
NTS. The bars show the s.e.m. These changes were compared to saline using a one-
way analysis of variance (ANOVA) and the means compared with Fisher’s LSD test. 
*** P<0.001 
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Figure 5.27  Chemoreflex: Histogram 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects of intra-atrial (i.a) injections (10 µl) of different doses (50, 100 
& 200 µg; n = 3) of sodium cyanide on 5-HT concentration in the NTS. The bars 
show the s.e.m. These changes were compared to saline using a one-way analysis of 
variance (ANOVA) and the means compared with Fisher’s LSD test. *** P<0.001 
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Figure 5.28  Depressor reflex: Histogram 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects of i.v. injections of different doses (0.5, 1 & 50 µg; n = 4) of 
noradrenaline on the 5-HT concentration in the NTS. The bars show the s.e.m. These 
changes were compared to saline using a one-way analysis of variance (ANOVA) and 
the means compared with Fisher’s LSD test. * P<0.05. 
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Figure 5.29  Pressor reflex: Histogram 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects of i.v. injections of different doses (5, 10 & 20 µg; n = 4) of 
sodium ntroprusside with that of saline on the 5-HT concentration in the NTS. The 
bars show the s.e.m. These changes were compared to saline using a one-way analysis 
of variance (ANOVA) and the means compared with Fisher’s LSD test and were 
found to be not significant. 
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5.11. Results: Effect of re-uptake inhibitors on the 
cardiopulmonary reflex 
 
Hemodynamic baseline data 
 
Baseline heart rate and blood pressure were measured 30s prior to commencement of 
the experimental protocol. The vehicle control experimental group had a baseline 
blood pressure of 112 ± 3 mmHg and a baseline heart rate of 410 ± 5 bpm. The 
citalopram experimental group had a baseline blood pressure of 102 ± 4 mmHg and a 
baseline heart rate of 399 ± 4 bpm. The D-22 experimental group had a baseline blood 
pressure of 105 ± 6 mmHg and a baseline heart rate of 401 ± 5 bpm.  
 
5-HT release baseline data 
 
The average absolute increases of extracellular 5-HT measured in response to 
phenylbiguanide (PBG; 10µg per animal) were 25 ± 6nM in the vehicle control 
experimental group, 18 ± 5nM in the citalopram group and 22 ± 8nM in the D-22 
group.  
 
Effect of re-uptake inhibitors 
 
Intravenous application of the selective 5-HT transporter inhibitor citalopram (1mg 
kg-1; n= 5, figure 5.30) caused no significant change in the evoked increase in 
extracellular 5-HT concentration in the NTS following intra atrial application of the 
5-HT3 agonist PBG. In the presence of citalopram the increase in extracellular 5-HT 
changed by -26.4 ± 12.4%. This was not significantly different from vehicle control 
(saline, 1ml kg-1; n=6) control, which caused a change of -9.2 ± 7.6% over pre-drug 
controls. There were also no effects on the bradycardia and hypotension caused by 
PBG in the presence of citalopram, -60 ± 7 mmHg and -243 ± 40 bpm, respectively. 
This was compared to vehicle control, after which hypotension was -64 ± 10 mmHg 
and bradycardia was -141 ± 28 bpm.  
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Intravenous application of the OCT3 and PMAT inhibitor D-22 (600µg kg-1; n= 5, 
figure 5.31) caused a potentiation of the expected increase in extracellular 5-HT 
concentration in the NTS following intra atrial application of the 5-HT3 agonist PBG. 
In the presence of D-22 the increase in extracellular 5-HT was potentiated by -210 ± 
53%. This was significantly different (P<0.001) compared from control (saline, 1ml 
kg-1) control, which caused a change of -9.2 ± 7.6%. D-22 also increased the 
bradycardia caused by cardiopulmonary reflex activation, which now was -348 ± 32 
bpm. This was significantly different from control. The hypotension caused by 
cardiopulmonary reflex activation was now 37 ± 7mmHg but was not significantly 
from control. Combined data is shown in figure 5.32. 
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Figure 5.30  Cardiopulmonary reflex traces: Citalopram 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
increase in the 5-HT concentration in the NTS and decreases in arterial blood pressure 
(BP) and heart rate (HR) caused by stimulation of the cardiopulmonary reflex by 
intra-atrial (i.a) injection of phenylbiguanide (PBG; 10 µg in 10 µl) in absence and 
presence of citalopram (1 mg kg-1; i.v.). The 2nd PBG injection is 6 min after 
administration of citalopram.  
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Figure 5.31  Cardiopulmonary reflex traces: D-22   
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing the 
increase in the 5-HT concentration in the NTS and decreases in arterial blood pressure 
(BP) and heart rate (HR) caused by stimulation of the cardiopulmonary reflex by 
intra-atrial (i.a) injection of phenylbiguanide (PBG; 10 µg in 10 µl) in the absence and 
presence of decynium-22 (D-22; i.v., 600µg kg-1). The 2nd PBG injection is 3 min 
after administration of D-22.  
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Figure 5.32 Effect of Citalopram and Decynium-22 on the 
cardiopulmonary reflex: Combined data 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects (i.v.) of saline (control, 1ml kg-1, n=6), citalopram (1mg kg-1, 
n=5) and decynium-22 (D-22; 600µg kg-1, n=4). on increases in the 5-HT 
concentration in the NTS and the decreases in mean arterial blood pressure (BP) and 
heart rate (HR) caused by intra-atrial (i.a.) injection of phenylbiguanide (10 µg in 10 
µl). The bars show the s.e.m. These changes were compared to control using a one-
way analysis of variance (ANOVA) and the means compared with Fisher’s LSD test. 
*** P<0.001 
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5.12. Discussion 
 
5.12.1. Main findings  
 
The present data demonstrate that activation of sensory afferents, either electrically or 
physiologically (cardiopulmonary, chemo- and baroreceptors), increases extracellular 
5-HT in the NTS in anaesthetized rats. This 5-HT increase is stimulation frequency 
and calcium dependent, as detected by fast-cyclic voltammetry.  
 
Further, the evidence indicates that the low affinity, high capacity re-uptake system 
consisting of OCT3 and/or PMAT is responsible for the removal of 5-HT released 
from vagal afferents. 
 
5.12.2. Signal verification 
 
Using the guidelines for validation of an electrochemical signal set out by Phillips and 
Wightman (2003) the present study first sought to first confirm the identity of the 
electrochemical signal recorded in the NTS. To this end, the in vitro data demonstrate 
a high selectivity for 5-HT over noradrenaline. Further, the electrochemical signal 
recorded in vivo closely matches that recorded in vitro with a known concentration of 
5-HT. The release of detected 5-HT is also consistent with ability of 5-HT antagonist 
to block reflex activation of NTS neurons (Ramage & Villalon, 2008). However, the 
signal was not increased by blockade of 5-HT transporter (5-HTT/SERT) with 
citalopram (Hyttel, 1982) at a dose known to decrease the removal of 5-HT when 
directly applied to the NTS. Although the voltammetric scan is optimised for 5-HT, 
this observation may infer that the voltammetric electrode is detecting another 
monoamine. It is relevant here that noradrenaline terminals and cell bodies (the A2 
group) are found in the NTS (Fuxe, 1965, Takahashi et al., 1980, Kalia et al., 1985, 
see Rinaman, 2011) and further vagal afferents also make synaptic connection with 
the A2 group (Sumal et al., 1983) and can activate these neurons (Appleyard et al., 
2007). Nevertheless, in the present study the selective noradrenaline uptake inhibitor 
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desipramine (Glowinski & Axelrod, 1964), at a dose that decreases the removal of 
noradrenaline applied to NTS but not 5-HT, also failed to increase the evoked 
voltammetry signal. Furthermore, the evoked voltammetry signal was significantly 
and acutely decreased (by approximately 50%) after i.v. application of para-
chlorophenylalanine (p‑CPA). p‑CPA is a brain-permeant 5-HT synthesis inhibitor 
(Koe & Weissman, 1966), which leaves CNS noradrenaline unchanged but reduces 
the 5-HT concentration (Ito & Schanberg, 1975). In addition, in the present 
experiments, α‑methyl-p-tyrosine (AMPT) given i.v. failed to affect the evoked 
voltammetric signal. AMPT has been shown to be a selective noradrenaline depletor 
(Udenfriend et al., 1965). The dose used in the present study has been shown to cause 
a decline after 15 min in the evoked noradrenaline release as detected by voltammetry 
in the ventral bed nucleus of the stria terminalis (Park et al., 2011). This supports the 
view that the optimised voltammetric scan for 5-HT is detecting 5-HT rather than 
noradrenaline. In support of this, data from brainstem slices have shown that evoked 
EPSCs recorded from NTS neurons and caused by stimulation of the solitary tract are 
attenuated by blockade of 5-HT3 receptors (Wan & Browning, 2008, Hosford et al., 
2013, see thesis chapter 3), while blockade of α1‑adrenceptors had no effect on the 
solitary tract- evoked EPSCs (Zhang & Mifflin, 2007). Thus it is unlikely that the 
evoked voltammetric signal contains noradrenaline.   
  
A possible reason for the failure of blockade of the 5-HT high-affinity, low-capacity 
transporter (5-HTT or SERT) to increase the evoked voltammetric signal could be due 
to activation of 5-HT1A receptors; such an interpretation has been used to explain the 
delay in the onset of the therapeutic effect of antidepressants (also see DISCUSSION 
3.9.2). That is, although 5-HT uptake is blocked immediately the activation of 5-HT1A 
receptors causes an initial reduction in the overall release of 5‑HT in the cortex until 
the 5-HT1A receptor desensitizes (see Artigas et al., 1996). However, treatment with 
the archetypical 5‑HT1A antagonist WAY-100635 (Forster et al., 1995) did not 
uncover a potentiating action of citalopram. Interestingly, WAY-100635 given alone 
caused a significant decrease in the bradycardia evoked by electrical stimulation of 
the vagus. This is consistent with the physiological role of 5‑HT1A receptors in the 
excitatory regulation of cardiac vagal preganglionic neurons (Bogle et al., 1990, 
Wang & Ramage, 2001). Further, this inhibition was reversed by addition of 
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citalopram implying that citalopram had caused an increase in the extracellular 5‑HT 
concentration within this pathway, although alone it had no effect on these reflexes. 
The site of action is probably at the level of nucleus ambiguus (Wang & Ramage, 
2001), the location of cardiac vagal preganglionic neurons. This implies that the 
removal of extracellular 5-HT at the level of the nucleus ambiguus is different from 
than in the NTS.  
  
5.12.3. Low affinity, high capacity re-uptake systems 
 
This study has shown that blockade of the low affinity, high capacity transporters, 
the organic cation transporter 3 (OCT3)/plasma membrane monoamine transporter 
(PMAT), with decynium-22 (D-22; Schomig et al., 1993, Duan & Wang, 2010) does 
potentiate the evoked 5-HT voltammetric signal. The failure of corticosterone (Engel 
& Wang, 2005), even at high doses, to effect the removal of 5-HT applied to the NTS 
suggests that OCT3 is not involved and the removal of 5‑HT in the NTS is by PMAT 
(see thesis chapter 4). Interestingly, PMAT is approximately 70% more effective in 
transporting 5-HT compared to noradrenaline (Duan & Wang, 2010). Functionally, 
the increase in extracellular of 5-HT caused by D-22 was associated with significant 
increase in the bradycardia evoked by both vagal and cardiopulmonary stimulation, 
which again is consistent with the excitatory role of 5-HT in these pathways (see 
Ramage & Villalon, 2008). The failure to see any potentiation of reflex fall in blood 
pressure is presumably due to the profound hypotension caused by i.v. D-22 and 
explained by the α1‑adrenoceptor antagonist activity of D-22 (Russ et al., 1996). It 
should be noted that this profound hypotensive action does not play a role in the 
ability of D-22 to potentiate the evoked voltammetric 5-HT signal, as a similar fall in 
BP caused by ganglion blocker chlorisondamine did not affect the signal. Again the 
ability of the blockade of PMAT, but not of the 5-HT transporter, to increase the 
evoked 5-HT signal is consistent with observation that the amplitude of solitary tract 
evoked EPSCs recorded from NTS neurons in the brainstem slice are increased in 
amplitude in the presence D-22 (see thesis chapter 3). In addition, the number of 
spontaneous EPSCs recorded after a train of solitary tract stimulation were doubled 
by D-22 but not citalopram (see thesis chapter 3). These combined data demonstrate 
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that the regulation of the increase in extracellular levels of 5-HT within NTS caused 
by afferent stimulation is regulated by PMAT and not the 5-HT transporter. This 
result differs from that reported in substantia nigra. In this brain region the increase in 
extracellular 5-HT evoked by stimulating the dorsal raphé, also detected by 
voltammetry, is under the regulation of the 5-HT transporter (Hashemi et al., 2009). It 
should be noted that the evoked increase in extracellular 5-HT in the substantia nigra 
is in a similar concentration range to that recorded in the present study. A possible 
reason for this difference may be at the level of the NTS; 5‑HT release evoked by 
visceral afferents involves volume transmission or paracrine transmission rather than 
wired transmission. The 5-HT is not being released into classical synapses but is 
dispersed over a larger area, an effect known as paracrine transmission (see Ramage, 
2009, Fuxe et al., 2013).  
  
 
5.12.4. The interplay of 5-HT and glutamate release 
 
The present data would indicate that vagal afferents cause the release of 5-HT, 
however glutamate is considered to be the major transmitter released by 
cardiovascular/visceral afferents in the NTS (see Talman, 1997, Baude et al., 2009). 
Blockade of glutamate receptors with kynurenate (see Stone & Addae, 2002) 
indicated that approximately half of the signal is dependent on glutamate release from 
vagal afferents. This remaining signal could also be potentiated with D-22, which 
would be consistent with the signal identity being 5-HT. It may be argued that not all 
of the glutamate receptors were blocked, however increasing the dose 10-fold failed 
to have any further effect on the evoked 5-HT signal. However, the cardiovascular 
response to electrical stimulation of the vagus was reversed, a small rise in blood 
pressure and a tachycardia was then observed. This may simply reflect the ability of 
the high dose of kynurenate to penetrate further into the brainstem blocking other sites 
in these reflex pathways i.e. those of the ventral surface. However, it could be also be 
explained by the unmasking of the actions of other transmitters released during vagal 
stimulation, in analogy the actions of GABAB receptors in the NTS are unmasked 
after blockade of GABAA receptors (Wang et al., 2010). 
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Further, blockade of Ca2+ channels with Cd2+ caused a 90% reduction of the evoked 
5-HT voltammetric signal and there was nearly complete inhibition of the reflex 
evoked cardiovascular changes. Overall theses observation suggests that there is a 
glutamate-dependent and glutamate-independent source of 5‑HT, which is released in 
response vagal afferent stimulation. This glutamate-independent release could come 
directly from vagal afferent terminals (see INTRODUCTION) and/or involve the release 
of another transmitter from the vagal afferents, such as substance P (see Helke & 
Seagard, 2004).  
 
In general, the present data indicate that glutamate, presumably from vagal afferents, 
can cause the release of 5-HT. This is intriguing as in vivo (Jeggo et al., 2005) and in 
vitro (Wan & Browning, 2008) experiments have shown the opposite; that 5-HT by 
activating 5-HT3 receptors can cause the release of glutamate. Further, in vitro 
experiments have shown that this 5-HT-evoked glutamate release is dependent on the 
presence of vagal afferents (Wan & Browning, 2008), on which 5-HT3 receptors are 
located. If it is assumed that at least some of the 5-HT and glutamate released in the 
NTS by afferent activation comes from the afferent terminals then each substance 
must feed forward onto other terminals to increase the release of the other substance. 
This would operate to consolidate the afferent input signal to the NTS. Indeed, the 
NTS is known to have a very low failure rate when relaying afferent input (see 
Andresen & Paton, 2011). This may be method of strengthening synaptic 
transmission.  
 
5.12.5. Cardiovascular reflexes 
 
It should be noted that, as activation of both chemo- and baroreceptors can increase 
extracellular 5-HT in the NTS, glossopharyngeal afferents are similarly structured in 
their ability to release 5-HT and glutamate as vagal afferents. Further, it should be 
noted that the fall in blood pressure caused by i.v. sodium nitroprusside failed to 
increase  the voltammetric signal.  This is not unexpected as baroreceptor afferents 
firing is reduced, although a decrease in the voltammetric signal may have been 
expected. A possible explanation why no decrease was observed might be related to 
the fact that the voltammetric electrodes are detecting transmitter overflow rather than 
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transmitter changes within a synapse. Under normal basal conditions, extracellular 5-
HT concentration is tightly controlled by the high-affinity, low capacity re-uptake 
systems present within the NTS. This would mean that there is little efflux from 
release sites into the wider extracellular space, where it can be detected by 
voltammetry. Reducing drive by activation of the pressor reflex would do little to 
change the 5-HT efflux and thus the concentration measured by the electrode. 
 
5.12.6. Conclusion  
 
The present data demonstrate that, in the anaesthetised rat, stimulation of visceral 
afferents increases extracellular 5-HT levels in the NTS. This increase is due, in part, 
to the release of glutamate, presumably from visceral afferents. However, other 
possible sources such as 2nd order neurons have not been eliminated. The source of 
the 5-HT again has not been determined; it could be visceral afferents themselves 
and/or 5-HT terminals within the NTS. Published data also indicates NTS 5-HT 
release can itself cause the release glutamate.This 5-HT release, however surprising, 
is under the regulation of the high-capacity, low‑affinity transporter PMAT and not 
the low-capacity, high‑affinity 5-HT transporter.  
 
This is the first demonstration that PMAT plays a physiological role in the regulation 
of 5-HT transmission. This might due to the fact that 5-HT is acting as a volume 
transmitter in the NTS. Overall these data support the view that 5-HT is an important 
transmitter for homeostatic regulation at the level of NTS. 
 
 
5.12.7. Future experiments 
 
It may be possible that another transmitter is released by vagal afferents, apart from 
glutamate, that feeds forward to activate the release of 5-HT from other sources. It has 
been suggested that substance P could also be released from vagal afferent terminals 
(see Helke & Seagard, 2004). It could, conceivably, be substance P activating NK1 
receptors on 5-HT-containing terminals within the NTS to cause the release of 5-HT 
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as detected by voltammetry. Potent and selective NK1 receptor agonists, such as CP 
96345 (Snider et al., 1991), are available. Repeating the experiments detailed in 
section 5.9 but applying the NK1 antagonist instead of D-22 may supply the necessary 
evidence. If substance P release is contributing to the release of 5-HT then the NK1 
antagonist would further attenuate the extracellular 5-HT concentration increase 
caused by vagal stimulation in the present of kynurenate.  
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6. 5-HT AND GLUTAMATE RELEASE IN THE NTS IN A RODENT 
MODEL OF HEART FAILURE: A PILOT STUDY   
 
6.1. Introduction 
 
 
In man and in animal models, the baroreflex and the cardiopulmonary reflex are 
reportedly impaired in early heart failure (Sved et al., 2003, Modesti et al., 2004). 
Further, inappropriate alterations in these reflexes have been considered to underlie 
the majority of cases of hypertension (Guyenet, 2006, Flanagan et al., 2008). 
Maladaptive changes within systems governing cardiovascular reflexes can 
exacerbate heart failure and contribute to the progression of the disease (Kaye & 
Esler, 2005). The processing of these reflexes requires the release of various 
neurotransmitters within the NTS and an understanding of how different chemical 
transmitters are used here could be crucial to gaining insights into the failure of 
homeostatic mechanisms in heart failure.  
 
Now with an understanding of some of the basic physiology of 5-HT release in the 
NTS under normal physiological conditions it was hypothesised that during abnormal 
cardiovascular function 5-HT release would be modified. A rat model of post-
myocardial infarction-induced heart failure is available and has been used to 
investigate differences in signalling within the brainstem during heart failure (Marina 
et al., 2013). In the present study experiments were conducted to determine the effect 
of infarct-induced heart failure on the properties of 5-HT and glutamate released 
during activation of cardiovascular reflexes.   
 
 
6.2. Specific Aims 
 
 
• Validate the model of post-myocardial infarction-induced heart failure by assessing 
the pathophysiology of the heart in both sham and coronary artery-ligated rats. 
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• Determine if the properties of 5-HT release in the NTS caused by a range of 
frequencies of electrical vagal stimulation is modified in heart failure.  
 
• Investigate the differences in 5-HT release in the NTS during activation of the 
cardiopulmonary reflex in heart failure.  
 
• Investigate the changes in glutamate release caused by activation of the depressor 
reflex in heart failure. 
 
 
6.3. Supplementary methods 
 
Rat model of myocardial infarction-induced heart failure 
 
Myocardial infarct was induced by ligating the coronary artery according to the 
technique described in detail elsewhere (Pfeffer et al., 1979, 1991, Francis et al., 
2001). Briefly, rats 180-210g (n = 18) were anaesthetised with a mixture of ketamine 
(60 mg kg−1; i.m.) and medetomidine (250 µg kg−1, i.m.), an orotracheal cannula was 
put in place and the rat was artificially ventilated with O2-enriched room air. The 
heart was exteriorised via a left thoracotomy and the pericardium removed. The left 
anterior descending coronary artery was ligated on the border of the pulmonary 
outflow tract and the left atrium using a 5–0 Merisilk suture. The perfusion of the left 
ventricle was monitored visually by colour change to confirm successful occlusion of 
the coronary artery. Sham operated rats underwent exactly the same procedure except 
that the suture was passed around the coronary artery but not tied. The heart was 
returned to the thoracic cavity and the chest incision closed. Penicillin-streptomycin-
containing powder was applied to the incision site and anaesthesia was reversed with 
atipamezole (1 mg kg-1). 3 of the 18 animals died within 48 hours of surgery due to 
sudden cardiac death, as is common with this procedure. After at least 14 days post 
surgery the experimental animals were set up for measurement of 5-HT as described 
in METHODS  2.1. 
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Histology 
 
Upon completion of the experiment rats were sacrificed with an overdose of 
pentobarbitone (30 mg kg-1). The heart was removed and weighed immediately. The 
left ventricle was then removed with fine dissection scissors and wrapped in a plastic 
paraffin film to prevent dehydration. The tissue was then frozen at 20 °C for 20 min 
and then sectioned from the apex to the base into four transverse slices of 
approximately 1.5 mm. The sections were then immersed in a solution of 1% (w/v) 
triphenyl tetrazolium chloride (TTC) in 0.01M phosphate buffered saline. The 
solution was incubated at approximately 37 °C for 15-20min. The sections were then 
transferred to a 10% formalin solution overnight before being photographed. The area 
of the ventricle lumen and muscle was determined using computerised planimetry.  
 
Measurement of extracellular glutamate 
 
Experimental animals were set up as described in METHODS  2.1 up to the point of 
electrode implantation. For the measurement of extracellular glutamate concentration 
changes enzyme-encapsulated electrodes were used as described elsewhere (Gourine 
et al., 2008, Tian et al., 2009). The glutamate sensing electrodes, the ‘active 
electrode’, contains glutamate oxidase encapsulated in a matrix coated on a platinum 
wire (diameter 50µm, length 1mm). Glutamate oxidase converts glutamate to α-
ketoglutarate along with NH3 and H2O2. The platinum wire is held at a constant 
voltage of +500mV, sufficient to oxidise the H2O2. Increases in glutamate 
concentration feed-forward to increases in H2O2 and, in turn, increases current flux 
through the platinum electrode. The electrode is protected from interfering 
electroactive species, such as 5-HT by a permselective membrane. Additionally, a 
dual recording configuration was used to control for unknown oxidisable interferents. 
In addition to the ‘active’ glutamate electrode, a ‘null’ electrode was implanted in an 
equivalent position in the contralateral NTS. This electrode was identical but did not 
contain glutamate oxidase. Current changes at this electrode were subtracted from the 
current changes from the active electrode. 
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Specificity of glutamate electrodes 
 
The glutamate biosensor used in this study has been extensively validated for 
specificity for glutamate (Tian et al., 2009). The authors reported a relative response 
of a range of common interfering substances, including 5-HT, of less than 10% when 
compared to glutamate. They also reported that the sensor is unresponsive to changes 
in pH in the range expected to be encountered within the brain during intense 
neuronal activity. Further, the sensor retained sensitivity in low oxygen tension 
environment.  
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6.4. Results: Pathology 
 
Morphology and metabolic activity 
 
14 days after coronary artery ligation gross morphology of the left ventricle shows an 
enlarged ventricle with thinning of the external ventricle wall (Figure 6.1). When 
stained with redox indicator TTC the external left ventricle wall near the site of 
infarct remained white and that taken up by the remaining tissue was reduced to the 
red 1,3,5-triphenylformazan (TFP). In comparison the left ventricle section from the 
sham-operated rat shows no thinning of the left ventricle wall and deep red staining 
from TFP accumulation in the tissue. Note that the tissue from the sham operated 
heart stained a much deeper red than that from the ligated heart.  
 
Heart weight and ventricular ratio 
 
Hearts removed from sham-operated rats (n=6) had a wet weight of 3.3 ± 0.1g kg-1 of 
body weight. This was significantly increased (P<0.05) in rats with ligated hearts 
(n=8), which had a wet weight of 3.8 ± 0.2g kg-1 of body weight (Figure 6.2A). There 
was no significant difference in the wet weight of the ventricle in sham operated (2.1 
± 0.04g kg-1) and ventricles of ligated hearts (2.3 ± 0.1g kg-1). 
 
The ratio of left ventricular lumen cross sectional area to ventricular wall area was 
0.05 ± 0.003 in hearts removed from sham-operated rats. This was significantly 
greater (P<0.001) in hearts removed from ligated hearts, which had a ratio of 0.3 ± 
0.03 (Figure 6.2B). 
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Figure 6.1 Heart Failure pathology: Histology 
 
Photographs of two left ventricles stained with TTC taken from (left) a sham operated 
rat heart and (right) a rat heart with coronary vessel ligation. Both were sacrificed 
after 14 days. Cross sections are approximately 1.5mm thick and were taken the 
centre of the ventricle. Scale bar represent 5mm.  
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Figure 6.2 Heart Failure pathology: Histograms 
 
Rat model of post-myocardial infarction-induced heart failure:  
 
A) Histogram comparing wet heart mass of sham-operated rats (Sham; n=6) and 
coronary artery ligated rats (Heart Failure; n=8) sacrificed 14 days post-procedure. 
*P<0.05, Compared to control with Student’s paired t-test.  
 
B) Histogram comparing the ratio of left ventricular lumen cross sectional area to 
ventricular wall area in sham operated (Sham; n=6) and coronary artery ligated rats 
(Heart failure; n=8) sacrificed 14 days post-procedure. ***P<0.001, Compared to 
control with Student’s paired t-test. 
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6.5. Baseline haemodynamic values 
 
Heart rate measured over 5 min after induction of anaesthesia in animals that had 
undergone coronary ligation (n=8) was 356 ± 11bmp. This was not significantly 
different from that measured in sham-operated rats (n=6), which had a mean heart rate 
of 372 ± 14bmp.  
 
Mean arterial blood pressure measured over the same 5min period after induction of 
anaesthesia in animals that had undergone coronary ligation was 101 ± 4mmHg. This 
was found to be significantly different (P<0.05, Compared with Student’s paired t-
test) from sham-operated animals, which had a mean arterial blood pressure of 121 ± 
9mmHg. 
 
 
6.6. Electrical stimulation of the vagus in heart failure 
 
Extracellular 5-HT concentration in the NTS 
 
When the vagus nerve was stimulated at 10x threshold using frequencies of 10, 20 
and 50Hz, extracellular increases in 5-HT were 18.4 ± 3 nM, 50.5 ± 8.1nM and 82.4 ± 
21.4nM, respectively in animals that had undergone coronary ligation (n=3). In 
animals that had undergone the sham procedure stimulating at 10x threshold using 
frequencies of 10, 20 and 50Hz caused extracellular increases in 5-HT of 25 ± 11.5 
nM, 52.5 ± 7.0nM and 53.8 ± 12.0nM, respectively (Figure 6.3. No significant 
differences were found between the two groups at any stimulation frequency when 
compared with Student’s t-test.  
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Cardiovascular 
 
Vagus nerve stimulation at 10x threshold using frequencies of 10, 20 and 50Hz 
caused bradycardia of 17 ± 8 bpm, 22 ± 8 bpm and 43 ± 11 bpm, respectively in 
animals that had undergone coronary ligation (n=3). This was not significantly 
different from animals that had undergone the sham procedure, in which the same 
simulation parameters of 10, 20 and 50Hz now caused bradycardia of 29 ± 11 bpm, 
31 ± 12 bpm and 32 ± 3 bpm.  
 
When the vagus nerve was stimulated at 10x threshold using frequencies of 10, 20 
and 50Hz hypotension of 20 ± 4 mmHg, 31 ± 8 mmHg and 34 ± 12 mmHg, 
respectively was produced in animals that had undergone coronary ligation (n=3). 
This was not significantly different from animals that had undergone the sham 
procedure, in which the same simulation parameters of 10, 20 and 50Hz now caused 
hypotension of 18 ± 4 mmHg, 25 ± 4 mmHg and 33 ± 3 mmHg. 
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Figure 6.3 Heart Failure Model: Histograms 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the different frequencies of electrical stimulation of the central end of the 
left vagus (1ms pulse-width, 10s duration) at 3 min intervals at different frequencies 
and 10x threshold (threshold range was between 70-110 µA) on changes (Δ) in the 5-
HT concentration in the NTS as detected by fast cyclic voltammetry. Each column is 
the mean (±s.e.m) data from 3 rats in each experimental group.  
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6.7. Results: Cardiovascular reflexes 
 
Cardiopulmonary reflex 
 
In animals that had undergone coronary artery ligation, activation of the 
cardiopulmonary reflex by intra atrial (i.a.) injection of the 5-HT3 receptor agonist 
phenylbiguanide (10µg per animal) caused an increase in extracellular 5-HT of 29 ±  
6nM. This was significantly different (P< 0.05) from sham-operated animals, in 
which by i.a. injection of phenylbiguanide caused an increased in extracellular 5-HT 
of 10 ± 0.4nM (Figure 6.5).  
 
The decrease in blood pressure and the decrease in heart rate caused by i.a. injection 
of phenylbiguanide were 34 ± 5mmHg and -148 ± 39bpm in animals that had 
undergone coronary artery ligation. In sham-operated animals these changes were 58 
± 6mmHg and -191 ± 12bpm. The hypotension was found to be significantly 
decreased in rats that had undergone coronary ligation (P< 0.05). 
 
All data represent n=4 taken from two animals in each experimental group (2 ligated, 
2 sham). Representative experimental traces are shown in figure 6.4. 
  
 311 
Figure 6.4 5-HT release in heart failure: Cardiopulmonary reflex traces 
 
 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rats A) having 
undergone coronary artery ligation and B) having undergone a sham procedure 
showing an increase in the 5-HT concentration in the NTS, a decrease in arterial 
blood pressure (BP) and decrease in heart rate (HR) caused by an i.a. injection of 
phenylbiguanide (PBG; 10µg).
A 
B 
Figure 6.5 Heart Failure Model: Cardiopulmonary reflex histograms 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects on mean increases in extracellular 5-HT concentration ([5-HT]) 
in the NTS and the decreases in mean arterial blood pressure (BP) and heart rate (HR) 
caused by i.a. injection of the 5-HT3 agonist phenylbiguanide (10µg per animal) in 
animals that had undergone coronary artery ligation (Heart Failure; n=4 in 2 animals) 
or sham procedure (Sham; n=4 in 2 animals). The bars show the s.e.m. These changes 
were compared with unpaired Student’s t-test. * P<0.05.  
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6.8. Results: Glutamate release in heart failure 
 
In animals that had undergone coronary artery ligation (n=3) activation of the 
depressor reflex by i.v. injection of the α1-adrenoceptor agonist phenylephrine (3µg 
per animal) caused an increase in extracellular glutamate 1.6 ± 0.2µM that was 
significantly different (P< 0.05) when compared to sham-operated animals (n=3), in 
which i.v. injection of phenylephrine caused an increased in extracellular glutamate 
by 0.6 ± 0.2µM (Figure 6.7).  
 
The increase in blood pressure and the decrease in heart rate caused by i.v. injection 
of phenylephrine were 46 ± 2mmHg and -25 ± 4bpm in animals that had undergone 
coronary artery ligation. In sham-operated animals these changes were 49 ± 8mmHg 
and -43 ± 12bpm. There were no significant differences found between the two 
experimental groups.  
 
Representative experimental traces are shown in figure 6.6.  
 
Activation of the pressor reflex by i.v. injection of nitric oxide donor vasodilator 
sodium nitroprusside (SNP; 50µg per animal; n=2) was found to have no effect on 
extracellular glutamate concentration in the NTS in animals that had undergone 
coronary artery ligation or sham procedure (Figure 6.8). 
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Figure 6.6 Glutamate release in heart failure: Depressor reflex trace 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat having 
undergone coronary vessel ligation showing an increase in the glutamate 
concentration in the NTS, an increase in arterial blood pressure (BP) and decrease in 
heart rate (HR) caused by an i.v. injection of phenylephrine (3µg). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 6.7 Glutamate release in heart failure: Histograms 
 
Anaesthetised artificially ventilated, neuromuscular-blocked male rats: histograms 
comparing the effects on mean increases in extracellular glutamate concentration 
([GLUT]) in the NTS and the increases in mean arterial blood pressure (BP) and 
decreases in heart rate (HR) caused by i.v. injection of the α1-adrenoceptor agonist 
phenylephrine (3µg per animal) in animals that had undergone A) coronary artery 
ligation (Heart Failure, n=3) or B) sham procedure (Sham, n=3).The bars show the 
s.e.m. These changes were compared using unpaired Student’s t-test. * P<0.05. 
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Figure 6.8 Glutamate release in heart failure: Pressor trace 
 
An anaesthetised artificially ventilated, neuromuscular-blocked male rat showing no 
change in the glutamate concentration in the NTS, a decrease in arterial blood 
pressure (BP) and increase in heart rate (HR) caused by an i.v. injection of sodium 
nitroprusside (SNP; 50µg ). 
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6.9. Discussion  
 
6.9.1. Main findings 
 
Activation of the cardiopulmonary reflex was found to cause an approximately 3-fold 
increase in extracellular 5-HT in animals with heart failure compared with those that 
had undergone the sham procedure. Equally, the increase in extracellular glutamate 
concentration evoked by activation of the depressor reflex was found to be higher in 
animals with heart failure than in those that had undergone the sham procedure. 
Interestingly, when the increase in extracellular 5-HT increased is evoked by 
electrical stimulation there is no difference between the two experimental groups. 
Lastly, activation of the pressor reflex failed to modify extracellular glutamate 
concentrations in both experimental groups.   
 
6.9.2. Conclusion 
 
The present study suggests that in heart failure caused by myocardial infarction, 
glutamate and 5-HT transmission are augmented within the NTS when the depressor 
reflex and the cardiopulmonary are activated, respectively. This conclusion is 
supported by the data obtained from direct, real-time electrochemical measurement of 
the two transmitters within the NTS during reflex activation. These data suggest that 
compensatory mechanisms are activated centrally to modulate cardiovascular 
reflexes. Whether these changes are maladaptive and they have an impact on the 
progression of the pathology is yet to be determined.  
 
6.9.3. Future experiments 
 
As this was only a preliminary set of experiments using this rodent model of heart 
failure, a full investigation of changes seen in the 5-HT and glutamate released during 
reflex activation is necessary. The changes in glutamatergic transmission would be of 
particular interest.  
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7. GENERAL DISCUSSION 
 
7.1. Conclusions 
 
The present experiments have investigated the neuropharmacology of the release and 
re-uptake of 5-HT both in vitro and in vivo with respect to the afferent processing 
within the NTS. Efforts have been made to verify the pharmacological selectivity and 
effectiveness of the compounds used to manipulate the monoamine re-uptake 
mechanisms in the NTS. Additionally, experiments have begun to assess the changes 
in the regulation of transmitter release as a result of chronic heart failure that may 
occur in the NTS. From the data it is possible to conclude the following points: 
 
1) 5-HT is released within the NTS upon stimulation of vagal afferents. At least half 
of the detected 5-HT is not due to glutamate release and may be directly released by 
vagal afferent terminals within the NTS. The remaining 5-HT is released from other 
sources that require glutamate to be released from vagal afferents. This indicates that 
5-HT terminals located within the NTS, arising from medullary raphé, must be also 
activated by vagal input to release this 5-HT.  Is should be noted that 5-HT has also 
been demonstrated to release glutamate the NTS. These combined data imply that 5-
HT and glutamate must feed forward onto other terminals to increase the release of 
each other. This form of synaptic consolidation may serve to improve reliability of 
transmission within the NTS.  
 
2) A low-affinity, high-capacity monoamine uptake transporter, probably PMAT 
rather than OCT3, and not the high-affinity, low-capacity 5-HT transporter is 
involved in the regulation of the rise in extracellular concentration of 5-HT in the 
NTS in response vagal afferent stimulation. This is evident both in the brainstem slice 
and from the anaesthetized rat preparation. This could be indicative of 5-HT acting as 
a volume transmitter within the NTS. 
 
3) In the NTS slice, augmenting extracellular 5-HT concentration with re-uptake 
inhibitors unmask a presynaptic 5-HT1A receptor that is inhibitory to glutamate 
release. This is effect persists despite an abundance of presynaptic 5-HT3 receptors, 
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which are excitatory. In this arrangement 5-HT1A receptors are protected from 
activation by re-uptake systems. This may be because the 5-HT1A receptor is located 
remote from the sites where 5-HT is released. This is further evidence that 5-HT acts 
as a volume transmitter within the NTS.  
 
4) Re-uptake inhibitors are often used to clarify the identity of an unknown 
electrochemical signal. However, little data exists regarding the acute effects, dosing 
and selectivity of these drug when used in vivo. Direct assessment of a range of re-
uptake inhibitors has shown that citalopram and desipramine are selective for 5-HT 
and noradrenaline, respectively, at doses of 1mg kg-1 when administered i.v. in vivo.  
 
5) Heart failure causes an augmentation of glutamate and 5-HT release within the 
NTS. These neurogenic changes could represent a maladaptive compensation and 
may contribute to disease progression.  
 
 
7.2. Limitations 
 
Anaesthesia 
 
In vivo experimental design must always balance the level of control afforded by the 
use of anaesthesia and neuromuscular blockade with the desire to maintain as close to 
normal physiology as possible. The experiments presented in chapters 4, 5 and 6 all 
use the anaesthetised rat preparation. As a result confounding factors such as animal 
movement, changes in ventilation and blood gases were controlled or removed.  
 
However, while anaesthesia allows for more invasive and technically advanced 
experiments to be carried out on the whole animal, it must be recognised that 
anaesthetic drugs are themselves a confounding factor. Cardiovascular reflexes 
function to maintain the physiology of awake animals. As anaesthetics all have 
depressant actions on neural circuits controlling these reflexes, so cannot be expected 
to behave as they would in the absence of these drugs. Nevertheless, care has been 
taken to minimise the impact by the selection of an anaesthetic agent, α-chloralose, 
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widely used in this type of research due to its low depressant action on cardiovascular, 
respiratory, and reflex functions (Nakao et al., 2001). However, it is still known to 
alter the physiology of some aspects of the cardiovascular system. For example 
baroreflex and chemoreflex are blunted by chloralose anaesthesia when compared to 
awake animals (Covert et al., 1988, Kellett, 2005). It should also be noted that only a 
few studies have investigated cardiovascular reflexes in awake animals due to 
technical difficulty and limitations. This makes using anaesthetised preparations more 
advantageous as direct comparisons with the established literature can be made.  
 
It may be possible in future studies to perform voltammetry in the awake rat. This has 
already been achieved for dopamine (Rebec et al., 1997) and a technique developed 
by Michelini and Bonagamba (1988) would allow implantation of microelectrodes 
into the NTS of awake, freely moving and unrestrained rat. 
 
Brainstem slice preparation 
 
The brainstem slice preparation used in this thesis avoids the need for anaesthesia 
completely. However, there are other significant limitations of the brainstem slice 
preparation when compared to studying NTS function in the intact brain. Firstly, the 
ability to relate end-organ functional changes (heart rate, blood pressure) to 
neurophysiological changes seen in the brain is impossible. Secondly, the brain 
requires networks of neurons to function and preparation of the slice will remove 
many inputs to the NTS. Therefore, it is important to interpret results accordingly and 
use the data obtained in slice preparations to design in vivo studies to support any 
conclusions. 
 
 
7.3. Future studies 
 
Determining the contribution of glia to the spontaneously released glutamate in the 
NTS would be the focus of one future experiment. The present study used a metabolic 
inhibitor in an attempt to dissect out functional aspects of the glutamate release from 
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glia. Although this is an important first step in elucidating the role of glia in the NTS, 
a more specific and versatile method of manipulating glial function is necessary to 
explore their role fully. To this end, it is possible to specifically target glia with an 
adeno-associated viral vector (AAV) using a glial-specific promoter. Glial fibrillary 
acidic protein (GFAP) is a cytoskeletal component abundantly expressed in astrocytes 
but, importantly, not expressed by neurons (Brenner et al., 1994). Vectors with this 
promoter have been used recently to express channel rhodopsin (ChR) in astrocytes. 
ChR is a light sensitive nonspecific cation channel and, when activated, facilitate a 
low flux of calcium across the cell membrane, which can then trigger calcium waves 
and subsequent astroglial signalling (see Gradinaru et al., 2007). Such an 
experimental approach has been used to great effect in the brainstem to demonstrate 
respiratory responses were triggered when astrocytes were specifically stimulated 
(Gourine et al., 2010).  
 
Additionally, it is possible to introduce an inhibitory G-protein-coupled receptor (Gi) 
that is activated by an inert ligand, known as DREADDs (designer receptors 
exclusively activated by designer drug), using the same vial vector with a GFAP 
promoter (see Wess et al., 2013). Expression of Gi coupled DREADD has been used 
previously to silence excitable cells in vivo and in vitro by inhibiting cAMP 
production (Ray et al., 2011). Using this technique it may be possible to temporarily 
inhibit the release of gliotransmitters. 
 
Using these two experimental approaches, first in vitro, it would be possible to 
determine the contribution of the glia to the spontaneously released glutamate as 
recorded in the NTS-containing brainstem slice preparation. Secondly, by silencing 
the astrocytes while applying 5-HT3 agonists it would be possible to determine if 
astrocytes are activated and contribute to the increase in mEPSCs caused by 5-HT3 
activation.  
 
This experimental approach can also be used in vivo to selectively activate 5-HT-
containing cells within the NTS. A specific promoter can be used to limit the 
expression of rhodopsin to cells that express 5-HT. More selective activation/ 
inhibition of these cells would allow the physiological role of 5-HT within the NTS to 
be elucidated.  
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